
<html lang="en"     class="pb-page"  data-request-id="2d018e74-d202-47c7-82b3-cac80bc35f23"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-5;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.8b02036;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo" /></meta><meta name="dc.Creator" content="Brian H.  White" /></meta><meta name="dc.Creator" content="Kerry  Whalen" /></meta><meta name="dc.Creator" content="Kristina  Kriksciukaite" /></meta><meta name="dc.Creator" content="Rossitza  Alargova" /></meta><meta name="dc.Creator" content="Tsun  Au Yeung" /></meta><meta name="dc.Creator" content="Patrick  Bazinet" /></meta><meta name="dc.Creator" content="Adam  Brockman" /></meta><meta name="dc.Creator" content="Michelle  DuPont" /></meta><meta name="dc.Creator" content="Haley  Oller" /></meta><meta name="dc.Creator" content="Charles-Andre  Lemelin" /></meta><meta name="dc.Creator" content="Patrick  Lim Soo" /></meta><meta name="dc.Creator" content="Benoît  Moreau" /></meta><meta name="dc.Creator" content="Samantha  Perino" /></meta><meta name="dc.Creator" content="James M.  Quinn" /></meta><meta name="dc.Creator" content="Gitanjali  Sharma" /></meta><meta name="dc.Creator" content="Rajesh  Shinde" /></meta><meta name="dc.Creator" content="Beata  Sweryda-Krawiec" /></meta><meta name="dc.Creator" content="Richard  Wooster" /></meta><meta name="dc.Creator" content="Mark T.  Bilodeau" /></meta><meta name="dc.Description" content="Somatostatin receptor 2 (SSTR2) is frequently overexpressed on several types of solid tumors, including neuroendocrine tumors and small-cell lung cancer. Peptide agonists of SSTR2 are rapidly inter..." /></meta><meta name="Description" content="Somatostatin receptor 2 (SSTR2) is frequently overexpressed on several types of solid tumors, including neuroendocrine tumors and small-cell lung cancer. Peptide agonists of SSTR2 are rapidly inter..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 8, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b02036" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b02036" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b02036" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b02036" /></link>
        
    
    

<title>Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b02036" /></meta><meta property="og:title" content="Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0001.jpeg" /></meta><meta property="og:description" content="Somatostatin receptor 2 (SSTR2) is frequently overexpressed on several types of solid tumors, including neuroendocrine tumors and small-cell lung cancer. Peptide agonists of SSTR2 are rapidly internalized upon binding to the receptor and linking a toxic payload to an SSTR2 agonist is a potential method to kill SSTR2-expressing tumor cells. Herein, we describe our efforts towards an efficacious SSTR2-targeting cytotoxic conjugate; examination of different SSTR2-targeting ligands, conjugation sites, and payloads led to the discovery of 22 (PEN-221), a conjugate consisting of microtubule-targeting agent DM1 linked to the C-terminal side chain of Tyr3–octreotate. PEN-221 demonstrates in vitro activity which is both potent (IC50 = 10 nM) and receptor-dependent (IC50 shifts 90-fold upon receptor blockade). PEN-221 targets high levels of DM1 to SSTR2-expressing xenograft tumors, which has led to tumor regressions in several SSTR2-expressing xenograft mouse models. The safety and efficacy of PEN-221 is currently under evaluation in human clinical trials." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b02036"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b02036">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b02036&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b02036&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b02036&amp;href=/doi/10.1021/acs.jmedchem.8b02036" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2708-2719</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b02032" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00025" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Brian H. White</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian H. White</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#2b495c43425f4e6b5f4a595d4e4f4a5f5305484446"><span class="__cf_email__" data-cfemail="5735203f3e23321723362521323336232f7934383a">[email protected]</span></a>. Phone: (617)-639-1845.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+H.++White">Brian H. White</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kerry Whalen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kerry Whalen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kerry++Whalen">Kerry Whalen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kristina Kriksciukaite</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kristina Kriksciukaite</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kristina++Kriksciukaite">Kristina Kriksciukaite</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rossitza Alargova</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rossitza Alargova</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rossitza++Alargova">Rossitza Alargova</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tsun Au Yeung</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tsun Au Yeung</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tsun++Au+Yeung">Tsun Au Yeung</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Patrick Bazinet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patrick Bazinet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patrick++Bazinet">Patrick Bazinet</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adam Brockman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adam Brockman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adam++Brockman">Adam Brockman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michelle DuPont</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michelle DuPont</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michelle++DuPont">Michelle DuPont</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haley Oller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haley Oller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haley++Oller">Haley Oller</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Charles-Andre Lemelin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Charles-Andre Lemelin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Charles-Andre++Lemelin">Charles-Andre Lemelin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Patrick Lim Soo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patrick Lim Soo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patrick++Lim+Soo">Patrick Lim Soo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Benoît Moreau</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Benoît Moreau</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Beno%C3%AEt++Moreau">Benoît Moreau</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Samantha Perino</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samantha Perino</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samantha++Perino">Samantha Perino</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James M. Quinn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James M. Quinn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+M.++Quinn">James M. Quinn</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gitanjali Sharma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gitanjali Sharma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gitanjali++Sharma">Gitanjali Sharma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rajesh Shinde</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rajesh Shinde</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rajesh++Shinde">Rajesh Shinde</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Beata Sweryda-Krawiec</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Beata Sweryda-Krawiec</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Beata++Sweryda-Krawiec">Beata Sweryda-Krawiec</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard Wooster</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Wooster</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Wooster">Richard Wooster</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Mark T. Bilodeau</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark T. Bilodeau</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark+T.++Bilodeau">Mark T. Bilodeau</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7502-9041" title="Orcid link">http://orcid.org/0000-0001-7502-9041</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b02036&amp;href=/doi/10.1021%2Facs.jmedchem.8b02036" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2708–2719</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 8, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 December 2018</li><li><span class="item_label"><b>Published</b> online</span>8 February 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 March 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b02036" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b02036</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2708%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBrian%2BH.%2BWhite%252C%2BKerry%2BWhalen%252C%2BKristina%2BKriksciukaite%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D5%26contentID%3Dacs.jmedchem.8b02036%26title%3DDiscovery%2Bof%2Ban%2BSSTR2-Targeting%2BMaytansinoid%2BConjugate%2B%2528PEN-221%2529%2Bwith%2BPotent%2BActivity%2Bin%2BVitro%2Band%2Bin%2BVivo%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2719%26publicationDate%3DMarch%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b02036"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1313</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">14</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b02036" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;H. White&quot;},{&quot;first_name&quot;:&quot;Kerry&quot;,&quot;last_name&quot;:&quot;Whalen&quot;},{&quot;first_name&quot;:&quot;Kristina&quot;,&quot;last_name&quot;:&quot;Kriksciukaite&quot;},{&quot;first_name&quot;:&quot;Rossitza&quot;,&quot;last_name&quot;:&quot;Alargova&quot;},{&quot;first_name&quot;:&quot;Tsun&quot;,&quot;last_name&quot;:&quot;Au Yeung&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;Bazinet&quot;},{&quot;first_name&quot;:&quot;Adam&quot;,&quot;last_name&quot;:&quot;Brockman&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;DuPont&quot;},{&quot;first_name&quot;:&quot;Haley&quot;,&quot;last_name&quot;:&quot;Oller&quot;},{&quot;first_name&quot;:&quot;Charles-Andre&quot;,&quot;last_name&quot;:&quot;Lemelin&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;Lim Soo&quot;},{&quot;first_name&quot;:&quot;Benoît&quot;,&quot;last_name&quot;:&quot;Moreau&quot;},{&quot;first_name&quot;:&quot;Samantha&quot;,&quot;last_name&quot;:&quot;Perino&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;M. Quinn&quot;},{&quot;first_name&quot;:&quot;Gitanjali&quot;,&quot;last_name&quot;:&quot;Sharma&quot;},{&quot;first_name&quot;:&quot;Rajesh&quot;,&quot;last_name&quot;:&quot;Shinde&quot;},{&quot;first_name&quot;:&quot;Beata&quot;,&quot;last_name&quot;:&quot;Sweryda-Krawiec&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Wooster&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;T. Bilodeau&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;2708-2719&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b02036&quot;},&quot;abstract&quot;:&quot;Somatostatin receptor 2 (SSTR2) is frequently overexpressed on several types of solid tumors, including neuroendocrine tumors and small-cell lung cancer. Peptide agonists of SSTR2 are rapidly internalized upon binding to the receptor and linking a toxic payload to an SSTR2 agonist is a potential method to kill SSTR2-expressing tumor cells. Herein, we describe our efforts towards an efficacious SSTR2-targeting cytotoxic conjugate; examination of different SSTR2-targeting ligands, conjugation sites, and payloads led to the discovery of 22 (PEN-221), a conjugate consisting of microtubule-targeting agent DM1 linked to the C-terminal side chain of Tyr3–octreotate. PEN-221 demonstrates in vitro activity which is both potent (IC50 = 10 nM) and receptor-dependent (IC50 shifts 90-fold upon receptor blockade). PEN-221 targets high levels of DM1 to SSTR2-expressing xenograft tumors, which has led to tumor regressions in several SSTR2-expressing xenograft mouse models. The safety and efficacy of PEN-221 is currently unde&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b02036&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b02036" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b02036&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b02036" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b02036&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b02036" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b02036&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b02036&amp;href=/doi/10.1021/acs.jmedchem.8b02036" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b02036" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b02036" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b02036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b02036%26sid%3Dliteratum%253Aachs%26pmid%3D30735385%26genre%3Darticle%26aulast%3DWhite%26date%3D2019%26atitle%3DDiscovery%2Bof%2Ban%2BSSTR2-Targeting%2BMaytansinoid%2BConjugate%2B%2528PEN-221%2529%2Bwith%2BPotent%2BActivity%2Bin%2BVitro%2Band%2Bin%2BVivo%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D5%26spage%3D2708%26epage%3D2719%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a>,</li><li><a href="/action/doSearch?ConceptID=291290" title="Conjugate acid-base pairs">Conjugate acid-base pairs</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/jmcmar.2019.62.issue-5/20190314/jmcmar.2019.62.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Somatostatin receptor 2 (SSTR2) is frequently overexpressed on several types of solid tumors, including neuroendocrine tumors and small-cell lung cancer. Peptide agonists of SSTR2 are rapidly internalized upon binding to the receptor and linking a toxic payload to an SSTR2 agonist is a potential method to kill SSTR2-expressing tumor cells. Herein, we describe our efforts towards an efficacious SSTR2-targeting cytotoxic conjugate; examination of different SSTR2-targeting ligands, conjugation sites, and payloads led to the discovery of 22 (PEN-221), a conjugate consisting of microtubule-targeting agent DM1 linked to the C-terminal side chain of Tyr<sup>3</sup>–octreotate. PEN-221 demonstrates in vitro activity which is both potent (IC<sub>50</sub> = 10 nM) and receptor-dependent (IC<sub>50</sub> shifts 90-fold upon receptor blockade). PEN-221 targets high levels of DM1 to SSTR2-expressing xenograft tumors, which has led to tumor regressions in several SSTR2-expressing xenograft mouse models. The safety and efficacy of PEN-221 is currently under evaluation in human clinical trials.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68474" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68474" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Antibody-drug conjugates (ADCs) have shown promise in improving the therapeutic index of anticancer agents through selective targeting of active agents to tumor cells while lowering systemic toxicity. The approval of brentuximab vedotin,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> trastuzumab emtansine,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and inotuzumab ozogamicin<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> have demonstrated the value of antibody-directed therapies in the treatment of patients with cancer. However, despite the clinical promise ADCs have demonstrated, several challenges preclude their use in the treatment of patients with solid tumors. Solid tumors are frequently poorly vascularized<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and the rate of diffusion of antibodies through solid tumor tissue is extremely slow,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> which can lead to low levels of ADC uptake within solid tumors.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> A potential alternative approach to ligand-directed therapies of solid tumors is the use of miniaturized constructs, such as peptide- or small molecule-drug conjugates.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Although small (>5 kDa) constructs typically suffer from poor pharmacokinetics, their ability to rapidly diffuse through solid tumor tissue frequently allows for extremely high levels of targeted construct uptake into solid tumors.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">Somatostatin is a peptide hormone produced by paracrine cells within the gastrointestinal tract, lungs, pancreas, and the central nervous system. Somatostatin is produced in two active forms (SST14 and SST28), and the biological effects include neurotransmission, inhibition of gastrointestinal endocrine secretion, and cell proliferation. These effects are produced by somatostatin’s interaction with five somatostatin receptors (SSTR1–5). Although somatostatin itself is cleared within minutes in vivo,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> investigations into peptide analogues of somatostatin have yielded longer-lived peptide analogues selective for all somatostatin receptor subtypes.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Of particular note is the peptide analogue octreotide,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> a long-lasting SSTR2 agonist that inhibits secretion of growth hormone through its action at SSTR2 and is approved for use for treatment of acromegaly and symptomatic treatment of patients with carcinoid tumors.</div><div class="NLM_p last">In addition to its role in the endocrine system, SSTR2 is overexpressed on the cell surface of various types of solid tumors, including small-cell lung cancers,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> gastroenteropancreatic neuroendocrine tumors,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> carcinoids, and islet cell tumors.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Expression of SSTR2 is limited outside the central nervous system and since SSTR2 agonists are rapidly internalized into SSTR2-expressing cells upon receptor engagement,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> SSTR2-mediated drug targeting represents a promising method to deliver compounds into SSTR2-expressing tumors.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> As part of our ongoing effort to explore miniaturized drug conjugates that can rapidly target chemotoxic payloads to solid tumors, we set out to develop an SSTR2-targeted peptide-payload construct that demonstrated SSTR2-mediated cytotoxicity and was able to induce tumor regressions of several different SSTR2-expressing xenografts.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33620" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33620" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis</h3><div class="NLM_p">Initial conjugates were constructed by linking SSTR2 agonist octreotide to various commercially available cytotoxic payloads. Because the accumulation of the active agent would be limited by number of copies of SSTR2 expressed at the cell surface, potent cytotoxic payloads were examined to ensure that payload delivered via receptor-mediated endocytosis would be sufficient to kill the tumor cell. Microtubule-targeting agents DM1,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> cabazitaxel,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and monomethyl auristatin E<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (MMAE) were selected as potential payloads; synthesis of the corresponding disulfide-linkable constructs <b>1</b>, <b>2</b>, and <b>3</b> are shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Because cabazitaxel and MMAE require linking through nonthiol heteroatoms, a disulfide carbonate or carbamate linker<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> was employed for these payloads. In addition, maleimide <b>5</b> containing DM1 linked through a lysosomally-cleaved Gly–Phe–Leu–Gly sequence<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> was synthesized.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0015.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Payload/Linker Combinations<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2,2′-dipyridyldisulfide, dimethylformamide (DMF), AcOH, 0.2 M NaOAc; (b) 2-(2-pyridinyldithio)ethanol <i>p</i>-nitrophenyl carbonate, 4-dimethylaminopyridine (DMAP), dichloromethane (DCM); (c) 2-(2-pyridinyldithio)ethanol <i>p</i>-nitrophenyl carbonate, DMF, diisopropylethylamine; (d) dicyclohexyl carbodiimide, <i>N</i>-hydroxysuccinimide, DMF, 3-aminopropylmaleimide, diisopropylethylamine; (e) trifluoroacetic acid (TFA); (f) DM1, DMF, pH 5.6 acetate buffer; and (g) 6-maleimidohexanoic acid isobutyl carbonic anhydride, DMF, pyridine, 0 °C.</p></p></figure><div class="NLM_p">Octreotide was then derivatized with a protected thiol for conjugation to the thiol-reactive payload derivatives (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Selective protection of the lysine side chain with a Boc group, following reductive amination with <i>S</i>-trityl-3-mercaptopropionaldehyde provided <b>6a</b>. Global deprotection and reaction of the free thiol at the N-terminus with the appropriate payload provided DM1 conjugate <b>7</b>, cabazitaxel conjugate <b>8</b>, MMAE conjugate <b>9</b>, and protease-cleavable DM1 conjugate <b>10</b>. A protected thiol was appended to the N-terminus of vapreotide<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and Tyr<sup>3</sup>–octreotate analogously to <b>7</b>. In addition, cyclic 6-mer peptide <b>13</b><a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> with a pendant thiol was made via solid phase synthesis. Conjugation of these ligands with DM1 yielded vapreotide conjugate <b>11</b>, Tyr<sup>3</sup>–octreotate conjugate <b>12</b>, and cyclic 6-mer conjugate <b>14</b>, respectively.</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Octreotide, Vapreotide, Tyr<sup>3</sup>–Octreotate, and Cyclic 6-mer Conjugates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BocOSu, DMF, −40 °C to room temperature; (b) <i>S</i>-trityl 3-mercaptopropionaldehyde, NaBH(OAc)<sub>3</sub>; (c) TFA, triisopropylsilane; (d) <b>1</b>, DMF, pH 7.4 phosphate buffer; (e) <b>2</b>, DMF, pH 5.6 acetate buffer; (f) <b>3</b>, DMF, pH 5.6 acetate buffer; (g) <b>5</b>, DMF, pH 5.6 acetate buffer; (h) iterative solid phase peptide synthesis (SPPS) with: <i>N</i>α-fluorenylmethyloxycarbonyl (Fmoc)-<i>N</i>ε-Boc-lysine, <i>N</i>α-Fmoc-N<sup>in</sup>-Boc-<span class="smallcaps smallerCapital">d</span>-tryptophan, Fmoc-tyrosine(<i>t</i>Bu), <i>N</i>α-Fmoc-<i>N</i>ε-(<i>S</i>-trityl-3-mercaptopropionate)-lysine, Fmoc-phenylalanine; (i) 1% TFA in DCM; (j) <i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate (HATU), 1-hydroxy-7-azabenzotriazole, DMF, <i>i</i>Pr<sub>2</sub>NEt; and (k) 95:2.5:2.5 TFA/1,2-ethanedithiol (EDT)/water.</p></p></figure><div class="NLM_p">Additional Tyr<sup>3</sup>–octreotate/DM1 conjugates were synthesized by selecting alternative conjugation points on Tyr<sup>3</sup>–octreotate that maintained the Tyr–DTrp–Lys–Thr SSTR2 binding pharmacophore (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Thus, Tyr<sup>3</sup>–octreotate analogues were synthesized containing protected thiols on the N-terminal side chain (<b>16</b>), C-terminus (<b>18</b>), or an activated disulfide bond on the C-terminal side chain (<b>21</b>). Subsequent conjugation of DM1 provided N-terminal side chain conjugate <b>17</b>, the C-terminal conjugate <b>19</b>, and the C-terminal side chain conjugate <b>22</b>.</div><figure id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Tyr<sup>3</sup>–Octreotate/DM1 Conjugates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) iterative SPPS with Fmoc-<i>S</i>-trityl-cysteine, Fmoc-threonine(<i>t</i>Bu), <i>N</i>α-Fmoc-<i>N</i>ε-Boc lysine, <i>N</i>α-Fmoc-<i>N</i><sup>in</sup>-Boc-<span class="smallcaps smallerCapital">d</span>-tryptophan, Fmoc-tyrosine(<i>t</i>Bu), Fmoc-<i>S</i>-trityl-cysteine; (b) 95:2.5:2.5 TFA/EDT/water; (c) I<sub>2</sub>, CH<sub>3</sub>CN/water; (d) Boc<sub>2</sub>O, <i>i</i>Pr<sub>2</sub>NEt, DMF; (e) Et<sub>2</sub>NH, DCM; (f) Boc-<i>O</i>-(<i>S</i>-trityl-2-mercaptoethyl)-<span class="smallcaps smallerCapital">d</span>-tyrosine <i>N</i>-hydroxysuccinimide ester, DMF, <i>i</i>Pr<sub>2</sub>NEt; (g) TFA, iPr<sub>3</sub>SiH; (h) <b>1</b>, DMF, <i>i</i>Pr<sub>2</sub>NEt; (i) Boc<sub>2</sub>O, DMF, <i>i</i>Pr<sub>2</sub>NEt; (j) <i>S</i>-trityl cysteamine HCl, DMF, HATU, <i>i</i>Pr<sub>2</sub>NEt; (k) iterative SPPS with: Fmoc-threonine(<i>t</i>Bu), <i>N</i>α-Fmoc-<i>N</i>ε-Boc lysine, <i>N</i>α-Fmoc-<i>N</i><sup>in</sup>-Boc-<span class="smallcaps smallerCapital">d</span>-tryptophan, Fmoc-tyrosine(<i>t</i>Bu), Fmoc-<i>S</i>-trityl-cysteine, Boc-<span class="smallcaps smallerCapital">d</span>-phenylalanine; (l) I<sub>2</sub>, DMF; (m) 20% trifluoroethanol in DCM; (n) HATU, CH<sub>2</sub>Cl<sub>2</sub>, <i>S</i>-trityl-cysteine amide, <i>i</i>Pr<sub>2</sub>NEt; (o) 2,2′-dithiodipyridine, 1,1,3,3-tetramethyldisiloxane, trifluoroethanol, 12N HCl; and (p) DM1, THF, pH 3.7 acetate buffer.</p></p></figure><div class="NLM_p">Additional SSTR2-targeting conjugates linked at the C-terminal side chain were synthesized as shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Modification of the C-terminal amino acid and appending DM1 resulted in conjugates <b>27</b>–<b>30</b>. Additional payloads were also appended onto the C-terminal side chain; conjugation of DM4,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> cabazitaxel, or MMAE resulted in conjugates <b>31</b>, <b>33</b>, and <b>34</b> respectively. In addition, conjugation of DM1 through a maleimide resulted in noncleavable conjugate <b>32</b>. Finally, a nonbinding control conjugate <b>37</b> was synthesized (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of C-Terminal Side Chain Conjugates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HATU, CH<sub>2</sub>Cl<sub>2</sub>, TrtS–CH<sub>2</sub>–CH(R)–NH<sub>2</sub>; (b) 2,2′-dithiodipyridine, 1,1,3,3-tetramethyldisiloxane, trifluoroethanol, 12N HCl; (c) HATU, CH<sub>2</sub>Cl<sub>2</sub>, TrtS–CR<sub>2</sub><sup>2</sup>–CH(R<sup>1</sup>)–NH<sub>2</sub><i>i</i>Pr<sub>2</sub>NEt; (d) TFA, thioanisole, water, triisopropylsilane; (e) Dap(Dde)-NH<sub>2</sub>, HATU, CH<sub>2</sub>Cl<sub>2</sub>, <i>i</i>Pr<sub>2</sub>NEt; (f) hydrazine, DMF; (g) maleimidoacetic acid, HATU, CH<sub>2</sub>Cl<sub>2</sub>; (h) 92.5:2.5:2.5:2.5 TFA/thioanisole/water/triisopropylsilane; (i) DM1, DMF, pH 4.6 acetate buffer; (j) <b>1</b>, DMF, pH 4.6 acetate buffer; (k) <b>1</b>, DMF, pH 7.4 phosphate buffer; (l) DM4, DMF, pH 7.4 phosphate buffer; (m) DM1, DMF, 0.2 M NaOAc; (n) <b>2</b>, DMF, pH 5.6 acetate buffer; and (o) <b>3</b>, DMF, pH 5.6 acetate buffer.</p></p></figure><figure id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Nonbinding Control<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) iterative SPPS with Fmoc-threonine(<i>t</i>Bu), <i>N</i>α-Fmoc-<i>N</i>ε-Boc lysine, <i>N</i>α-Fmoc-<i>N</i><sup>in</sup>-Boc-<span class="smallcaps smallerCapital">d</span>-tryptophan, Fmoc-tyrosine(<i>t</i>Bu), Fmoc-<i>S</i>-trityl-cysteine, Fmoc-<span class="smallcaps smallerCapital">d</span>-phenylalanine; (b) 92.5:2.5:2.5:2.5 TFA/thioanisole/water/triisopropylsilane; (c) I<sub>2</sub>, CH<sub>3</sub>CN/water; (d) <i>N</i>-Boc-<i>N</i>′-(4-nitrophenylcarbamate)-1,6-hexanediamine, THF, <i>i</i>Pr<sub>2</sub>NEt, DMAP, 50 °C; (e) <i>S</i>-trityl-cysteine amide, DMF, HATU, <i>i</i>Pr<sub>2</sub>NEt; (f) piperidine, DMF; (g) TFA, triisopropylsilane; and (h) <b>1</b>, DMF, pH 7.4 phosphate buffer.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Biological Data</h3><div class="NLM_p">Each conjugate was evaluated for SSTR2 affinity by displacement of [I<sup>125</sup>]Tyr<sup>11</sup>-SST14 from isolated membrane fractions of SSTR2-expressing CHO-K1 cells. In addition, in vitro cytotoxicity of the octreotide conjugates was assessed in SSTR2-expressing NCI-H524 cells. Each conjugate was incubated with NCI-H524 cells for 2 h either alone or in the presence of 100 μM octreotide, followed by washout and a further 70 h incubation; a typical in vitro experiment is shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. Incubations in the presence of octreotide were performed to fully occupy cell surface SSTR2 and prevent receptor-mediated uptake of the conjugate. A shift in potency under receptor blockade, compared with conjugate alone, was considered crucial in demonstrating that the cytotoxic effects of the conjugate are dependent on receptor binding and internalization. In vitro data for compounds <b>7–12</b>, <b>14</b>, <b>17</b>, <b>19</b>, and <b>22</b> are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><figure id="fig1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0013.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Payload and conjugate cytotoxicity of <b>7</b> and <b>8</b> in NCI-H524 cells with and without receptor blockade, plus their respective payloads.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SSTR2 Binding Data and H524 Cell Assay Data for <b>7</b>–<b>12</b>, <b>14</b>, <b>17</b>, <b>19</b>, <b>22</b>, Payloads, and SST14</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">structure<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">SSTR2 K<sub>i</sub> (pM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">H524 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">H524 IC<sub>50</sub> w/blockade (nM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">DM1-S(CH<sub>2</sub>)<sub>3</sub>-DPhe-[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">221</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">MMAE-CO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>SS(CH<sub>2</sub>)<sub>3</sub>-DPhe-[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol</td><td class="colsep0 rowsep0" align="left">770</td><td class="colsep0 rowsep0" align="left">150</td><td class="colsep0 rowsep0" align="left">157</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">cabazitaxel-CO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>SS(CH<sub>2</sub>)<sub>3</sub>-DPhe-[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol</td><td class="colsep0 rowsep0" align="left">260</td><td class="colsep0 rowsep0" align="left">1473</td><td class="colsep0 rowsep0" align="left">560</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">DM1-Mal-GLFG-MC-S(CH<sub>2</sub>)<sub>3</sub>-DPhe-[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol</td><td class="colsep0 rowsep0" align="left">140</td><td class="colsep0 rowsep0" align="left">75</td><td class="colsep0 rowsep0" align="left">202</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">DM1-S(CH<sub>2</sub>)<sub>3</sub>-DPhe-[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">190</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">115</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">DM1-S(CH<sub>2</sub>)<sub>3</sub>-DPhe-[Cys-Tyr-DTrp-Lys-Thr-Cys]-Thr-OH</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">757</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">DM1-S(CH<sub>2</sub>)<sub>2</sub>CO-[NMeLys-Tyr-DTrp-Lys-Thr-Phe]</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">865</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">DTyr(CH<sub>2</sub>CH<sub>2</sub>SDM1)-[Cys-Tyr-DTrp-Lys-Thr-Cys]-Thr-OH</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">198</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">DPhe-[Cys-Tyr-DTrp-Lys-Thr-Cys]-Thr-NHCH<sub>2</sub>CH<sub>2</sub>S-DM1</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">528</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">DPhe-[Cys-Tyr-DTrp-Lys-Thr-Cys]-Cys(DM1)-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">910</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DM1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">n/a</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">n/a</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MMAE</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">n/a</td><td class="colsep0 rowsep0" align="left">3.7</td><td class="colsep0 rowsep0" align="left">n/a</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cabazitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">n/a</td><td class="colsep0 rowsep0" align="left">0.26</td><td class="colsep0 rowsep0" align="left">n/a</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SST14</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">n/a</td><td class="colsep0 rowsep0" align="left">n/a</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Brackets indicate peptide cyclization. Parentheses after amino acids indicate side chain substitution. Mal = 3-aminopropylmaleimide, MC = maleimidocaproyl.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">All values determined in duplicate. n/a = not applicable.</p></div></div></div><div class="NLM_p">The performance of these conjugates that utilize octreotide as the targeting ligand was noticeably affected by the payload; whereas DM1 conjugate <b>7</b> showed potency near that of payload alone, the potency of both cabazitaxel conjugate <b>8</b> and MMAE conjugate <b>9</b> were several orders of magnitude worse than their respective payloads. Additionally, only <b>7</b> exhibited any signs of receptor-dependent cytotoxicity. The receptor affinity was also clearly affected by the payload, as both <b>8</b> and <b>9</b> had lower affinity for SSTR2 than DM1 conjugate <b>7</b>. Although replacement of the disulfide linker with a protease-cleavable linker (<b>10</b>) did not significantly change the receptor affinity, it was less potent in the NCI-H524 cellular assay, indicating that disulfide linkers might be optimal for release upon SSTR2-mediated internalization.</div><div class="NLM_p">Although conjugate <b>7</b> demonstrated initial signs of receptor-dependent cytotoxicity, the receptor affinity was significantly worse than native ligand SST14. Given that conjugates may have to compete against endogenous somatostatin for uptake in SSTR2-expressing cells, and the knowledge that tumor uptake of small molecule-drug conjugates is predicted to track with receptor affinity,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> it was important to examine alternative SSTR2-targeting ligands to improve receptor affinity. The Tyr<sup>3</sup>–octreotate targeting ligand of conjugate <b>12</b> clearly provided superior receptor affinity compared to octreotide conjugate <b>7</b>, following the pattern observed with radiolabeled conjugates.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Conjugate <b>12</b> also provided the largest window between cellular potency of the conjugate and potency under receptor blockade. Vapreotide conjugate <b>11</b> appeared nearly as potent in the cellular assay, but this potency did not shift nearly as much under receptor blockade, indicating that some of the cellular potency may come from either passive permeability of the more lipophilic ligand or conjugate instability and extracellular release of the payload under the assay conditions. Cyclic 6-mer targeting ligand conjugate <b>14</b> did not demonstrate any noticeable advantages to octreotide conjugate <b>7</b> in terms of in vitro properties.</div><div class="NLM_p">Examination of Tyr<sup>3</sup>–octreotate conjugates linked to DM1 at sites other than the N-terminus shows that substitution at either the N-terminal side chain (<b>17</b>) or C-terminal side chain (<b>22</b>) maintained receptor affinity and cellular potency compared to N-terminal conjugate <b>12</b>. Only C-terminal conjugate <b>19</b> showed inferior receptor affinity and cellular potency among Tyr<sup>3</sup>–octreotate/DM1 conjugates. To differentiate these conjugates, several compounds were evaluated in vivo for their ability to target DM1 to SSTR2-expressing NCI-H69 tumors. Selected conjugates were administered to NCI-H69 tumor-bearing mice at 1 mg/kg iv, whereas unconjugated DM1 was dosed as a control at 0.4 mg/kg. At 24 h, tumors were excised and treated with excess tris-2-carboxyethylphosphine (TCEP) to reduce any disulfide bonds. The resulting free thiols were trapped with <i>N</i>-ethylmaleimide (NEM) and the total DM1–NEM adduct levels were measured. Values normalized for total DM1 dose are presented in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. Conjugates <b>7</b>, <b>11</b>, and <b>19</b>, each with SSTR2 affinity >100 pM, exhibited equal, or only slightly superior, DM1 tumor accumulation compared with untargeted DM1. Tyr<sup>3</sup>–octreotate conjugates <b>12</b>, <b>17</b>, and <b>22</b> were superior to other targeting ligand DM1 conjugates. Importantly, conjugate <b>22</b> demonstrated the greatest ability to deliver DM1 to an SSTR2-expressing tumor.</div><figure id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0014.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Dose-normalized DM1 levels in NCI-H69 tumors 24 h after conjugate dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additional conjugates with payloads conjugated at the C-terminal side chain are shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Modification of the C-terminal amide of <b>22</b> to an acid (<b>27</b>) or amino alcohol (<b>29</b>) maintained receptor affinity, but noticeably reduced potency in NCI-H524 cells. Complete removal of the C-terminal amide (<b>28</b>) maintained cellular potency, but reduced receptor affinity.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Data for Compounds <b>22</b>, <b>27</b>–<b>34</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0012.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center" char=".">SSTR2 K<sub>i</sub> (pM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">H524 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">H524 IC<sub>50</sub> w/blockade (nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">S-DM1</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">910</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">CO<sub>2</sub>H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">S-DM1</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">183</td><td class="colsep0 rowsep0" align="char" char=".">1597</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">S-DM1</td><td class="colsep0 rowsep0" align="char" char=".">61</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">692</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">S-DM1</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">42</td><td class="colsep0 rowsep0" align="char" char=".">1389</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">S-DM1</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">1041</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">S-DM4</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="char" char=".">581</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NH-MalAc-DM1<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">140</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char=".">2524</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">SSCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>-cabazitaxel</td><td class="colsep0 rowsep0" align="char" char=".">970</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">SSCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>-MMAE</td><td class="colsep0 rowsep0" align="char" char=".">180</td><td class="colsep0 rowsep0" align="char" char=".">1258</td><td class="colsep0 rowsep0" align="char" char=".">1427</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">MalAc = maleimidoacetate.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">All values determined in duplicate.</p></div></div></div><div class="NLM_p">Slower releasing hindered disulfides were also examined.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Appending a gem-dimethyl group on the payload side by using DM4<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> rather than DM1 (<b>31</b>) resulted in reduced cellular potency and receptor affinity. However, placing the gem-dimethyl group on the ligand side of the disulfide bond by utilizing penicillamine as the linking amino acid rather than cysteine (<b>30</b>) showed in vitro properties similar to <b>22</b>. Noncleavable DM1 conjugate <b>32</b> does demonstrate receptor-dependent cytotoxicity, showing that the release of free payload is not strictly necessary for toxicity, however, conjugate <b>32</b> was significantly less potent than disulfide-linked conjugates <b>22</b> and <b>30</b>.</div><div class="NLM_p">We investigated if the C-terminal side chain conjugation site of <b>22</b> was amenable to delivery of other microtubule agent payloads. Analogues of <b>22</b>, where the payload has been replaced by either cabazitaxel (<b>33</b>) or MMAE (<b>34</b>), show that the in vitro properties of conjugates linked at the C-terminal side chain are payload-dependent. The SSTR2 binding affinity of both <b>33</b> and <b>34</b> was dramatically reduced compared to <b>22</b>, and neither exhibited much receptor-dependent cytotoxicity. To evaluate if this reduced binding affinity obtained with other payloads had functional consequences for SSTR2 activity, we examined <b>22</b> and <b>33</b> in an SSTR2 internalization assay (DiscoverX) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). While DM1 conjugate <b>22</b> is more efficacious than native ligand SST28 at inducing receptor internalization, the cabazitaxel conjugate <b>33</b> was much less potent at inducing receptor internalization, demonstrating that the inferior receptor affinity of <b>33</b> also leads to reduced SSTR2 agonist activity. Thus, although the C-terminal side chain of Tyr<sup>3</sup>–octreotate appears to be an excellent site for DM1 conjugation, the effectiveness of this conjugation site does not translate for other payloads.</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. SSTR2 internalization by <b>22</b>, <b>33</b>, and SST28.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further explore the importance of the release rate of the disulfide linker, <b>22</b> and <b>30</b> were examined in several additional in vitro and in vivo studies. Stability experiment of both compounds in 5 mM glutathione (GSH) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) demonstrated that <b>30</b> possessed better stability to reducing conditions. However, side-by-side comparisons of both <b>22</b> and <b>30</b> in beagle dog (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) show that the increased stability of the linker does not dramatically affect pharmacokinetics. Although <b>30</b> had a modestly higher area under the curve (AUC) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), this change is only 1.6-fold, suggesting that the stability of the linker is not the major metabolic liability of <b>22</b>. In an SSTR2-expressing NCI-H69 mouse xenograft (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), both <b>22</b> and <b>30</b> were able to induce complete regressions at 2.0 mg/kg iv without any body weight loss (see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b02036/suppl_file/jm8b02036_si_001.csv" class="ext-link">Supporting Information</a>); however, <b>22</b> was more potent at 1.3 mg/kg. Thus, the improved stability of <b>30</b> and its modestly better plasma pharmacokinetics did not translate into greater efficacy.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Stability of <b>22</b> and <b>30</b> in 5 mM GSH at 37 °C.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Beagle dog pharmacokinetics (<i>n</i> = 1) of 0.1 mg/kg <b>22</b> and <b>30</b> iv.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>22</b> and <b>30</b> in NCI-H69 xenograft efficacy. Arrows indicate dosing days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Select Beagle Dog PK Parameters</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center" char="."><b>22</b></th><th class="colsep0 rowsep0" align="center" char="."><b>30</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">2.33</td><td class="colsep0 rowsep0" align="char" char=".">1.38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μmol/L)</td><td class="colsep0 rowsep0" align="char" char=".">0.708</td><td class="colsep0 rowsep0" align="char" char=".">0.867</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC 0–6 h (μmol/(L h))</td><td class="colsep0 rowsep0" align="char" char=".">0.470</td><td class="colsep0 rowsep0" align="char" char=".">0.769</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL/(kg min))</td><td class="colsep0 rowsep0" align="char" char=".">1.66</td><td class="colsep0 rowsep0" align="char" char=".">1.09</td></tr></tbody></table></div></div><div class="NLM_p">To demonstrate in vivo receptor dependence of <b>22</b>, it was compared with conjugate <b>37</b>, which is structurally similar but with the lysine residue of the SSTR2 binding pharmacophore capped with a 1,6-hexanediamine urea. This particular capping group was selected to keep the overall charge and lipophilicity of <b>37</b> similar to that of <b>22</b>. However, this modification of the lysine residue almost completely abolished SSTR2 binding as well as receptor-dependent cytotoxicity (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Conjugate <b>37</b> (0.7 mg/kg iv) was not efficacious in an NCI-H69 xenograft model (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <b>22</b> and <b>37</b> in NCI-H69 xenograft efficacy. Arrows indicate dosing days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SSTR2 Binding Data and H524 Cell Assay Data of <b>22</b> and Its Nonbinding Control <b>37</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">SSTR2 K<sub>i</sub></th><th class="colsep0 rowsep0" align="center" char=".">H524 IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">H524 IC<sub>50</sub> w/blockade (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">22 pM</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">910</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">3.35 μM</td><td class="colsep0 rowsep0" align="char" char=".">581</td><td class="colsep0 rowsep0" align="char" char=".">644</td></tr></tbody></table></div></div><div class="NLM_p">Conjugate <b>22</b> was tested for binding against all five somatostatin receptor isoforms, indicating good selectivity for SSTR2 (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). While binding to SSTR2 is close to that of the native ligand SST14, SSTR5 binding is 30-fold lower than the native ligand, and binding to all other isoforms is >600-fold lower than the native ligand. In addition, <b>22</b> was examined for selectivity against other G protein coupled receptors (GPCRs); <b>22</b> was evaluated against a panel of 119 GPCRs, examining for both agonist and antagonist activity. Conjugate <b>22</b> was inactive against all GPCRs in this panel except for SSTR2 and SSTR5 (see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b02036/suppl_file/jm8b02036_si_002.pdf" class="ext-link">Supporting Information</a>). In addition, the passive permeability of <b>22</b> was extremely low (Caco-2 A–B <i>P</i><sub>app</sub> = 0.018 × 10<sup>–6</sup> cm/s), indicating that the entry of <b>22</b> into non-SSTR2 expressing cells, either through other receptors or passive diffusion, would be minimal. The activity of <b>22</b> was also examined in other SSTR2-positive xenografts. Conjugate <b>22</b> demonstrated complete regressions in HCC-33 small-cell lung carcinoma xenografts at 1.0 mg/kg iv and IMR-32 neuroblastoma xenografts at 1.5 mg/kg iv (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><figure id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0011.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <b>22</b> in HCC-33 (top) and IMR-32 (bottom) xenografts. Arrows indicate dosing days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SSTR2 Selectivity of <b>22</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">SSTR1 K<sub>d</sub></th><th class="colsep0 rowsep0" align="center">SSTR2 K<sub>d</sub></th><th class="colsep0 rowsep0" align="center">SSTR3 K<sub>d</sub></th><th class="colsep0 rowsep0" align="center">SSTR4 K<sub>d</sub></th><th class="colsep0 rowsep0" align="center">SSTR5 K<sub>d</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">310 nM</td><td class="colsep0 rowsep0" align="left">16 pM</td><td class="colsep0 rowsep0" align="left">19.8 nM</td><td class="colsep0 rowsep0" align="left">5.48 μM</td><td class="colsep0 rowsep0" align="left">9.6 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SST14</td><td class="colsep0 rowsep0" align="left">290 pM</td><td class="colsep0 rowsep0" align="left">5 pM</td><td class="colsep0 rowsep0" align="left">32 pM</td><td class="colsep0 rowsep0" align="left">200 pM</td><td class="colsep0 rowsep0" align="left">320 pM</td></tr></tbody></table></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02045" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02045" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have examined several SSTR2 agonist ligands, conjugation sites, and microtubule agent payloads for their ability to target payloads to SSTR2-expressing cells. Optimization for receptor affinity and receptor-dependent cellular potency have led to the discovery PEN-221 (<b>22</b>), a novel maytansinoid-containing conjugate targeted to SSTR2. Uniquely among SSTR2-targeting peptide conjugates, the payload of <b>22</b> is conjugated at the C-terminal side chain, which allows for good receptor affinity and excellent levels of DM1 delivered into SSTR2-expressing tumors. Conjugate <b>22</b> has excellent affinity for SSTR2, is very potent at inducing receptor internalization, and has good selectivity for SSTR2 over other somatostatin receptor subtypes as well as other GPCRs. PEN-221 (<b>22</b>) is able to induce regressions in several SSTR2-expressing xenograft models and is currently being evaluated in human clinical trials.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45007" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45007" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemistry General Methods</h3><div class="NLM_p last">DM1, DM4, and MMAE were purchased from Ontario Chemicals, cabazitaxel was purchased from Indena, octreotide and vapreotide were purchased from ChemPep, Tyr<sup>3</sup>–octreotate was synthesized at ChemPartner, and all other reagents were purchased from Chem-Impex, Sigma-Aldrich, Fisher Scientific, or Ark Pharm, and used without further purification. Solid phase peptide synthesis was carried out on a CEM Liberty Blue peptide synthesizer. All silica gel chromatography was carried out on RediSep Rf Gold silica gel disposable flask columns (20–40 μm) on a Teledyne Isco combiflash system. Reverse phase chromatography was carried out on RediSep Rf Gold C18 reverse phase columns (20–40 μm) and preparative HPLC purification was done on a Waters Sunfire C18 OBD Prep HPLC column, 100 Å, 5 μm, 30 × 150 mm. Final compounds were lyophilized on an SP Scientific Benchtop Pro 9 EL lyophilizer. Chemical purities were >95% for all final compounds, as assessed by an Agilent 1100 LC-MS with an Agilent Eclipse Plus C18 column, 3.5 μm, 4.6 × 100 mM, with detection at 254 and 280 nm. Mass spectrometry data were gathered on an Agilent G1946D mass spectrometer with electrospray ionization. Procedures for the synthesis of compounds <b>1</b>–<b>19</b> and <b>23</b>–<b>37</b> are in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b02036/suppl_file/jm8b02036_si_001.csv" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Radioligand Binding Assays</h3><div class="NLM_p last">Radioligand binding assays were performed at Eurofins Discovery Services, Taipei. CHO-K1 cells stably transfected with a plasmid encoding the desired human somatostatin receptor were used to prepare membranes in modified 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid pH 7.4 buffer using standard techniques. An aliquot (1 μg for SSTR1, 0.1 μg for SSTR2, 0.375 μg for SSTR3, 0.25 μg for SSTR4, 2 μg for SSTR5) of membrane was incubated with 0.03 nM (SSTR2) or 0.1 nM (all other SSTRs) [<sup>125</sup>I]somatostatin for either 240 min (SSTR2) or 120 min (all other SSTRs) at 25 °C. Nonspecific binding was estimated in the presence of 1 μM somatostatin. Membranes were filtered and washed three times and the filters were counted to determine specifically bound [<sup>125</sup>I]somatostatin. Compound treatment was performed at six concentrations, with 10 nM as the highest concentration and 5-fold dilutions for SSTR2, 10 μM and 3-fold dilutions for SSTR1 and SSTR4, or 1 μM and 10-fold dilutions for SSTR3 and SSTR5.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Cytotoxicity Assay</h3><div class="NLM_p last">NCI-H524 (ATCC) human lung cancer cells were plated in 96 well, V-bottomed plates (Costar) at a concentration of 5000 cells/well and 24 h later were treated with the compound for 2 h. The starting dose of the compound was 10 μM and 3-fold serial dilutions were performed for a total of ten points. For experiments with octreotide competition, the cells were first treated with 100 μM octreotide acetate (Chempep) for 30 min and then treated with the compound as above. After 2 h compound treatment, the cells were spun down, the drug containing media was removed and fresh complete medium was added and used to resuspend the cells, which were spun again. After removal of the wash media, the cells were resuspended in complete medium and then transferred into white walled, flat bottomed 96 well plates. The cells were further incubated for an additional 70 h to measure inhibition of cell proliferation. Proliferation was measured using the Cell Titer Glo reagent using the standard protocol (Promega) and a Glomax multi + detection system (Promega). Percent proliferation inhibition was calculated using the following formula: % inhibition = (control – treatment)/control × 100. Control is defined as vehicle alone. IC<sub>50</sub> curves were generated using nonlinear regression analysis (four parameter) with GraphPad Prism 6.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Xenograft Studies</h3><div class="NLM_p last">All studies were conducted in accordance with the Tarveda Therapeutics Institutional Animal Care and Use Committee (IACUC). All mice were treated in accordance with the OLAW Public Health Service Policy on Human Care and Use of Laboratory Animals and the ILAR Guide for the Care and Use of Laboratory Animals. To establish a subcutaneous xenograft model, NCI-H69 (ATCC) human small-cell lung cancer cells or HCC-33 (ATCC) human small-cell lung cancer cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum, or IMR-32 (ATCC) neuroblastoma cancer cells were cultured in Eagle’s minimum essential medium containing 10% fetal bovine serum. The cells were cultured in tissue culture flasks in a humidified incubator at 37 °C, in an atmosphere of 5% CO<sub>2</sub> and 95% air. The cells were harvested, centrifuged, and resuspended in media and Matrigel (1:1 ratio) at a concentration of 2.5 × 10<sup>7</sup> cells/mL. Female athymic nude mice (CrTac:NCr-Foxn1nu, Taconic) were implanted subcutaneously in the right flank with 2.5 × 10<sup>6</sup> cells (NCI-H69, HCC-33) or 1 × 10<sup>7</sup> cells (IMR-32). When tumors reached a volume of 150–250 mm<sup>3</sup> mice were randomized into groups of 10 with a similar mean tumor size. Compounds were formulated at the desired dose in 10% propylene glycol in 5 mM citrate buffer (pH = 4) for NCI-H69 xenografts or 0.1% Solutol HS 15/5% mannitol/water for injection (WFI) for HCC-33 and IMR-32 xenografts. Mice received intravenous injection of compound into the tail vein on days indicated. The tumor volume was measured in two dimensions using calipers and the volume was calculated using the formula: (<i>w</i><sup>2</sup> × <i>l</i>)/2 = mm<sup>3</sup>. The results were plotted as the mean tumor volume ± standard error of the mean of each group over time.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> DM1 Analysis in NCI-H69 Tumors</h3><div class="NLM_p">NCI-H69 tumors were established as above. When tumors reached a volume of 250–600 mm<sup>3</sup>, mice were randomized into groups of 3. Compounds were formulated in either 10% propylene glycol in WFI (DM1) or 10% propylene glycol in 5 mM citrate buffer pH = 4 (all others). Twenty-four hours after dosing, tumors were excised, weighed, and 0.1 M of ammonium bicarbonate buffer pH 8.0 (Fisher Scientific) was added to the tumors at the ratio of 1:4 (w/v). The samples were kept on ice and homogenized for 20–30 s each or until no intact tissue was observed. DM1 stock solution in methanol (Fisher Scientific) was used to prepare standards and assay controls in the blank NCI-H69 tumor homogenate.</div><div class="NLM_p last">For analysis, a 100 μL of the tumor homogenate sample was added onto a 96-well plate followed by the addition of 10 μL of 0.5 M tris[2-carboxyethyl]phosphine, TCEP (Sigma-Aldrich) and 400 μL of acetonitrile (Fisher Scientific). The plate was capped, mixed, and incubated on an orbital shaker for 15 min at 37 °C. Then 50 μL of 0.2 M <i>N</i>-ethylmaleimide, NEM (Sigma-Aldrich) was added and the plate was incubated at 37 °C on an orbital shaker for another 15 min. After incubation, 10 μL of internal standard was added and the plate was centrifuged for 5 min at 3700 × <i>g</i>. The clear supernatant was transferred to a new plate for liquid chromatography–mass spectrometry (LC–MS)/MS analysis.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> SSTR2 Internalization</h3><div class="NLM_p last">The PathHunter eXpress SSTR2 Activated GPCR Internalization Assay from DiscoverX was used to measure SSTR2 internalization. The cells were plated according to the manufacture’s protocol and incubated for 24 h. After 24 h, compounds were added at a starting concentration of 300 nM, which was then diluted to 3-fold for 11 data points. Compounds and cells were then incubated for 4 h. The detection reagent was then added according to the manufactures protocol and incubated for 60 min at room temperature, after which the chemiluminescent signal was measured.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> GSH Stability</h3><div class="NLM_p">A 5 mM solution of GSH was made in phosphate buffered saline and 990 μL aliquots were dispensed into Eppendorf tubes. To each tube was added 10 μL of stock solution of either <b>22</b> or <b>30</b> (1 mM in MeOH), and the solutions were incubated at 37 °C. At 30 min, 1 h, 2 h, 4 h, and 6 h, 100 μL of GSH solution was added to 600 μL of 500 μM <i>N</i>-ethylmaleimide solution in 1% ethanol and the samples were analyzed for parent conjugate by LC-MS/MS.</div><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Boc-DPhe-cyclo[Cys-Tyr(<i>t</i>Bu)-DTrp(Boc)-Lys(Boc)-Thr(<i>t</i>Bu)-Cys]-OH (<b>20a</b>)</h4><div class="NLM_p last">Fmoc-cystine(Trt)-OH was loaded onto 2-chlorotrityl resin (30.0 g, 0.739 mmol/g loading). Iterative deprotection with 4:1 DMF/piperidine and coupling subsequently with Fmoc-threonine(<i>t</i>Bu), <i>N</i>α-Fmoc-<i>N</i>ε-Boc-lysine, <i>N</i>α-Fmoc-<i>N</i><sup>in</sup>-Boc-<span class="smallcaps smallerCapital">d</span>-tryptophan, Fmoc-tyrosine(<i>t</i>Bu), Fmoc-cysteine(Trt), and Boc-<span class="smallcaps smallerCapital">d</span>-phenylalanine gave 90.2 g of the protected linear peptide (60.2 g total peptide loaded, 0.369 mmol/g loading of final protected resin). A portion of this linear peptide (10.0 g, 3.69 mmol) was taken and DMF (25 mL) and pyridine (1.16 g, 14.7 mmol) were added. A solution of iodine (1.87 g, 7.36 mmol) in DMF (25 mL) was added, and the resin was stirred for 20 min at room temperature. The resin was drained, washed with DMF (25 mL), and additional DMF (25 mL) and pyridine (1.16 g, 14.7 mmol) were added. A solution of iodine (1.87 g, 7.36 mmol) in DMF (25 mL) was added and the resin was stirred for 20 min at room temperature. The resin was drained, washed with DMF (2 × 25 mL) and dichloromethane (4 × 20 mL). The resin was then treated with 4:1 dichloromethane/hexafluoroisopropanol (60 mL) for 1 h. The dichloromethane/hexafluoroisopropanol solution was collected, the resin was washed with dichloromethane (25 mL), and treated again with 4:1 dichloromethane/hexafluoroisopropanol (60 mL) for 1 h. The dichloromethane/hexafluoroisopropanol solution was collected, the resin was washed with dichloromethane (25 mL), and the combined dichloromethane/hexafluoroisopropanol solutions and dichloromethane washings were dried in vacuo. The remaining solid was loaded onto an 80 g silica gel column. Elution with 0–10% methanol in dichloromethane provided <b>20a</b> (2.97 g, 2.18 mmol, 59% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.11 (d, <i>J</i> = 8.4 Hz, 1H), δ 7.98 (s, 1H), δ 7.55 (d, <i>J</i> = 8 Hz, 1H), δ 7.49 (br s, 1H), δ 7.24–7.21 (m, 8H), δ 7.08 (d, <i>J</i> = 7.2 Hz, 2H), δ 6.84 (d, <i>J</i> = 8 Hz, 2H), δ 4.99–4.90 (m, 2H), δ 4.64 (t, <i>J</i> = 6.8 Hz, 1H), δ 4.49–4.40 (m, 2H), δ 4.15 (t, <i>J</i> = 4.8 Hz, 1H), δ 4.06 (dd, <i>J</i> = 13.2, 2.8 Hz, 1H), δ 3.20–3.01 (m, 3H), δ 3.01–2.90 (m, 5H), δ 2.90–2.78 (m, 5H), δ 1.66 (s, 9H), δ 1.41 (s, 9H), δ 1.36 (s, 9H), δ 1.28 (s, 9H), δ 1.26 (s, 9H), δ 1.25–1.18 (m, tH), δ 0.70 (br s, 2H).</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Boc-DPhe-cyclo[Cys-Tyr(<i>t</i>Bu)-DTrp(Boc)-Lys(Boc)-Thr(<i>t</i>Bu)-Cys]-Cys(Trt)-NH<sub>2</sub> (<b>20b</b>)</h4><div class="NLM_p last">A flask was charged with <b>20a</b> (19.0 g, 14.0 mmol), <i>S</i>-trityl-<span class="smallcaps smallerCapital">l</span>-cysteine amide (5.57 g, 15.6 mmol), and HATU (5.84 g, 15.4 mmol). Dichloromethane (190 mL) was added, followed by diisopropylethylamine (4.88 mL, 27.9 mmol). The reaction mixture was stirred at room temperature for 3 h and then loaded directly onto a 330 g silica gel column. Elution with 0–10% methanol in dichloromethane provided <b>20b</b> (23.8 g, 13.9 mmol, 99% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.12 (d, <i>J</i> = 8.4 Hz, 1H), δ 7.51 (d, <i>J</i> = 7.6 Hz, 1H), δ 7.44 (s, 1H), δ 7.38–7.30 (m, 9H), δ 7.28–7.15 (m, 13H), δ 7.09 (d, <i>J</i> = 7.6 Hz, 1H), δ 6.87 (d, <i>J</i> = 8.4 Hz, 2H), δ 5.59–5.40 (m, 2H), δ 4.68 (d, <i>J</i> = 3.6 Hz, 1H), δ 4.57 (dd, <i>J</i> = 10, 5.2 Hz, 1H), δ 4.49 (dd, <i>J</i> = 10.4, 5.2 Hz, 1H), δ 5.36–4.29 (m, 2H), δ 4.11 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), δ 3.97 (dt, <i>J</i> = 10, 3.6 Hz, 1H), δ 3.22 (dd, <i>J</i> = 11.6, 4 Hz, 1H), δ 3.11–3.00 (m, 5H), δ 2.96–2.58 (m, 14H), δ 1.67 (s, 9H), δ 1.42 (s, 9H), δ 1.29 (s, 9H), δ 1.27–1.24 (m, 8H), δ 1.17 (s, 9H), δ 1.07 (d, <i>J</i> = 6.4 Hz, 3H), δ 0.55 (br s, 2H).</div></div><div id="sec4_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-Cys(SPy)-NH<sub>2</sub> (<b>21</b>)</h4><div class="NLM_p last">A flask was charged with <b>20b</b> (3.77 g, 2.03 mmol) and 2,2′-dithiodipyridine (536 mg, 2.43 mmol). Trifluoroethanol (19 mL) was added, the mixture was sonicated until everything went into solution (∼5 min). 1,1,3,3-Tetramethyldisiloxane (0.715 mL, 4.05 mmol) was added, followed by 12N aqueous HCl (3.8 mL). The reaction mixture was stirred at room temperature for 1 h, after which acetonitrile (38 mL) was added. The resulting suspension was stirred for 30 min, then filtered and the remaining solid was washed with additional acetonitrile (30 mL). The remaining solid was dissolved in 1 M aqueous acetic acid (100 mL). The solution was stirred for 2 h, then loaded directly onto a 275 g C18 Aq Isco column. The column was flushed with 150 mL aqueous 100 mM ammonium acetate, followed by 300 mL water with 0.1% acetic acid. A gradient of 0–45% acetonitrile in water with 0.1% acetic acid was then run, and the product-containing fractions pooled, approximately half the volume removed under vacuum, and the remaining material was frozen and lyophilized to give <b>21</b> as the acetate salt (2.04 g, 1.58 mmol, 77% yield). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.42 (d, <i>J</i> = 9.5 Hz, 1H), δ 7.83–7.78 (m, 2H), δ 7.45 (d, <i>J</i> = 8 Hz, 1H), δ 7.33–7.27 (m, 6H), δ 7.23–7.21 (m, 2H), δ 7.09–7.06 (m, 3H), δ 7.01–6.99 (m, 2H), δ 6.76 (d, <i>J</i> = 6.5 Hz, 2H), δ 5.09–5.02 (m, 3H), δ 4.64–4.61 (m, 2H), δ 4.39 (q, <i>J</i> = 3 Hz, 1H), δ 4.13 (dd, <i>J</i> = 11.5, 5 Hz, 1H), δ 3.96 (dd, <i>J</i> = 11, 4 Hz, 1H), δ 3.74 (dd, <i>J</i> = 8, 6.5 Hz, 1H), δ 3.25 (dd, <i>J</i> = 13.5, 9.5 Hz, 1H), δ 3.12–3.01 (m, 4H), δ 2.94–2.82 (m, 6H), δ 2.62–2.58 (m, 2H), δ 1.92 (s, acetate), δ 1.69 (br s, 1H), δ 1.34–1.22 (m, 6H), δ 0.52 (br s, 2H). ESI MS (+) (<i>m</i>/<i>z</i>): calcd for C<sub>53</sub>H<sub>66</sub>N<sub>12</sub>O<sub>10</sub>S<sub>4</sub> = 1158.4, found = 1159.4 (M + H).</div></div><div id="sec4_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-Cys(DM1)-NH<sub>2</sub> (PEN-221, <b>22</b>)</h4><div class="NLM_p last">A flask was charged with <b>21</b> acetate salt (645 mg, 0.461 mmol) and this was dissolved in a mixture of THF (10 mL) and pH 3.7 acetate buffer (10 mL, made from mixing 9.0 mL 0.2 M AcOH and 1.0 mL 0.2 M NaOAc). To this was then added a solution of DM1 (359 mg, 0.470 mmol) in THF (10 mL). The reaction mixture was stirred at room temperature for 1 h, and the reaction mixture was concentrated under vacuum at 35 °C at 10 mbar for 45 min to remove the THF. DMF (3 mL) and 1% aqueous acetic acid (9 mL) were added, and the reaction mixture was loaded onto a 100 g C18 Aq Isco gold column. Elution with a gradient of 5–40% acetonitrile in water with 0.1% AcOH provided <b>22</b> as the acetate salt (777 mg, 0.408 mmol, 86% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.42 (d, <i>J</i> = 7.6 Hz, 1H), δ 7.35–7.23 (m, 6H), δ 7.10–7.02 (m, 6H), δ 6.76 (d, <i>J</i> = 8 Hz, 2H), δ 6.67 (d, <i>J</i> = 11.2 Hz, 1H), δ 6.64 (s, 1H), δ 6.57 (dd, <i>J</i> = 14.4, 11.6 Hz, 1H), δ 5.70 (dd, <i>J</i> = 15.6, 8.8 Hz, 1H), δ 5.45 (q, <i>J</i> = 7.2 Hz, 1H), δ 4.99–4.96 (m, 2H), δ 4.68–4.59 (m, 3H), δ 4.41–4.38 (m, 2H), δ 4.18 (td, <i>J</i> = 10, 5.2 Hz, 1H), δ 4.07 (dd, <i>J</i> = 10.8, 4.8 Hz, 1H), δ 3.92 (s, 3H), δ 3.88 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), δ 3.79 (t, <i>J</i> = 6.8 Hz, 1H), δ 3.64 (d, <i>J</i> = 12.4 Hz, 1H), δ 3.55 (d, <i>J</i> = 9.2 Hz, 1H), δ 3.33 (s, 3H), δ 3.20 (d, <i>J</i> = 13.2 Hz, 1H), δ 3.16 (s, 3H), δ 3.11–3.06 (m, 2H), δ 3.03–2.86 (m, 9H), δ 2.85 (s, 3H), δ 2.84–2.77 (m, 3H), δ 2.66 (d, <i>J</i> = 14 Hz, 1H), δ 2.59 (t, <i>J</i> = 8 Hz, 2H), δ 2.12 (dd, <i>J</i> = 14.4, 2 Hz, 1H), δ 1.94 (s, acetate), δ 1.66 (s, 3H), δ 1.64–1.47 (m, 4H), δ 1.30 (d, <i>J</i> = 6.8 Hz, 3H), δ 1.28 (d, <i>J</i> = 6 Hz, 3H), δ 1.27–1.23 (m, 3H), δ 1.22 (d, <i>J</i> = 6.8 Hz, 3H), δ 0.83 (s, 3H), δ 0.47–0.41 (m, 2H). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD) δ 176.19, δ 174.76, δ 173.96, δ 173.18, δ 172.88, δ 172.69, δ 172.28, δ 171.29, δ 169.91, δ 157.61, δ 155.39, δ 143.19, δ 142.90, δ 140.50, δ 138.06, δ 137.05, δ 134.59, δ 131.67, δ 130.72, δ 130.12, δ 129.78, δ 128.84, δ 128.65, δ 126.87, δ 125.15, δ 123.06, δ 122.58, δ 120.29, δ 119.66, δ 119.46, δ 116.40, δ 115.28, δ 112.57, δ 110.37, δ 89.89, δ 81.82, δ 79.55, δ 75.76, δ 68.89, δ 68.21, δ 61.97, δ 61.46, δ 58.34, δ 57.36, δ 57.15, δ 56.44, δ 56.43, δ 56.26, δ 54.15, δ 54.02, δ 53.91, δ 53.61, δ 47.48, δ 45.53, δ 42.19, δ 40.47, δ 40.46, δ 40.37, δ 40.29, δ 39.71, δ 37.97, δ 36.74, δ 34.91, δ 33.56, δ 31.30, δ 28.19, δ 27.60, δ 23.55, δ 20.50, δ 15.83, δ 14.88, δ 13.93, δ 12.73. ESI MS (+) (<i>m</i>/<i>z</i>): calcd for C<sub>83</sub>H<sub>109</sub>ClN<sub>14</sub>O<sub>20</sub>S<sub>4</sub> = 1784.6, found = 893.4 [(M + 2H)/2].</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29"><a href="/doi/suppl/10.1021/acs.jmedchem.8b02036" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48861" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48861" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b02036" class="ext-link">10.1021/acs.jmedchem.8b02036</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Mouse body weights for the NCI-H69 xenograft study (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), GPCR screening data, and molecular formula strings and biological data in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b02036/suppl_file/jm8b02036_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Procedures for the synthesis of compounds <b>1</b>–<b>19</b> and <b>23</b>–<b>37</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b02036/suppl_file/jm8b02036_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b02036/suppl_file/jm8b02036_si_001.csv">jm8b02036_si_001.csv (6.63 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b02036/suppl_file/jm8b02036_si_002.pdf">jm8b02036_si_002.pdf (2.89 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b02036" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian H. White</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f99b8e91908d9cb98d988b8f9c9d988d81d79a9694"><span class="__cf_email__" data-cfemail="1a786d72736e7f5a6e7b686c7f7e7b6e6234797577">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kerry Whalen</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kristina Kriksciukaite</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rossitza Alargova</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tsun Au Yeung</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick Bazinet</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adam Brockman</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle DuPont</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haley Oller</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles-Andre Lemelin</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick Lim Soo</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benoît Moreau</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samantha Perino</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James M. Quinn</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gitanjali Sharma</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rajesh Shinde</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beata Sweryda-Krawiec</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Wooster</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark T. Bilodeau</span> - <span class="hlFld-Affiliation affiliation">Tarveda Therapeutics, 134 Coolidge Avenue, Watertown, Massachusetts 02472, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7502-9041" title="Orcid link">http://orcid.org/0000-0001-7502-9041</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All authors are current or former employees of Tarveda Therapeutics.<br /></br></div></li></ul></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations used</td></tr><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody-drug conjugate</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">EDT</td><td class="NLM_def"><p class="first last">1,2-ethanedithiol</p></td></tr><tr><td class="NLM_term">FMOC</td><td class="NLM_def"><p class="first last">fluorenylmethyloxycarbonyl</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G protein coupled receptor</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">MMAE</td><td class="NLM_def"><p class="first last">monomethyl auristatin E</p></td></tr><tr><td class="NLM_term">NEM</td><td class="NLM_def"><p class="first last"><i>N</i>-ethylmaleimide</p></td></tr><tr><td class="NLM_term">SPPS</td><td class="NLM_def"><p class="first last">solid phase peptide synthesis</p></td></tr><tr><td class="NLM_term">SSTR</td><td class="NLM_def"><p class="first last">somatostatin receptor</p></td></tr><tr><td class="NLM_term">TCEP</td><td class="NLM_def"><p class="first last">tris-2-carboxyethylphosphine</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82745" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82745" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 25 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnock-Jones, K. P.</span></span> <span> </span><span class="NLM_article-title">Brentuximab vedotin: A review of its use in patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0031-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1007%2Fs40265-013-0031-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=23494187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmtLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=371-381&author=K.+P.+Garnock-Jones&title=Brentuximab+vedotin%3A+A+review+of+its+use+in+patients+with+Hodgkin+lymphoma+and+systemic+anaplastic+large+cell+lymphoma+following+previous+treatment+failure&doi=10.1007%2Fs40265-013-0031-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure</span></div><div class="casAuthors">Garnock-Jones, Karly P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-381</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Brentuximab vedotin (ADCETRIS) is an antibody-drug conjugate that is specifically targeted against CD30-pos. cancer cells such as those in Hodgkin lymphoma or systemic anaplastic large cell lymphoma (ALCL).  I.v. brentuximab vedotin was assocd. with an overall objective response rate (primary endpoint) of 75 % in 102 patients with Hodgkin lymphoma who had relapsed after high-dose chemotherapy and autologous haematopoietic stem cell transplantation, in a noncomparative, multicentre, phase II trial.  In 58 patients with relapsed systemic ALCL after at least one prior treatment, i.v. brentuximab vedotin was assocd. with an overall objective response rate (primary endpoint) of 86 % in a noncomparative, multicentre, phase II trial.  Tumor redns. were obsd. in 94 % of patients with Hodgkin lymphoma and 97 % of patients with systemic ALCL, and most tumors decreased in size by >65 % and >85 %, resp.  The estd. 12-mo survival rates were 89 % and 52 %, resp.  Brentuximab vedotin was generally well tolerated in these trials.  The most common adverse event was peripheral neuropathy; approx. one-half of patients with this adverse event experienced complete resoln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1oswD_tecebVg90H21EOLACvtfcHk0ljH6dNDRlnp9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmtLzE&md5=88bc8455c2c215b86c1913d71385328c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0031-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0031-5%26sid%3Dliteratum%253Aachs%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DBrentuximab%2520vedotin%253A%2520A%2520review%2520of%2520its%2520use%2520in%2520patients%2520with%2520Hodgkin%2520lymphoma%2520and%2520systemic%2520anaplastic%2520large%2520cell%2520lymphoma%2520following%2520previous%2520treatment%2520failure%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D371%26epage%3D381%26doi%3D10.1007%2Fs40265-013-0031-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V.</span></span> <span> </span><span class="NLM_article-title">Ado-trastuzumab emtansine (T-DM1): An antibody-drug conjugate (ADC) for HER2-positive breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6949</span>– <span class="NLM_lpage">6964</span>, <span class="refDoi"> DOI: 10.1021/jm500766w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500766w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGlu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6949-6964&author=J.+M.+Lambertauthor=R.+V.+Chari&title=Ado-trastuzumab+emtansine+%28T-DM1%29%3A+An+antibody-drug+conjugate+%28ADC%29+for+HER2-positive+breast+cancer&doi=10.1021%2Fjm500766w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer</span></div><div class="casAuthors">Lambert, John M.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6949-6964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that combines the antitumor properties of the humanized anti-human epidermal growth factor receptor 2 (HER2) antibody, trastuzumab, with the maytansinoid, DM1, a potent microtubule-disrupting agent, joined by a stable linker.  Upon binding to HER2, the conjugate is internalized via receptor-mediated endocytosis, and an active deriv. of DM1 is subsequently released by proteolytic degrdn. of the antibody moiety within the lysosome.  Initial clin. evaluation led to a phase III trial in advanced HER2-pos. breast cancer patients who had relapsed after prior treatment with trastuzumab and a taxane, which showed that T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine.  In 2013, T-DM1 received FDA approval for the treatment of patients with HER2-pos. metastatic breast cancer who had previously received trastuzumab and a taxane, sep. or in combination, the first ADC to receive full approval based on a randomized study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYAu4MvRWFwLVg90H21EOLACvtfcHk0lg8sPSKh5pfzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGlu7rE&md5=3ddee50cc227097126dd47e7683a6ac7</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm500766w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500766w%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DAdo-trastuzumab%2520emtansine%2520%2528T-DM1%2529%253A%2520An%2520antibody-drug%2520conjugate%2520%2528ADC%2529%2520for%2520HER2-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6949%26epage%3D6964%26doi%3D10.1021%2Fjm500766w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner-Johnston, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehmann, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ananthakrishnan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandendries, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, M.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radiotherapy</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">571</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1111/bjh.14094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1111%2Fbjh.14094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=27101934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GlurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2016&pages=571-581&author=A.+Goyauthor=A.+Foreroauthor=N.+Wagner-Johnstonauthor=W.+C.+Ehmannauthor=M.+Tsaiauthor=K.+Hatakeauthor=R.+Ananthakrishnanauthor=A.+Volkertauthor=E.+Vandendriesauthor=M.+Ogura&title=A+phase+2+study+of+inotuzumab+ozogamicin+in+patients+with+indolent+B-cell+non-Hodgkin+lymphoma+refractory+to+rituximab+alone%2C+rituximab+and+chemotherapy%2C+or+radiotherapy&doi=10.1111%2Fbjh.14094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy</span></div><div class="casAuthors">Goy, Andre; Forero, Andres; Wagner-Johnston, Nina; Christopher Ehmann, W.; Tsai, Michaela; Hatake, Kiyohiko; Ananthakrishnan, Revathi; Volkert, Angela; Vandendries, Erik; Ogura, Michinori</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">571-581</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">This phase 2 study evaluated the efficacy and safety of inotuzumab ozogamicin (InO) in patients with indolent B-cell non-Hodgkin lymphoma (NHL) refractory to rituximab alone, rituximab plus chemotherapy or anti-CD20 radioimmunotherapy.  Patients received InO 1·8 mg/m2 i.v. on a 28-d cycle for a planned 4-8 cycles.  The initial InO dose and schedule could be adjusted for tolerability and patients were allowed to receive 2 addnl. cycles (up to 8 total) after achieving a complete response (CR).  The primary endpoint was overall response.  Eighty-one patients were enrolled, among whom 48 (59%) received ≥3 InO cycles and 13 (16%) completed the treatment phase.  The overall response rate was 67% (CR, 31%).  Median (95% confidence interval) progression-free survival was 12·7 (8·9-26·9) months; median overall survival was not reached.  Haematol. adverse events (AEs) were common, particularly thrombocytopenia (74%) and neutropenia (56%).  These were also the most common AEs leading to treatment discontinuation (37% and 11%, resp.); 58% of patients reported AEs leading to treatment discontinuation.  InO demonstrated robust activity in these heavily pretreated patients, although treatment duration was limited by haematol. toxicities.  Addnl. studies may det. dosing regimens that allow for reduced toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlYcLyGqN9e7Vg90H21EOLACvtfcHk0lg8sPSKh5pfzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GlurvJ&md5=cee25294b1cd1a32e22744ec8e5c3517</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fbjh.14094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.14094%26sid%3Dliteratum%253Aachs%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DForero%26aufirst%3DA.%26aulast%3DWagner-Johnston%26aufirst%3DN.%26aulast%3DEhmann%26aufirst%3DW.%2BC.%26aulast%3DTsai%26aufirst%3DM.%26aulast%3DHatake%26aufirst%3DK.%26aulast%3DAnanthakrishnan%26aufirst%3DR.%26aulast%3DVolkert%26aufirst%3DA.%26aulast%3DVandendries%26aufirst%3DE.%26aulast%3DOgura%26aufirst%3DM.%26atitle%3DA%2520phase%25202%2520study%2520of%2520inotuzumab%2520ozogamicin%2520in%2520patients%2520with%2520indolent%2520B-cell%2520non-Hodgkin%2520lymphoma%2520refractory%2520to%2520rituximab%2520alone%252C%2520rituximab%2520and%2520chemotherapy%252C%2520or%2520radiotherapy%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2016%26volume%3D174%26spage%3D571%26epage%3D581%26doi%3D10.1111%2Fbjh.14094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span> <span> </span><span class="NLM_article-title">Transport of molecules, particles, and cells in solid tumors</span>. <i>Annu. Rev. Biomed. Eng.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1146/annurev.bioeng.1.1.241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1146%2Fannurev.bioeng.1.1.241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=11701489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADyaK1MXnvFyit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1999&pages=241-263&author=R.+K.+Jain&title=Transport+of+molecules%2C+particles%2C+and+cells+in+solid+tumors&doi=10.1146%2Fannurev.bioeng.1.1.241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Transport of molecules, particles, and cells in solid tumors</span></div><div class="casAuthors">Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biomedical Engineering</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">241-263, 5plates</span>CODEN:
                <span class="NLM_cas:coden">ARBEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-9829</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 177 refs.  Extraordinary advances in mol. biol. and biotechnol. have led to the development of a vast no. of therapeutic anticancer agents.  To reach cancer cells in a tumor, a blood-borne therapeutic mol., particle, or cell must make its way into the blood vessels of the tumor and across the vessel wall into the interstitium, which it then must migrate through.  Unfortunately, tumors often develop in ways that hinder these steps.  The goal of research in this area is to analyze each of these steps exptl. and theor. and integrate the resulting information into a unified theor. framework.  This paradigm of anal. and synthesis has fostered a better understanding of physiol. barriers in solid tumors and aided in the development of novel strategies to exploit and/or overcome these barriers for improved cancer detection and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4aSvBc5FwIbVg90H21EOLACvtfcHk0lg8sPSKh5pfzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnvFyit7c%253D&md5=3a5f87c8d6604d7ddf2a8d35f173a270</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1146%2Fannurev.bioeng.1.1.241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.bioeng.1.1.241%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DTransport%2520of%2520molecules%252C%2520particles%252C%2520and%2520cells%2520in%2520solid%2520tumors%26jtitle%3DAnnu.%2520Rev.%2520Biomed.%2520Eng.%26date%3D1999%26volume%3D1%26spage%3D241%26epage%3D263%26doi%3D10.1146%2Fannurev.bioeng.1.1.241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span> <span> </span><span class="NLM_article-title">Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution</span>. <i>Microvasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1016/0026-2862(91)90026-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1016%2F0026-2862%2891%2990026-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=2051960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A280%3ADyaK3M3ntVWltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1991&pages=252-272&author=L.+T.+Baxterauthor=R.+K.+Jain&title=Transport+of+fluid+and+macromolecules+in+tumors.+IV.+A+microscopic+model+of+the+perivascular+distribution&doi=10.1016%2F0026-2862%2891%2990026-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution</span></div><div class="casAuthors">Baxter L T; Jain R K</div><div class="citationInfo"><span class="NLM_cas:title">Microvascular research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">252-72</span>
        ISSN:<span class="NLM_cas:issn">0026-2862</span>.
    </div><div class="casAbstract">The therapeutic efficacy of various genetically engineered macromolecules is determined by their delivery and distribution in tumors.  We have recently developed mathematical models which describe the interstitial velocity, pressure, and concentration profiles of macromolecules over the length scale of a solid tumor (Baxter and Jain, Microvas.  Res. 1989, 1990, 1991).  Nonspecific and specific antibodies and antibody fragments were chosen as typical macromolecules.  The focus of the present investigation was microscopic transport, i.e., the distribution of pressure and solutes around individual blood vessels.  Analytical solutions were obtained for interstitial velocities and pressures, while the concentration profiles were calculated numerically using the finite element method.  The microscopic model describes flow patterns around an individual blood vessel in an infinite medium and concentration profiles around a single blood vessel in a network of capillaries.  Our analysis is novel in that it incorporates interstitial convection, asymmetric filtration, and transcapillary convection to describe interstitial transport in tumors.  The purpose of this model was to determine the effect of extravascular binding and interstitial convection on the distribution of macromolecules on a microscopic scale and to test the continuum hypothesis assumed in our previously published macroscopic models.  An approximate one-dimensional model was compared with a more accurate two-dimensional model.  The results of our microscopic model confirm that the continuum hypothesis used in our previous macroscopic model is reasonable.  On a microscopic length scale diffusion is dominant, and short range distortions in the flow field do not significantly affect the penetration of macromolecules into the tissue.  In addition, our model confirms the results of Fujimori et al. (Cancer Res., 1989) concerning a "binding site barrier." The implications of our results for cancer therapy are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVeX6-t8nFPpPlX7E30qdzfW6udTcc2eaDyypEUHlvLLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M3ntVWltQ%253D%253D&md5=105d5c53fcf7658ee554430fbdd2425b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2F0026-2862%2891%2990026-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0026-2862%252891%252990026-8%26sid%3Dliteratum%253Aachs%26aulast%3DBaxter%26aufirst%3DL.%2BT.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DTransport%2520of%2520fluid%2520and%2520macromolecules%2520in%2520tumors.%2520IV.%2520A%2520microscopic%2520model%2520of%2520the%2520perivascular%2520distribution%26jtitle%3DMicrovasc.%2520Res.%26date%3D1991%26volume%3D41%26spage%3D252%26epage%3D272%26doi%3D10.1016%2F0026-2862%2891%2990026-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beckman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiner, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, H. M.</span></span> <span> </span><span class="NLM_article-title">Antibody constructs in cancer therapy</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1002/cncr.22402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1002%2Fcncr.22402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=17154393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhs1yrs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=170-179&author=R.+A.+Beckmanauthor=L.+M.+Weinerauthor=H.+M.+Davis&title=Antibody+constructs+in+cancer+therapy&doi=10.1002%2Fcncr.22402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors</span></div><div class="casAuthors">Beckman, Robert A.; Weiner, Louis M.; Davis, Hugh M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">170-179</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Whereas over 85% of human cancers are solid tumors, of the 8 monoclonal antibodies (mAbs) currently approved for cancer therapy, 25% are directed at solid tumor surface antigens (Ags).  This shortfall may be due to barriers to achieving adequate exposure in solid tumors.  Advancements in tumor biol., protein engineering, and theor. modeling of macromol. transport are currently enabling identification of crit. phys. properties for antitumor Abs.  It is now possible to structurally modify Abs or even replace full Abs with a plethora of Ab constructs.  These constructs include Fab and Fab'2 fragments, scFvs, multivalent scFvs (e.g., diabodies and tribodies), minibodies (e.g., scFv-CH3 dimers), bispecific Abs, and camel variable functional heavy chain domains.  The purpose of the article is to provide investigators with a conceptual framework for exploiting the recent scientific advancements.  The focus is on 2 properties that govern tumor exposure: 1) phys. properties that enable penetration of and retention by tumors, and 2) favorable plasma pharmacokinetics.  It is demonstrated that manipulating mol. size, charge, valence, and binding affinity can optimize these properties.  These manipulations hold the key to promoting tumor exposure and to ultimately creating successful Ab therapies for solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXPq7VKRTrJ7Vg90H21EOLACvtfcHk0lgLyiEvT9R5Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhs1yrs74%253D&md5=17855fd18999c717f902117ecdeb4cca</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fcncr.22402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.22402%26sid%3Dliteratum%253Aachs%26aulast%3DBeckman%26aufirst%3DR.%2BA.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26aulast%3DDavis%26aufirst%3DH.%2BM.%26atitle%3DAntibody%2520constructs%2520in%2520cancer%2520therapy%26jtitle%3DCancer%26date%3D2007%26volume%3D109%26spage%3D170%26epage%3D179%26doi%3D10.1002%2Fcncr.22402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vrettos, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezö, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzakos, A. G.</span></span> <span> </span><span class="NLM_article-title">On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site</span>. <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.3762/bjoc.14.80</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.3762%2Fbjoc.14.80" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=29765474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOnsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=930-954&author=E.+I.+Vrettosauthor=G.+Mez%C3%B6author=A.+G.+Tzakos&title=On+the+design+principles+of+peptide-drug+conjugates+for+targeted+drug+delivery+to+the+malignant+tumor+site&doi=10.3762%2Fbjoc.14.80"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site</span></div><div class="casAuthors">Vrettos, Eirinaios I.; Mezo, Gabor; Tzakos, Andreas G.</div><div class="citationInfo"><span class="NLM_cas:title">Beilstein Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">930-954</span>CODEN:
                <span class="NLM_cas:coden">BJOCBH</span>;
        ISSN:<span class="NLM_cas:issn">1860-5397</span>.
    
            (<span class="NLM_cas:orgname">Beilstein-Institut zur Foerderung der Chemischen Wissenschaften</span>)
        </div><div class="casAbstract">Cancer is the second leading cause of death affecting nearly one in two people, and the appearance of new cases is projected to rise by >70% by 2030.  To effectively combat the menace of cancer, a variety of strategies have been exploited.  Among them, the development of peptide-drug conjugates (PDCs) is considered as an inextricable part of this armamentarium and is continuously explored as a viable approach to target malignant tumors.  The general architecture of PDCs consists of three building blocks: the tumor-homing peptide, the cytotoxic agent and the biodegradable connecting linker.  The aim of the current review is to provide a spherical perspective on the basic principles governing PDCs, as also the methodol. to construct them.  We aim to offer basic and integral knowledge on the rational design towards the construction of PDCs through analyzing each building block, as also to highlight the overall progress of this rapidly growing field.  Therefore, we focus on several intriguing examples from the recent literature, including important PDCs that have progressed to phase III clin. trials.  Last, we address possible difficulties that may emerge during the synthesis of PDCs, as also report ways to overcome them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRxpOdZLKXfrVg90H21EOLACvtfcHk0lgLyiEvT9R5Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOnsLvP&md5=595fce13e61b3e6f58a8ae6969e8b2c8</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.14.80&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.14.80%26sid%3Dliteratum%253Aachs%26aulast%3DVrettos%26aufirst%3DE.%2BI.%26aulast%3DMez%25C3%25B6%26aufirst%3DG.%26aulast%3DTzakos%26aufirst%3DA.%2BG.%26atitle%3DOn%2520the%2520design%2520principles%2520of%2520peptide-drug%2520conjugates%2520for%2520targeted%2520drug%2520delivery%2520to%2520the%2520malignant%2520tumor%2520site%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2018%26volume%3D14%26spage%3D930%26epage%3D954%26doi%3D10.3762%2Fbjoc.14.80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vergote, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leamon, C. P.</span></span> <span> </span><span class="NLM_article-title">Vintafolide: A novel targeted therapy for the treatment of folate receptor expressing tumors</span>. <i>Ther. Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1177/1758834015584763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1177%2F1758834015584763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=26136852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslSisLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=206-218&author=I.+Vergoteauthor=C.+P.+Leamon&title=Vintafolide%3A+A+novel+targeted+therapy+for+the+treatment+of+folate+receptor+expressing+tumors&doi=10.1177%2F1758834015584763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors</span></div><div class="casAuthors">Vergote, Ignace; Leamon, Christopher P.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">206-218</span>CODEN:
                <span class="NLM_cas:coden">TAMOB8</span>;
        ISSN:<span class="NLM_cas:issn">1758-8340</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite advances in the development of molecularly targeted therapies, limited improvements in overall survival have been noted among many cancer patients with solid tumors, primarily due to development of drug resistance.  Accordingly, there is an unmet need for new targeted therapies and treatment approaches for cancer, esp. for overcoming resistance.  Expression of the folate receptor is upregulated in many tumor types and thus represents an ideal target for cancer treatment.  Several folate receptor targeted therapies are in development, including the small mol. drug conjugate vintafolide, the monoclonal antibody farletuzumab, and the antibody-drug conjugate IMGN853.  The role of the folate receptor as a target in cancer progression and resistance as well as emerging preclin. and clin. data from studies on those folate receptor targeted agents that are in development with a focus on vintafolide are reviewed.  The folate receptor has several unique properties, such as high expression in several tumor types, that make it a rational target for cancer treatment, and allow for selective delivery of folate receptor targeted agents.  Earlystage clin. data in lung and ovarian cancer suggest that vintafolide has the potential for combination with other std. approved agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI7r6KUhT807Vg90H21EOLACvtfcHk0lghHQxnvsKsDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslSisLvJ&md5=72a74bbe7e67ad2c02989d8601555d63</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1177%2F1758834015584763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758834015584763%26sid%3Dliteratum%253Aachs%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DLeamon%26aufirst%3DC.%2BP.%26atitle%3DVintafolide%253A%2520A%2520novel%2520targeted%2520therapy%2520for%2520the%2520treatment%2520of%2520folate%2520receptor%2520expressing%2520tumors%26jtitle%3DTher.%2520Adv.%2520Med.%2520Oncol.%26date%3D2015%26volume%3D7%26spage%3D206%26epage%3D218%26doi%3D10.1177%2F1758834015584763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittrup, K. D.</span></span> <span> </span><span class="NLM_article-title">A modeling analysis on the effects of molecular size and binding affinity on tumor targeting</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2861</span>– <span class="NLM_lpage">2871</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1158%2F1535-7163.MCT-09-0195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=19825804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2861-2871&author=M.+M.+Schmidtauthor=K.+D.+Wittrup&title=A+modeling+analysis+on+the+effects+of+molecular+size+and+binding+affinity+on+tumor+targeting&doi=10.1158%2F1535-7163.MCT-09-0195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A modeling analysis of the effects of molecular size and binding affinity on tumor targeting</span></div><div class="casAuthors">Schmidt, Michael M.; Wittrup, K. Dane</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2861-2871</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A diverse array of tumor targeting agents ranging in size from peptides to nanoparticles is currently under development for applications in cancer imaging and therapy.  However, it remains largely unclear how size differences among these mols. influence their targeting properties.  Here, we develop a simple, mechanistic model that can be used to understand and predict the complex interplay between mol. size, affinity, and tumor uptake.  Empirical relationships between mol. radius and capillary permeability, interstitial diffusivity, available vol. fraction, and plasma clearance were obtained using data in the literature.  These relationships were incorporated into a compartmental model of tumor targeting using MATLAB to predict the magnitude, specificity, time dependence, and affinity dependence of tumor uptake for mols. across a broad size spectrum.  In the typical size range for proteins, the model uncovers a complex trend in which intermediate-sized targeting agents (MW, ∼25 kDa) have the lowest tumor uptake, whereas higher tumor uptake levels are achieved by smaller and larger agents.  Small peptides accumulate rapidly in the tumor but require high affinity to be retained, whereas larger proteins can achieve similar retention with >100-fold weaker binding.  For mols. in the size range of liposomes, the model predicts that antigen targeting will not significantly increase tumor uptake relative to untargeted mols.  All model predictions are shown to be consistent with exptl. observations from published targeting studies.  The results and techniques have implications for drug development, imaging, and therapeutic dosing. [Mol Cancer Ther 2009;8(10):2861-71].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIy-sqAvgserVg90H21EOLACvtfcHk0lghHQxnvsKsDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7K&md5=da1ea6be17fad4873d808e883eacbf78</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0195%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DM.%2BM.%26aulast%3DWittrup%26aufirst%3DK.%2BD.%26atitle%3DA%2520modeling%2520analysis%2520on%2520the%2520effects%2520of%2520molecular%2520size%2520and%2520binding%2520affinity%2520on%2520tumor%2520targeting%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2861%26epage%3D2871%26doi%3D10.1158%2F1535-7163.MCT-09-0195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pimstone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kronheim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berelowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, M.</span></span> <span> </span><span class="NLM_article-title">Metabolic clearance and plasma half-disappearance time exogenous somatostatin in man</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1210/jcem-48-1-50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1210%2Fjcem-48-1-50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=422706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADyaE1MXotFantA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1979&pages=50-53&author=M.+Sheppardauthor=B.+Shapiroauthor=B.+Pimstoneauthor=S.+Kronheimauthor=M.+Berelowitzauthor=M.+Gregory&title=Metabolic+clearance+and+plasma+half-disappearance+time+exogenous+somatostatin+in+man&doi=10.1210%2Fjcem-48-1-50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man</span></div><div class="casAuthors">Sheppard, Michael; Shapiro, Brahm; Pimstone, Bernard; Kronheim, Shirley; Berelowitz, Michael; Gregory, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-3</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    </div><div class="casAbstract">The metabolic clearance rate (MCR) and half-disappearance time of exogenously administered somatostatin  [51110-01-1] were measured during and after cessation of a const. infusion.  Studies were performed on normal volunteers and patients with chronic liver disease and chronic renal failure.  Normal subjects had a mean MCR of 1949 mL/min, similar to values found in 5 patients with chronic liver disease.  However, patients with chronic renal failure showed a highly significant lowering of the MCR (501 mL/min).  The rate of disappearance of somatostatin after infusion was linear for 7-10 min, after which a much slower component was obsd.  In normal subjects, the t1/2 of the 1st component varied from 1.1-3.0 min, in patients with liver disease it varied from 1.2-4.8 min, and in patients with chronic renal failure it varied from 2.6-4.9 min.  The kidney hay have a role in the metabolic clearance of exogenously administered somatostatin, or uremia may impair catabolism nonspecifically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoumdLZ6AdD6LVg90H21EOLACvtfcHk0lghHQxnvsKsDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXotFantA%253D%253D&md5=79af9924ff1b57f189d95f45a736ef61</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1210%2Fjcem-48-1-50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem-48-1-50%26sid%3Dliteratum%253Aachs%26aulast%3DSheppard%26aufirst%3DM.%26aulast%3DShapiro%26aufirst%3DB.%26aulast%3DPimstone%26aufirst%3DB.%26aulast%3DKronheim%26aufirst%3DS.%26aulast%3DBerelowitz%26aufirst%3DM.%26aulast%3DGregory%26aufirst%3DM.%26atitle%3DMetabolic%2520clearance%2520and%2520plasma%2520half-disappearance%2520time%2520exogenous%2520somatostatin%2520in%2520man%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D1979%26volume%3D48%26spage%3D50%26epage%3D53%26doi%3D10.1210%2Fjcem-48-1-50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hannon, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weckbecker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troxler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span> <span> </span><span class="NLM_article-title">Drug design at peptide receptors</span>. <i>J. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1385/JMN:18:1-2:15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1385%2FJMN%3A18%3A1-2%3A15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=11931345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD38XisVShs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2002&pages=15-27&author=J.+P.+Hannonauthor=C.+Nunnauthor=B.+Stolzauthor=C.+Brunsauthor=G.+Weckbeckerauthor=I.+Lewisauthor=T.+Troxlerauthor=K.+Hurthauthor=D.+Hoyer&title=Drug+design+at+peptide+receptors&doi=10.1385%2FJMN%3A18%3A1-2%3A15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Drug design at peptide receptors: somatostatin receptor ligands</span></div><div class="casAuthors">Hannon, Jason P.; Nunn, Caroline; Stolz, Barbara; Bruns, Christian; Weckbecker, Gisbert; Lewis, Ian; Troxler, Thomas; Hurth, Konstanze; Hoyer, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">15-27</span>CODEN:
                <span class="NLM_cas:coden">JMNEES</span>;
        ISSN:<span class="NLM_cas:issn">0895-8696</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review.  Somatostatin (SRIF, somatotropin release inhibiting factor), discovered for its inhibitory action on growth hormone (GH) secretion from pituitary, is an abundant neuropeptide.  Two forms, SRIF14 and SRIF28 exist.  Recently, a second family of peptides with very similar sequences and features was described; the cortistatins (CST), CST17 and CST29 which are brain selective.  The five cloned SRIF receptors (sst1-5) belong to the G-protein coupled/heptathelical receptor family.  Structural and operational features distinguish two classes of receptors; SRIF1-sst2/sst3/sst5 (high affinity for octreotide or seglitide) and SRIF2=sst1/sst4 (very low affinity for the aforementioned ligands).  The affinity of SRIF receptors for somatostatins and cortistatins is equally high, and it is not clear whether selective receptors do exist for one or the other of the peptides.  Several radiologlands label all SRIF receptors, e.g., [125I] LTT-SRIF28, [125I] CGP23996, [125I] Tyr10cortistatin or [125I] Tyr11SRIF14.  In contrast, [125I] Tyr3octreotide, [125I] BIM23027, [125I] MK678 or [125I] D-Trp8SRIF14 label predominantly SRIF1 sites, esp. sst2 and possibly sst5 receptors.  In brain, [125I]Tyr3octreotide binding equates with sst2 receptor mRNA distribution.  Native SRIF2 receptors can be labeled with [125I]SRIF14 in the presence of high NaCl in brain (sst1) or lung (sst4) tissue.  Short cyclic or linear peptide analogs show selectivity for sst2/sst5 (octreotide, lanreotide, BIM 23027), sst1 (CH-275), sst3 (sst3-ODN-8), or sst5 receptors (BIM 23268); although claims for selectivity have not always been confirmed.  Beta peptides with affinity for SRIF receptors are also reported.  The general lack of SRIF receptor antagonists is unique for peptide receptors, although CYN 154806 is a selective and potent sst2 antagonist.  Nonpeptide ligands are still rare, although a no. of mols. have been reported with selectivity and potency for sst1 (L757,519), sst2 (L779,976), sst3 (L796,778), sst4 (NNC 26-9100, L803,087) or sst1/sst5 receptors (L817,018).  Such mols. are essential to establish the role of SRIF receptors, e.g., sst1 in hypothalamic glutamate currents: sst2 in inhibiting release of GH, glucagon, TSH, gastric acid secretion, pain, seizures and tumor growth, and sst5 in vascular remodeling and inhibition of insulin and GH release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1Db87Wp-xlrVg90H21EOLACvtfcHk0ljiv-wmhwUFtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XisVShs7k%253D&md5=5fcec52cbf5fe4f7dd0dae9eb8fda5c4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1385%2FJMN%3A18%3A1-2%3A15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FJMN%253A18%253A1-2%253A15%26sid%3Dliteratum%253Aachs%26aulast%3DHannon%26aufirst%3DJ.%2BP.%26aulast%3DNunn%26aufirst%3DC.%26aulast%3DStolz%26aufirst%3DB.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DWeckbecker%26aufirst%3DG.%26aulast%3DLewis%26aufirst%3DI.%26aulast%3DTroxler%26aufirst%3DT.%26aulast%3DHurth%26aufirst%3DK.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DDrug%2520design%2520at%2520peptide%2520receptors%26jtitle%3DJ.%2520Mol.%2520Neurosci.%26date%3D2002%26volume%3D18%26spage%3D15%26epage%3D27%26doi%3D10.1385%2FJMN%3A18%3A1-2%3A15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doepfner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huguenin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petcher, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pless, J.</span></span> <span> </span><span class="NLM_article-title">SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1140</span>, <span class="refDoi"> DOI: 10.1016/0024-3205(82)90087-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1016%2F0024-3205%2882%2990087-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=6128648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADyaL38XlslGhtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1982&pages=1133-1140&author=W.+Bauerauthor=U.+Brinerauthor=W.+Doepfnerauthor=R.+Hallerauthor=R.+Hugueninauthor=P.+Marbachauthor=T.+J.+Petcherauthor=J.+Pless&title=SMS+201-995%3A+A+very+potent+and+selective+octapeptide+analogue+of+somatostatin+with+prolonged+action&doi=10.1016%2F0024-3205%2882%2990087-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">SMS 201-995:  a very potent and selective octapeptide analog of somatostatin with prolonged action</span></div><div class="casAuthors">Bauer, Wilfried; Briner, Ulrich; Doepfner, Wolfgang; Haller, Roland; Huguenin, Rene; Marbach, Peter; Petcher, Trevor J.; Pless, Janos</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1133-40</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    </div><div class="casAbstract">Cyclic H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol) (SMS 201-995)  [83150-76-9] in vitro is 3 times more potent than the native hormone in inhibiting the secretion of growth hormone.  SMS 201-995 is highly resistant to degrdn. by pure enzymes and by tissue homogenates.  In vivo in rat and rhesus monkey it is at least 20 times more active than somatostatin  [38916-34-6], is much longer acting, and in both species is much more selective in inhibiting the secretion of growth hormone than that of insulin.  The compd. is active by several routes of administration including oral and is well-tolerated both in lab. animals and in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8bqAn6MorPbVg90H21EOLACvtfcHk0ljiv-wmhwUFtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XlslGhtLg%253D&md5=4c532216bf02dd0e17b2e7bc324fd5eb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2882%2990087-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252882%252990087-X%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DW.%26aulast%3DBriner%26aufirst%3DU.%26aulast%3DDoepfner%26aufirst%3DW.%26aulast%3DHaller%26aufirst%3DR.%26aulast%3DHuguenin%26aufirst%3DR.%26aulast%3DMarbach%26aufirst%3DP.%26aulast%3DPetcher%26aufirst%3DT.%2BJ.%26aulast%3DPless%26aufirst%3DJ.%26atitle%3DSMS%2520201-995%253A%2520A%2520very%2520potent%2520and%2520selective%2520octapeptide%2520analogue%2520of%2520somatostatin%2520with%2520prolonged%2520action%26jtitle%3DLife%2520Sci.%26date%3D1982%26volume%3D31%26spage%3D1133%26epage%3D1140%26doi%3D10.1016%2F0024-3205%2882%2990087-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szepeshazi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shally, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carney, D. N.</span></span> <span> </span><span class="NLM_article-title">Somatostatin receptor expression in lung cancer</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1682</span>– <span class="NLM_lpage">1687</span>, <span class="refDoi"> DOI: 10.1016/0959-8049(94)00351-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1016%2F0959-8049%2894%2900351-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1994&pages=1682-1687&author=K.+J.+O%E2%80%99Byrneauthor=G.+Halmosauthor=J.+Pinskiauthor=K.+Grootauthor=K.+Szepeshaziauthor=A.+V.+Shallyauthor=D.+N.+Carney&title=Somatostatin+receptor+expression+in+lung+cancer&doi=10.1016%2F0959-8049%2894%2900351-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1016%2F0959-8049%2894%2900351-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0959-8049%252894%252900351-5%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26aulast%3DHalmos%26aufirst%3DG.%26aulast%3DPinski%26aufirst%3DJ.%26aulast%3DGroot%26aufirst%3DK.%26aulast%3DSzepeshazi%26aufirst%3DK.%26aulast%3DShally%26aufirst%3DA.%2BV.%26aulast%3DCarney%26aufirst%3DD.%2BN.%26atitle%3DSomatostatin%2520receptor%2520expression%2520in%2520lung%2520cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D1994%26volume%3D30%26spage%3D1682%26epage%3D1687%26doi%3D10.1016%2F0959-8049%2894%2900351-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaer, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laissue, J. A.</span></span> <span> </span><span class="NLM_article-title">Somatostatin receptor sst1-5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands</span>. <i>Eur. J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">836</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.1007/s002590100541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1007%2Fs002590100541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=11504080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvVWltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2001&pages=836-846&author=J.+C.+Reubiauthor=B.+Waserauthor=J.+C.+Schaerauthor=J.+A.+Laissue&title=Somatostatin+receptor+sst1-5+expression+in+normal+and+neoplastic+human+tissues+using+receptor+autoradiography+with+subtype-selective+ligands&doi=10.1007%2Fs002590100541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands</span></div><div class="casAuthors">Reubi, Jean Claude; Waser, Beatrice; Schaer, Jean-Claude; Laissue, Jean A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">836-846</span>CODEN:
                <span class="NLM_cas:coden">EJNMD9</span>;
        ISSN:<span class="NLM_cas:issn">0340-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Somatostatin receptors are known to be expressed in a large no. of human tumors and represent the basis for in vivo tumor targeting.  Stable somatostatin derivs. such as octreotide or lanreotide are the most frequently used radiopharmaceuticals acting through specific binding to somatostatin receptors; however, they do not bind with high affinity to all five receptor subtypes.  Whereas the mRNAs for most receptor subtypes have been detected in tumors, it is in most cases unclear which of the receptor subtype proteins are expressed.  Since in vitro receptor binding methods are close correlates and predictors of in vivo peptide receptor targeting, we took advantage of the recently developed subtype-selective analogs and evaluated approx. 200 tumors for their receptor subtype protein expression in specific binding assays using autoradiog. with 125I-[Leu8, D-Trp22, Tyr25]-somatostatin-28 and displacement by subtype-selective analogs.  The majority of the tested neuroblastomas, meningiomas, medulloblastomas, breast carcinomas, lymphomas, renal cell carcinomas, paragangliomas, small cell lung carcinomas and hepatocellular carcinomas predominantly expressed sst2.  The prostate carcinomas and sarcomas preferentially expressed sst1, while a majority of inactive pituitary adenomas displayed sst3 and, to a lesser extent, sst2.  Growth hormone-secreting pituitary adenomas preferentially expressed sst2 and sst5; gastroenteropancreatic tumors and phaeochromocytomas frequently displayed sst2 and/or sst1.  Non-neoplastic human tissues such as vessels, nerve plexus, pancreatic islets, prostatic stroma, adrenal medulla, spleen and germinal centers of the lymphoid tissues preferentially expressed sst2.  However, the human gastric mucosa predominantly expressed sst1 while colonic mucosa displayed sst2.  Interestingly, a minority of tumors showed a strong 125I-[Leu8, D-Trp22, Tyr25]-somatostatin-28 binding, of which less than 50% could be displaced by the sum of the five subtype-selective analogs.  This observation suggests the existence of an as yet unknown subtype in selected tumors.  This study is the first report to analyze the somatostatin receptor subtype expression in tumors with binding methods.  We conclude that sst2, with high affinity for current radiopharmaceuticals such as Octreoscan, is predominantly expressed in a majority of tumors.  Fewer tumor types (sarcomas, prostate cancers, inactive pituitary adenomas) preferentially express another subtype.  This information is of importance with regard to the clin. applications and development of somatostatin analogs with distinct receptor subtype selectivities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSjHWWOv5NoLVg90H21EOLACvtfcHk0ljjsa1UrjPOlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvVWltL0%253D&md5=4ed6a5fc97c34cceb64c50f6257c763f</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1007%2Fs002590100541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002590100541%26sid%3Dliteratum%253Aachs%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26aulast%3DWaser%26aufirst%3DB.%26aulast%3DSchaer%26aufirst%3DJ.%2BC.%26aulast%3DLaissue%26aufirst%3DJ.%2BA.%26atitle%3DSomatostatin%2520receptor%2520sst1-5%2520expression%2520in%2520normal%2520and%2520neoplastic%2520human%2520tissues%2520using%2520receptor%2520autoradiography%2520with%2520subtype-selective%2520ligands%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%26date%3D2001%26volume%3D28%26spage%3D836%26epage%3D846%26doi%3D10.1007%2Fs002590100541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Callison, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massion, P. P.</span></span> <span> </span><span class="NLM_article-title">Somatostatin receptors in lung cancer: From function to molecular imaging and therapeutics</span>. <i>J. Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.6058/jlc.2011.10.2.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.6058%2Fjlc.2011.10.2.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=25663834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFWitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=69-76&author=J.+C.+Callisonauthor=R.+C.+Walkerauthor=P.+P.+Massion&title=Somatostatin+receptors+in+lung+cancer%3A+From+function+to+molecular+imaging+and+therapeutics&doi=10.6058%2Fjlc.2011.10.2.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Somatostatin receptors in lung cancer: from function to molecular imaging and therapeutics</span></div><div class="casAuthors">Callison, J. Clay, Jr.; Walker, Ronald C.; Massion, Pierre P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-76</span>CODEN:
                <span class="NLM_cas:coden">JLCOAQ</span>;
        ISSN:<span class="NLM_cas:issn">1598-7809</span>.
    
            (<span class="NLM_cas:orgname">Korean Association for the Study of Lung Cancer</span>)
        </div><div class="casAbstract">A review.  Lung cancer is a deadly disease that is difficult to diagnose and even more difficult to treat effectively.  Many pathways are known to affect tumor growth, and targeting these pathways provides the cornerstone by which cancer is treated.  Somatostatin receptors (SSTR) are a family of G protein coupled receptors that signal to alter hormonal secretion, increase apoptosis, and decrease cellular proliferation.  These receptors are expressed in many normal and malignant cells, including both small cell and non-small cell lung cancer.  Synthetic analogs of SSTRs are com. available, but their effects in lung cancer are still largely uncertain.  Signaling pathway studies have shown that SSTRs signal through phosphotyrosine phosphatases to induce apoptosis as well as to decrease cell proliferation.  Radiolabeled SSTR2 analogs are utilized for radiog. imaging of tumors, which, when combined with positron emission tomog.-computed tomog. (PET-CT) may improve detection of lung cancer.  These radiolabeled SSTR2 analogs also hold promise for targeted chemotherapy as well as radiotherapy.  In this review, we summarize what is known about SSTRs and focus our discussion on the knowledge as it relates to lung cancer biol., as well as discuss current and future uses of these receptors for imaging and therapy of lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEXZMGo-vLIrVg90H21EOLACvtfcHk0ljjsa1UrjPOlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFWitrw%253D&md5=ff577795f05694bad9987327e2ff4fa9</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.6058%2Fjlc.2011.10.2.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.6058%252Fjlc.2011.10.2.69%26sid%3Dliteratum%253Aachs%26aulast%3DCallison%26aufirst%3DJ.%2BC.%26aulast%3DWalker%26aufirst%3DR.%2BC.%26aulast%3DMassion%26aufirst%3DP.%2BP.%26atitle%3DSomatostatin%2520receptors%2520in%2520lung%2520cancer%253A%2520From%2520function%2520to%2520molecular%2520imaging%2520and%2520therapeutics%26jtitle%3DJ.%2520Lung%2520Cancer%26date%3D2011%26volume%3D10%26spage%3D69%26epage%3D76%26doi%3D10.6058%2Fjlc.2011.10.2.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barbieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajetto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattarozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Würth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thellung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizzari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florio, T.</span></span> <span> </span><span class="NLM_article-title">Peptide receptor targeting in cancer: The somatostatin paradigm</span>. <i>Int. J. Pept.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>, <span class="NLM_elocation-id">926295</span> <span class="refDoi"> DOI: 10.1155/2013/926295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1155%2F2013%2F926295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=23476673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVSqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+Barbieriauthor=A.+Bajettoauthor=A.+Pattarozziauthor=M.+Gattiauthor=R.+W%C3%BCrthauthor=S.+Thellungauthor=A.+Corsaroauthor=V.+Villaauthor=M.+Nizzariauthor=T.+Florio&title=Peptide+receptor+targeting+in+cancer%3A+The+somatostatin+paradigm&doi=10.1155%2F2013%2F926295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">peptide receptor targeting in cancer: the somatostatin paradigm</span></div><div class="casAuthors">Barbieri, Federica; Bajetto, Adriana; Pattarozzi, Alessandra; Gatti, Monica; Wurth, Roberto; Thellung, Stefano; Corsaro, Alessandro; Villa, Valentina; Nizzari, Mario; Florio, Tullio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptides</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">926295, 20 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJPNJ4</span>;
        ISSN:<span class="NLM_cas:issn">1687-9775</span>.
    
            (<span class="NLM_cas:orgname">Hindawi Publishing Corp.</span>)
        </div><div class="casAbstract">A review.  Peptide receptors involved in pathophysiol. processes represent promising therapeutic targets.  Neuropeptide somatostatin (SST) is produced by specialized cells in a large no. of human organs and tissues.  SST primarily acts as inhibitor of endocrine and exocrine secretion via the activation of five G-protein-coupled receptors, named sst1-5, while in central nervous system, SST acts as a neurotransmitter/neuromodulator, regulating locomotory and cognitive functions.  Crit. points of SST/SST receptor biol., such as signaling pathways of individual receptor subtypes, homo- and hetero-dimerization, trafficking, and cross-talk with growth factor receptors, have been extensively studied, although functions assocd. with several pathol. conditions, including cancer, are still not completely unraveled.  Importantly, SST exerts antiproliferative and antiangiogenic effects on cancer cells in vitro, and on exptl. tumors in vivo.  Moreover, SST agonists are clin. effective as antitumor agents for pituitary adenomas and gastro-pancreatic neuroendocrine tumors.  However, SST receptors being expressed by tumor cells of various tumor histotypes, their pharmacol. use is potentially extendible to other cancer types, although to date no significant results have been obtained.  In this paper the most recent findings on the expression and functional roles of SST and SST receptors in tumor cells are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAJks4TkHrkrVg90H21EOLACvtfcHk0ljjsa1UrjPOlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVSqt7c%253D&md5=fc543678cb04c7297fc77cf0aeb24941</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1155%2F2013%2F926295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F926295%26sid%3Dliteratum%253Aachs%26aulast%3DBarbieri%26aufirst%3DF.%26aulast%3DBajetto%26aufirst%3DA.%26aulast%3DPattarozzi%26aufirst%3DA.%26aulast%3DGatti%26aufirst%3DM.%26aulast%3DW%25C3%25BCrth%26aufirst%3DR.%26aulast%3DThellung%26aufirst%3DS.%26aulast%3DCorsaro%26aufirst%3DA.%26aulast%3DVilla%26aufirst%3DV.%26aulast%3DNizzari%26aufirst%3DM.%26aulast%3DFlorio%26aufirst%3DT.%26atitle%3DPeptide%2520receptor%2520targeting%2520in%2520cancer%253A%2520The%2520somatostatin%2520paradigm%26jtitle%3DInt.%2520J.%2520Pept.%26date%3D2013%26doi%3D10.1155%2F2013%2F926295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">de Herder, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofland, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Lely, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberts, S. W. J.</span></span> <span> </span><span class="NLM_article-title">Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumors</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1677/erc.0.0100451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1677%2Ferc.0.0100451" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=451-458&author=W.+W.+de+Herderauthor=L.+J.+Hoflandauthor=A.+J.+van+der%0ALelyauthor=S.+W.+J.+Lamberts&title=Somatostatin+receptors+in+gastroentero-pancreatic+neuroendocrine+tumors&doi=10.1677%2Ferc.0.0100451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1677%2Ferc.0.0100451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.0.0100451%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BHerder%26aufirst%3DW.%2BW.%26aulast%3DHofland%26aufirst%3DL.%2BJ.%26aulast%3Dvan%2Bder%2BLely%26aufirst%3DA.%2BJ.%26aulast%3DLamberts%26aufirst%3DS.%2BW.%2BJ.%26atitle%3DSomatostatin%2520receptors%2520in%2520gastroentero-pancreatic%2520neuroendocrine%2520tumors%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2003%26volume%3D10%26spage%3D451%26epage%3D458%26doi%3D10.1677%2Ferc.0.0100451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Öberg, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwekkeboom, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenning, E. P.</span></span> <span> </span><span class="NLM_article-title">Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2010.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1053%2Fj.gastro.2010.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=20637207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A280%3ADC%252BC3cjptlGgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2010&pages=742-753&author=K.+E.+%C3%96bergauthor=J.+C.+Reubiauthor=D.+J.+Kwekkeboomauthor=E.+P.+Krenning&title=Role+of+somatostatins+in+gastroenteropancreatic+neuroendocrine+tumor+development+and+therapy&doi=10.1053%2Fj.gastro.2010.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy</span></div><div class="casAuthors">Oberg Kjell E; Reubi Jean-Claude; Kwekkeboom Dik J; Krenning Eric P</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">742-53, 753.e1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have increased in the past 20 years.  GEP-NETs are heterogeneous tumors, in terms of clinical and biological features, that originate from the pancreas or the intestinal tract.  Some GEP-NETs grow very slowly, some grow rapidly and do not cause symptoms, and others cause hormone hypersecretion and associated symptoms.  Most GEP-NETs overexpress receptors for somatostatins.  Somatostatins inhibit the release of many hormones and other secretory proteins; their effects are mediated by G protein-coupled receptors that are expressed in a tissue-specific manner.  Most GEP-NETs overexpress the somatostatin receptor SSTR2; somatostatin analogues are the best therapeutic option for functional neuroendocrine tumors because they reduce hormone-related symptoms and also have antitumor effects.  Long-acting formulations of somatostatin analogues stabilize tumor growth over long periods.  The development of radioactive analogues for imaging and peptide receptor radiotherapy has improved the management of GEP-NETs.  Peptide receptor radiotherapy has significant antitumor effects, increasing overall survival times of patients with tumors that express a high density of SSTRs, particularly SSTR2 and SSTR5.  The multi-receptor somatostatin analogue SOM230 (pasireotide) and chimeric molecules that bind SSTR2 and the dopamine receptor D2 are also being developed to treat patients with GEP-NETs.  Combinations of radioactive labeled and unlabeled somatostatin analogues and therapeutics that inhibit other signaling pathways, such as mammalian target of rapamycin (mTOR) and vascular endothelial growth factor, might be the most effective therapeutics for GEP-NETs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTu3Hef0q6yg5ZoeNcnHOQ9fW6udTcc2ebO7rTpmxGGZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjptlGgtA%253D%253D&md5=102bf2e644f11f9c9e4a15a8f6a6975e</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2010.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2010.07.002%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2596berg%26aufirst%3DK.%2BE.%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26aulast%3DKwekkeboom%26aufirst%3DD.%2BJ.%26aulast%3DKrenning%26aufirst%3DE.%2BP.%26atitle%3DRole%2520of%2520somatostatins%2520in%2520gastroenteropancreatic%2520neuroendocrine%2520tumor%2520development%2520and%2520therapy%26jtitle%3DGastroenterology%26date%3D2010%26volume%3D139%26spage%3D742%26epage%3D753%26doi%3D10.1053%2Fj.gastro.2010.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofland, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberts, S. W. J.</span></span> <span> </span><span class="NLM_article-title">Somatostatin receptor subtype expression in human tumors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">S31</span>– <span class="NLM_lpage">S36</span>, <span class="refDoi"> DOI: 10.1093/annonc/12.suppl_2.S31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1093%2Fannonc%2F12.suppl_2.S31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=11762349" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=S31-S36&author=L.+J.+Hoflandauthor=S.+W.+J.+Lamberts&title=Somatostatin+receptor+subtype+expression+in+human+tumors&doi=10.1093%2Fannonc%2F12.suppl_2.S31"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2F12.suppl_2.S31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252F12.suppl_2.S31%26sid%3Dliteratum%253Aachs%26aulast%3DHofland%26aufirst%3DL.%2BJ.%26aulast%3DLamberts%26aufirst%3DS.%2BW.%2BJ.%26atitle%3DSomatostatin%2520receptor%2520subtype%2520expression%2520in%2520human%2520tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2001%26volume%3D12%26spage%3DS31%26epage%3DS36%26doi%3D10.1093%2Fannonc%2F12.suppl_2.S31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cescato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eltschinger, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivier, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wester, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginj, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonbrunn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span> <span> </span><span class="NLM_article-title">Internalization of sst2, sst3, and sst5 receptors: Effects of somatostatin agonists and antagonists</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">502</span>– <span class="NLM_lpage">511</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=502-511&author=R.+Cescatoauthor=S.+Schulzauthor=B.+Waserauthor=V.+Eltschingerauthor=J.+E.+Rivierauthor=H.-J.+Westerauthor=M.+Cullerauthor=M.+Ginjauthor=Q.+Liuauthor=A.+Schonbrunnauthor=J.+C.+Reubi&title=Internalization+of+sst2%2C+sst3%2C+and+sst5+receptors%3A+Effects+of+somatostatin+agonists+and+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCescato%26aufirst%3DR.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DWaser%26aufirst%3DB.%26aulast%3DEltschinger%26aufirst%3DV.%26aulast%3DRivier%26aufirst%3DJ.%2BE.%26aulast%3DWester%26aufirst%3DH.-J.%26aulast%3DCuller%26aufirst%3DM.%26aulast%3DGinj%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSchonbrunn%26aufirst%3DA.%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26atitle%3DInternalization%2520of%2520sst2%252C%2520sst3%252C%2520and%2520sst5%2520receptors%253A%2520Effects%2520of%2520somatostatin%2520agonists%2520and%2520antagonists%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2006%26volume%3D47%26spage%3D502%26epage%3D511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schally, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armatis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, R.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csernus, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovács, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppán, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szepesházi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahán, Z.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">1794</span>– <span class="NLM_lpage">1799</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.4.1794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1073%2Fpnas.95.4.1794" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=1794-1799&author=A.+Nagyauthor=A.+V.+Schallyauthor=G.+Halmosauthor=P.+Armatisauthor=R.-Z.+Caiauthor=V.+Csernusauthor=M.+Kov%C3%A1csauthor=M.+Kopp%C3%A1nauthor=K.+Szepesh%C3%A1ziauthor=Z.+Kah%C3%A1n&title=Synthesis+and+biological+evaluation+of+cytotoxic+analogs+of+somatostatin+containing+doxorubicin+or+its+intensely+potent+derivative%2C+2-pyrrolinodoxorubicin&doi=10.1073%2Fpnas.95.4.1794"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.4.1794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.4.1794%26sid%3Dliteratum%253Aachs%26aulast%3DNagy%26aufirst%3DA.%26aulast%3DSchally%26aufirst%3DA.%2BV.%26aulast%3DHalmos%26aufirst%3DG.%26aulast%3DArmatis%26aufirst%3DP.%26aulast%3DCai%26aufirst%3DR.-Z.%26aulast%3DCsernus%26aufirst%3DV.%26aulast%3DKov%25C3%25A1cs%26aufirst%3DM.%26aulast%3DKopp%25C3%25A1n%26aufirst%3DM.%26aulast%3DSzepesh%25C3%25A1zi%26aufirst%3DK.%26aulast%3DKah%25C3%25A1n%26aufirst%3DZ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520cytotoxic%2520analogs%2520of%2520somatostatin%2520containing%2520doxorubicin%2520or%2520its%2520intensely%2520potent%2520derivative%252C%25202-pyrrolinodoxorubicin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D1794%26epage%3D1799%26doi%3D10.1073%2Fpnas.95.4.1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuselier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coy, D. H.</span></span> <span> </span><span class="NLM_article-title">A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, αVβ3/αVβ5 and MMP-2/-9</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>246</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2006.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1016%2Fj.canlet.2006.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=16644105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpvFWj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=246&publication_year=2007&pages=157-166&author=L.-C.+Sunauthor=J.+Luoauthor=V.+Mackeyauthor=J.+Fuselierauthor=D.+H.+Coy&title=A+conjugate+of+camptothecin+and+a+somatostatin+analog+against+prostate+cancer+cell+invasion+via+a+possible+signaling+pathway+involving+PI3K%2FAkt%2C+%CE%B1V%CE%B23%2F%CE%B1V%CE%B25+and+MMP-2%2F-9&doi=10.1016%2Fj.canlet.2006.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, αVβ3/αVβ5 and MMP-2/-9</span></div><div class="casAuthors">Sun, Li-Chun; Luo, Jing; Mackey, L. Vienna; Fuselier, Joseph A.; Coy, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">246</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">157-166</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Camptothecin (CPT) was conjugated to the N-terminal of a somatostatin analog (SSA) directly via a carbamate group and a basic N-terminal linking motif, D-Lys-D-Tyr-Lys-D-Tyr-D-Lys.  This new CPT-SSA conjugate termed JF-10-81 was evaluated as a receptor-specific delivery system for its anti-invasive and anti-angiogenic activities.  It was found that, in addn. to blocking migration and invasion of highly invasive prostate cancer PC-3 cells, this conjugate also inhibited in vitro capillary-like tube formation of endothelial cells and in vivo angiogenesis in C57B1/6N female mice.  JF-10-81 blocked PC-3 cell attachment to various extracellular matrix components, mainly to vitronectin, the ligand of cell surface receptors integrin αVβ3 and αVβ5.  Addnl., JF-10-81 reduced expression of integrins αVβ3 and αVβ5 on PC-3 cell surfaces, without effects on β1 or any αβ1 heterodimers.  This conjugate also inactivated phosphorylation of protein kinase B (PKB/Akt), down-regulated the expression of latent matrix metalloproteinase (MMP)-2 and MMP-9, but had little effect on MMP-3/-10.  Meanwhile, membrane type-1 matrix metalloproteinase (MT1-MMP) and the tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) were not detectable in PC-3 cells.  αVβ3/αVβ5 and MMP-2/-9 are known to be highly expressed in many tumor cells and play an important role in tumor progression.  The authors' results support that this conjugate could possibly inhibit prostate cancer PC-3 cell invasion through a signaling pathway involving PI3K/Akt, αVβ3/αVβ5 and MMP-2/-9, and this SSA could be used as an efficient vector to deliver CPT or other cytotoxic agents to target sites for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocuJklhNUdEbVg90H21EOLACvtfcHk0lgszZ2NU6a-dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpvFWj&md5=d1d681020c32108405c6935e666dd5fc</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2006.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2006.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.-C.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DMackey%26aufirst%3DV.%26aulast%3DFuselier%26aufirst%3DJ.%26aulast%3DCoy%26aufirst%3DD.%2BH.%26atitle%3DA%2520conjugate%2520of%2520camptothecin%2520and%2520a%2520somatostatin%2520analog%2520against%2520prostate%2520cancer%2520cell%2520invasion%2520via%2520a%2520possible%2520signaling%2520pathway%2520involving%2520PI3K%252FAkt%252C%2520%25CE%25B1V%25CE%25B23%252F%25CE%25B1V%25CE%25B25%2520and%2520MMP-2%252F-9%26jtitle%3DCancer%2520Lett.%26date%3D2007%26volume%3D246%26spage%3D157%26epage%3D166%26doi%3D10.1016%2Fj.canlet.2006.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Delpassand, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samarghandi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamiditabar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espenan, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erion, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dorisio, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kvols, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfangel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenning, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mojtahedi, A.</span></span> <span> </span><span class="NLM_article-title">Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: The first US phase 2 experience</span>. <i>Pancreas</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">518</span>– <span class="NLM_lpage">525</span>, <span class="refDoi"> DOI: 10.1097/MPA.0000000000000113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1097%2FMPA.0000000000000113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=24632546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFCkur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=518-525&author=E.+S.+Delpassandauthor=A.+Samarghandiauthor=S.+Zamanianauthor=E.+M.+Wolinauthor=M.+Hamiditabarauthor=G.+D.+Espenanauthor=J.+L.+Erionauthor=T.+M.+O%E2%80%99Dorisioauthor=L.+K.+Kvolsauthor=J.+Simonauthor=R.+Wolfangelauthor=A.+Campauthor=E.+P.+Krenningauthor=A.+Mojtahedi&title=Peptide+receptor+radionuclide+therapy+with+177Lu-DOTATATE+for+patients+with+somatostatin+receptor-expressing+neuroendocrine+tumors%3A+The+first+US+phase+2+experience&doi=10.1097%2FMPA.0000000000000113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor-Expressing Neuroendocrine Tumors: The First US Phase 2 Experience</span></div><div class="casAuthors">Delpassand, Ebrahim S.; Samarghandi, Amin; Zamanian, Sara; Wolin, Edward M.; Hamiditabar, Mohammadali; Espenan, Gregory D.; Erion, Jack L.; O'Dorisio, Thomas M.; Kvols, Larry K.; Simon, Jaime; Wolfangel, Robert; Camp, Arthur; Krenning, Eric P.; Mojtahedi, Alireza</div><div class="citationInfo"><span class="NLM_cas:title">Pancreas (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">518-525</span>CODEN:
                <span class="NLM_cas:coden">PANCE4</span>;
        ISSN:<span class="NLM_cas:issn">0885-3177</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs is a novel method of treatment in patients with metastatic neuroendocrine tumors (NETs).  For the first time in the United States, we present preliminary results of the treatment with Lutetium 177 (Lu) DOTATATE in patients with progressive NETs.  Methods: Thirty-seven patients with grade 1 and grade 2 disseminated and progressive gastroenteropancreatic NET were enrolled in a nonrandomized, phase 2 clin. trial.  Repeated cycles of 200 mCi (7.4 GBq; ±10%) were administered up to the cumulative dose of 800 mCi (29.6 GBq; ±10%).  Results: Among 32 evaluable patients, partial response and minimal response to treatment were seen in 28% and 3%, resp., and stable disease was seen in 41% of patients.  A total of 28% had progressive disease.  A response to treatment was significantly assocd. with lower burden of disease in the liver.  No significant acute or delayed hematol. or kidney toxicity was obsd.  An impressive improvement of performance status and quality of life were seen after Lu-DOTATATE therapy.  Conclusions: Treatment with multiple cycles of Lu-DOTATATE peptide receptor radionuclide therapy is well tolerated.  This treatment results in control of the disease in most patients, whereas systemic toxicities are limited and reversible.  Quality of life is also improved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLYzCnwZKdbVg90H21EOLACvtfcHk0lh_OFnptJNMPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFCkur8%253D&md5=b2e9414467870ee7e72b3ce50cd2ee6c</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1097%2FMPA.0000000000000113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMPA.0000000000000113%26sid%3Dliteratum%253Aachs%26aulast%3DDelpassand%26aufirst%3DE.%2BS.%26aulast%3DSamarghandi%26aufirst%3DA.%26aulast%3DZamanian%26aufirst%3DS.%26aulast%3DWolin%26aufirst%3DE.%2BM.%26aulast%3DHamiditabar%26aufirst%3DM.%26aulast%3DEspenan%26aufirst%3DG.%2BD.%26aulast%3DErion%26aufirst%3DJ.%2BL.%26aulast%3DO%25E2%2580%2599Dorisio%26aufirst%3DT.%2BM.%26aulast%3DKvols%26aufirst%3DL.%2BK.%26aulast%3DSimon%26aufirst%3DJ.%26aulast%3DWolfangel%26aufirst%3DR.%26aulast%3DCamp%26aufirst%3DA.%26aulast%3DKrenning%26aufirst%3DE.%2BP.%26aulast%3DMojtahedi%26aufirst%3DA.%26atitle%3DPeptide%2520receptor%2520radionuclide%2520therapy%2520with%2520177Lu-DOTATATE%2520for%2520patients%2520with%2520somatostatin%2520receptor-expressing%2520neuroendocrine%2520tumors%253A%2520The%2520first%2520US%2520phase%25202%2520experience%26jtitle%3DPancreas%26date%3D2014%26volume%3D43%26spage%3D518%26epage%3D525%26doi%3D10.1097%2FMPA.0000000000000113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Redko, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragozin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreii, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helena, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amnon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talia, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, O.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genady, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gary, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, drug release, and biological evaluation of new anticancer drug–bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety</span>. <i>Biopolymers</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">743</span>– <span class="NLM_lpage">752</span>, <span class="refDoi"> DOI: 10.1002/bip.22694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1002%2Fbip.22694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=26058565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWlu7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2015&pages=743-752&author=B.+Redkoauthor=E.+Ragozinauthor=B.+Andreiiauthor=T.+Helenaauthor=A.+Amnonauthor=S.+Z.+Taliaauthor=O.-H.+Morauthor=K.+Genadyauthor=G.+Gary&title=Synthesis%2C+drug+release%2C+and+biological+evaluation+of+new+anticancer+drug%E2%80%93bioconjugates+containing+somatostatin+backbone+cyclic+analog+as+a+targeting+moiety&doi=10.1002%2Fbip.22694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16dR"><div class="casContent"><span class="casTitleNuber">16d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety</span></div><div class="casAuthors">Redko, Boris; Ragozin, Elena; Andreii, Bazylevich; Helena, Tuchinsky; Amnon, Albeck; Talia, Shekhter Zahavi; Mor, Oron-Herman; Genady, Kostenich; Gary, Gellerman</div><div class="citationInfo"><span class="NLM_cas:title">Biopolymers</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">743-752</span>CODEN:
                <span class="NLM_cas:coden">BIPMAA</span>;
        ISSN:<span class="NLM_cas:issn">0006-3525</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Peptide conjugates contg. somatostatin (SST) cyclic analogs as a targeting moiety are able to deliver chemotherapeutic agents specifically to cancer cells expressing SST receptors (SSTRs), and hence increasing their local efficacy while limiting the peripheral toxicity.  Here, we report on the synthesis and biochem. characterization of new SSTR-specific anticancer peptide conjugates, with different anticancer payloads acting through different oncogenic mechanisms to evaluate their biol. activities and to provide a comparative study of their drug release profiles.  The SSTR2-specific backbone cyclic peptide 3207-86 was chosen for the synthesis of a variety of novel anticancer drug conjugates with a broad drug release capabilities.  The N-terminus of 3207-86 was equipped with GABA to generate free amino group available for the conjugation of chlorambucil, Camptothecin (CPT), Combretastatin 4A, ABT-751, and Amonafide through the formation of various biodegradable bonds.  The chemo- and biostability/drug release of all the synthetic compds. was investigated at various pHs and in the presence of mouse liver homogenate, resp.  Their selective cytotoxic effect was evaluated on several human cancer cell lines that overexpress SSTR2.  Compared with the free drugs, our peptide-drug conjugates exhibited considerable cytotoxic effect on cancer cell lines vs. low SSTR2-expressed human embryonic kidney cells.  Functional versatility of the conjugates was reflected in the variability of their drug release profiles, whereas the conserved sequence of a selective binding to the SSTR2 likely preserved their binding to the receptor and consequently their favorable toxicity toward targeted cancer cells. © 2015 Wiley Periodicals, Inc.  Biopolymers (Pept Sci) 104: 743-752, 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBjf0vFF_RnrVg90H21EOLACvtfcHk0lh_OFnptJNMPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWlu7nO&md5=e2d73778caf77a1bc42e54f252b10d8d</span></div><a href="/servlet/linkout?suffix=cit16d&amp;dbid=16384&amp;doi=10.1002%2Fbip.22694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.22694%26sid%3Dliteratum%253Aachs%26aulast%3DRedko%26aufirst%3DB.%26aulast%3DRagozin%26aufirst%3DE.%26aulast%3DAndreii%26aufirst%3DB.%26aulast%3DHelena%26aufirst%3DT.%26aulast%3DAmnon%26aufirst%3DA.%26aulast%3DTalia%26aufirst%3DS.%2BZ.%26aulast%3DMor%26aufirst%3DO.-H.%26aulast%3DGenady%26aufirst%3DK.%26aulast%3DGary%26aufirst%3DG.%26atitle%3DSynthesis%252C%2520drug%2520release%252C%2520and%2520biological%2520evaluation%2520of%2520new%2520anticancer%2520drug%25E2%2580%2593bioconjugates%2520containing%2520somatostatin%2520backbone%2520cyclic%2520analog%2520as%2520a%2520targeting%2520moiety%26jtitle%3DBiopolymers%26date%3D2015%26volume%3D104%26spage%3D743%26epage%3D752%26doi%3D10.1002%2Fbip.22694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ragozin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazylevich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuchinsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bovina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekhter Zahavi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oron-Herman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luboshits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gellerman, G.</span></span> <span> </span><span class="NLM_article-title">New somatostatin-drug conjugates for effective targeting pancreatic cancer</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3825</span>– <span class="NLM_lpage">3836</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.06.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1016%2Fj.bmc.2018.06.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=3825-3836&author=E.+Ragozinauthor=A.+Hesinauthor=A.+Bazylevichauthor=H.+Tuchinskyauthor=A.+Bovinaauthor=T.+Shekhter+Zahaviauthor=M.+Oron-Hermanauthor=G.+Kostenichauthor=M.+A.+Firerauthor=T.+Rubinekauthor=I.+Wolfauthor=G.+Luboshitsauthor=M.+Y.+Shermanauthor=G.+Gellerman&title=New+somatostatin-drug+conjugates+for+effective+targeting+pancreatic+cancer&doi=10.1016%2Fj.bmc.2018.06.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.06.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.06.032%26sid%3Dliteratum%253Aachs%26aulast%3DRagozin%26aufirst%3DE.%26aulast%3DHesin%26aufirst%3DA.%26aulast%3DBazylevich%26aufirst%3DA.%26aulast%3DTuchinsky%26aufirst%3DH.%26aulast%3DBovina%26aufirst%3DA.%26aulast%3DShekhter%2BZahavi%26aufirst%3DT.%26aulast%3DOron-Herman%26aufirst%3DM.%26aulast%3DKostenich%26aufirst%3DG.%26aulast%3DFirer%26aufirst%3DM.%2BA.%26aulast%3DRubinek%26aufirst%3DT.%26aulast%3DWolf%26aufirst%3DI.%26aulast%3DLuboshits%26aufirst%3DG.%26aulast%3DSherman%26aufirst%3DM.%2BY.%26aulast%3DGellerman%26aufirst%3DG.%26atitle%3DNew%2520somatostatin-drug%2520conjugates%2520for%2520effective%2520targeting%2520pancreatic%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D3825%26epage%3D3836%26doi%3D10.1016%2Fj.bmc.2018.06.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanagh, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteman, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leece, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovtun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldmacher, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeves, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blättler, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span> <span> </span><span class="NLM_article-title">Semisynthetic maytansine analogues for the targeted treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4392</span>– <span class="NLM_lpage">4408</span>, <span class="refDoi"> DOI: 10.1021/jm060319f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060319f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4392-4408&author=W.+C.+Widdisonauthor=S.+D.+Wilhelmauthor=E.+E.+Cavanaghauthor=K.+R.+Whitemanauthor=B.+A.+Leeceauthor=Y.+Kovtunauthor=V.+S.+Goldmacherauthor=H.+Xieauthor=R.+M.+Steevesauthor=R.+J.+Lutzauthor=R.+Zhaoauthor=L.+Wangauthor=W.+A.+Bl%C3%A4ttlerauthor=R.+V.+J.+Chari&title=Semisynthetic+maytansine+analogues+for+the+targeted+treatment+of+cancer&doi=10.1021%2Fjm060319f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Semisynthetic Maytansine Analogs for the Targeted Treatment of Cancer</span></div><div class="casAuthors">Widdison, Wayne C.; Wilhelm, Sharon D.; Cavanagh, Emily E.; Whiteman, Kathleen R.; Leece, Barbara A.; Kovtun, Yelena; Goldmacher, Victor S.; Xie, Hongsheng; Steeves, Rita M.; Lutz, Robert J.; Zhao, Robert; Wang, Lintao; Blaettler, Walter A.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clin. trials because of unacceptable systemic toxicity.  The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells.  A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized.  The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied.  Several of these maytansinoids were found to be even more potent in vitro than maytansine.  The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozfQO-pe0iJLVg90H21EOLACvtfcHk0ljIg3WklqwSPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D&md5=a06c19d2d5166b0ca806babf9624c48b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm060319f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060319f%26sid%3Dliteratum%253Aachs%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DWilhelm%26aufirst%3DS.%2BD.%26aulast%3DCavanagh%26aufirst%3DE.%2BE.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DLeece%26aufirst%3DB.%2BA.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DSteeves%26aufirst%3DR.%2BM.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBl%25C3%25A4ttler%26aufirst%3DW.%2BA.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26atitle%3DSemisynthetic%2520maytansine%2520analogues%2520for%2520the%2520targeted%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4392%26epage%3D4408%26doi%3D10.1021%2Fjm060319f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouchet, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galmarini, C. M.</span></span> <span> </span><span class="NLM_article-title">Cabazitaxel, a new taxane with favorable properties</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1358/dot.2010.46.10.1519019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1358%2Fdot.2010.46.10.1519019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1agurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=735-742&author=B.+P.+Bouchetauthor=C.+M.+Galmarini&title=Cabazitaxel%2C+a+new+taxane+with+favorable+properties&doi=10.1358%2Fdot.2010.46.10.1519019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cabazitaxel, a new taxane with favorable properties</span></div><div class="casAuthors">Bouchet, B. P.; Galmarini, C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">735-742</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Cabazitaxel is a new taxane characterized by convenient administration, a favorable pharmacokinetic and safety profile and a decreased propensity for P-glycoprotein (Pgp)-mediated drug resistance.  In preclin. studies cabazitaxel inhibited cell growth in a wide range of human cancer cell lines, including tumor models expressing Pgp.  Phase I clin. trials established that the cabazitaxel side effect profile is similar to that reported for taxanes, with neutropenia and neuropathy being the most commonly reported toxicities.  Further clin. studies have revealed that cabazitaxel is clin. active in women with taxane-resistant metastatic breast cancer and in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.  The TROPIC phase III trial concluded that, compared to mitoxantrone/prednisone, the combination cabazitaxel/prednisone conferred a statistically significantly longer overall survival in patients after treatment with a docetaxel-contg. regimen, providing the basis for its FDA approval in 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovgWY0kdE85bVg90H21EOLACvtfcHk0ljIg3WklqwSPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1agurzI&md5=8fd4e757a1fcaa14d8774166aab2be38</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1358%2Fdot.2010.46.10.1519019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2010.46.10.1519019%26sid%3Dliteratum%253Aachs%26aulast%3DBouchet%26aufirst%3DB.%2BP.%26aulast%3DGalmarini%26aufirst%3DC.%2BM.%26atitle%3DCabazitaxel%252C%2520a%2520new%2520taxane%2520with%2520favorable%2520properties%26jtitle%3DDrugs%2520Today%26date%3D2010%26volume%3D46%26spage%3D735%26epage%3D742%26doi%3D10.1358%2Fdot.2010.46.10.1519019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doronina, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toki, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torgov, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelsohn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerveny, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chace, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBlanc, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearing, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bovee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegall, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francisco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Development of potent monoclonal antibody auristatin conjugates for cancer therapy</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">778</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1038/nbt832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1038%2Fnbt832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=12778055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFertLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=778-784&author=S.+O.+Doroninaauthor=B.+E.+Tokiauthor=M.+Y.+Torgovauthor=B.+A.+Mendelsohnauthor=C.+G.+Cervenyauthor=D.+F.+Chaceauthor=R.+L.+DeBlancauthor=R.+P.+Gearingauthor=T.+D.+Boveeauthor=C.+B.+Siegallauthor=J.+A.+Franciscoauthor=A.+F.+Wahlauthor=D.+L.+Meyerauthor=P.+D.+Senter&title=Development+of+potent+monoclonal+antibody+auristatin+conjugates+for+cancer+therapy&doi=10.1038%2Fnbt832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Development of potent monoclonal antibody auristatin conjugates for cancer therapy</span></div><div class="casAuthors">Doronina, Svetlana O.; Toki, Brian E.; Torgov, Michael Y.; Mendelsohn, Brian A.; Cerveny, Charles G.; Chace, Dana F.; DeBlanc, Ron L.; Gearing, R. Patrick; Bovee, Tim D.; Siegall, Clay B.; Francisco, Joseph A.; Wahl, Alan F.; Meyer, Damon L.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">778-784</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We describe the in vitro and in vivo properties of monoclonal antibody (mAb)-drug conjugates consisting of the potent synthetic dolastatin 10 analogs auristatin E (AE) and monomethylauristatin E (MMAE), linked to the chimeric mAbs cBR96 (specific to Lewis Y on carcinomas) and cAC10 (specific to CD30 on hematol. malignancies).  The linkers used for conjugate formation included an acid-labile hydrazone and protease-sensitive dipeptides, leading to uniformly substituted conjugates that efficiently released active drug in the lysosomes of antigen-pos. (Ag+) tumor cells.  The peptide-linked mAb-valine-citrulline-MMAE and mAb-phenylalanine-lysine-MMAE conjugates were much more stable in buffers and plasma than the conjugates of mAb and the hydrazone of 5-benzoylvaleric acid-AE ester (AEVB).  As a result, the mAb-Val-Cit-MMAE conjugates exhibited greater in vitro specificity and lower in vivo toxicity than corresponding hydrazone conjugates.  In vivo studies demonstrated that the peptide-linked conjugates induced regressions and cures of established tumor xenografts with therapeutic indexes as high as 60-fold.  These conjugates illustrate the importance of linker technol., drug potency and conjugation methodol. in developing safe and efficacious mAb-drug conjugates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro97SFKtdQ7rVg90H21EOLACvtfcHk0ljIg3WklqwSPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFertLc%253D&md5=d77716ec93de5ac7473c18a597339086</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnbt832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt832%26sid%3Dliteratum%253Aachs%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DToki%26aufirst%3DB.%2BE.%26aulast%3DTorgov%26aufirst%3DM.%2BY.%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DChace%26aufirst%3DD.%2BF.%26aulast%3DDeBlanc%26aufirst%3DR.%2BL.%26aulast%3DGearing%26aufirst%3DR.%2BP.%26aulast%3DBovee%26aufirst%3DT.%2BD.%26aulast%3DSiegall%26aufirst%3DC.%2BB.%26aulast%3DFrancisco%26aufirst%3DJ.%2BA.%26aulast%3DWahl%26aufirst%3DA.%2BF.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DDevelopment%2520of%2520potent%2520monoclonal%2520antibody%2520auristatin%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Biotechnol.%26date%3D2003%26volume%3D21%26spage%3D778%26epage%3D784%26doi%3D10.1038%2Fnbt832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henne, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doorneweerd, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenbrink, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kularatne, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and activity of a folate peptide camptothecin prodrug</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">5350</span>– <span class="NLM_lpage">5355</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.07.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1016%2Fj.bmcl.2006.07.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=16901694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlCqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=5350-5355&author=W.+A.+Henneauthor=D.+D.+Doorneweerdauthor=A.+R.+Hilgenbrinkauthor=S.+A.+Kularatneauthor=P.+S.+Low&title=Synthesis+and+activity+of+a+folate+peptide+camptothecin+prodrug&doi=10.1016%2Fj.bmcl.2006.07.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and activity of a folate peptide camptothecin prodrug</span></div><div class="casAuthors">Henne, Walter A.; Doorneweerd, Derek D.; Hilgenbrink, Andrew R.; Kularatne, Sumith A.; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5350-5355</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A folate receptor targeted camptothecin prodrug was synthesized using a hydrophilic peptide spacer linked to folate via a releasable disulfide carbonate linker.  The conjugate was found to possess high affinity for folate receptor-expressing cells and inhibited cell proliferation in human KB cells with an IC50 of 10 nM.  Activity of the prodrug was completely blocked by excess folic acid, demonstrating receptor-mediated uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqISsLYrXKp-7Vg90H21EOLACvtfcHk0lg3AtMFckv8Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlCqtL8%253D&md5=716a8d5625943d4d9f152d17ec82ba42</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.07.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.07.076%26sid%3Dliteratum%253Aachs%26aulast%3DHenne%26aufirst%3DW.%2BA.%26aulast%3DDoorneweerd%26aufirst%3DD.%2BD.%26aulast%3DHilgenbrink%26aufirst%3DA.%2BR.%26aulast%3DKularatne%26aufirst%3DS.%2BA.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DSynthesis%2520and%2520activity%2520of%2520a%2520folate%2520peptide%2520camptothecin%2520prodrug%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D5350%26epage%3D5355%26doi%3D10.1016%2Fj.bmcl.2006.07.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Omelyanenko, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopečovà, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopeček, J.</span></span> <span> </span><span class="NLM_article-title">HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">600</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1097-0215(19980209)75:4<600::AID-IJC18>3.0.CO;2-C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1002%2F%28SICI%291097-0215%2819980209%2975%3A4%3C600%3A%3AAID-IJC18%3E3.0.CO%3B2-C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=9466663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADyaK1cXhtV2ltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1998&pages=600-608&author=V.+Omelyanenkoauthor=C.+Gentryauthor=P.+Kope%C4%8Dov%C3%A0author=J.+Kope%C4%8Dek&title=HPMA+copolymer-anticancer+drug-OV-TL16+antibody+conjugates.+II.+Processing+in+epithelial+ovarian+carcinoma+cells+in+vitro&doi=10.1002%2F%28SICI%291097-0215%2819980209%2975%3A4%3C600%3A%3AAID-IJC18%3E3.0.CO%3B2-C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro</span></div><div class="casAuthors">Omelyanenko, Vladimir; Gentry, Christine; Kopeckova, Pavla; Kopecek, Jindrich</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">600-608</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The binding, internalization, subcellular trafficking and in vitro cytotoxicity of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-anti-cancer drug-OV-TL16 antibody (Ab) conjugates in the ovarian carcinoma OVCAR-3 cell line have been investigated.  Adriamycin (ADR) and meso chlorin e6 mono(N-2-aminoethylamide) (Mce6) photosensitizer were used as anti-cancer drugs.  Targeted (Ab-contg.) conjugates were compared with non-targeted HPMA copolymer-drug conjugates and with free drugs.  Targeted conjugates were taken up rapidly by cells and detected within lysosomes by confocal fluorescence microscopy.  The ADR attached to polymer chains via a degradable GFLG spacer was released from the conjugate, diffused via the lysosomal membrane into the cytoplasm and ultimately accumulated in the cell nuclei.  In contrast, conjugates contg. ADR bound via the GG spacer accumulated in the lysosomes, but no fluorescence could be detected in the cell nuclei.  Binding the drugs to a non-targeted HPMA copolymer decreased their cytotoxicity in vitro.  The IC50 dose increased from 2 pM for free ADR to 150 μM for P(GFLG)-ADR (P is the HPMA copolymer backbone) and from 0.34 pM for free Mce6 (with light) to 290 μM for P-(GG)-Mce6.  However, attachment of OV-TL16 Abs rendered HPMA copolymer-drug conjugates biorecognizable by OVCAR-3 cells and markedly increased their cytotoxicity.  The IC50 doses were 4.4 and 0.38 μM for the targeted conjugates P(GFLG)-ADR-Ab and P(GG)-Mce6-Ab (with light), resp.  Biorecognition was shown to be specific by inhibition expts. with free Ab.  The findings indicate the potential of these conjugates as effective agents in the treatment of ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMEdOuzvzGhLVg90H21EOLACvtfcHk0lg3AtMFckv8Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtV2ltb4%253D&md5=326985aa62a3170e9e02346d71ce737e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819980209%2975%3A4%3C600%3A%3AAID-IJC18%3E3.0.CO%3B2-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819980209%252975%253A4%253C600%253A%253AAID-IJC18%253E3.0.CO%253B2-C%26sid%3Dliteratum%253Aachs%26aulast%3DOmelyanenko%26aufirst%3DV.%26aulast%3DGentry%26aufirst%3DC.%26aulast%3DKope%25C4%258Dov%25C3%25A0%26aufirst%3DP.%26aulast%3DKope%25C4%258Dek%26aufirst%3DJ.%26atitle%3DHPMA%2520copolymer-anticancer%2520drug-OV-TL16%2520antibody%2520conjugates.%2520II.%2520Processing%2520in%2520epithelial%2520ovarian%2520carcinoma%2520cells%2520in%2520vitro%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1998%26volume%3D75%26spage%3D600%26epage%3D608%26doi%3D10.1002%2F%28SICI%291097-0215%2819980209%2975%3A4%3C600%3A%3AAID-IJC18%3E3.0.CO%3B2-C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, R.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szoke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redding, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schally, A. V.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activity of highly potent octapeptide analogs of somatostatin</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">1896</span>– <span class="NLM_lpage">1900</span>, <span class="refDoi"> DOI: 10.1073/pnas.83.6.1896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1073%2Fpnas.83.6.1896" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1986&pages=1896-1900&author=R.-Z.+Caiauthor=B.+Szokeauthor=R.+Luauthor=D.+Fuauthor=T.+W.+Reddingauthor=A.+V.+Schally&title=Synthesis+and+biological+activity+of+highly+potent+octapeptide+analogs+of+somatostatin&doi=10.1073%2Fpnas.83.6.1896"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.83.6.1896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.83.6.1896%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DR.-Z.%26aulast%3DSzoke%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DD.%26aulast%3DRedding%26aufirst%3DT.%2BW.%26aulast%3DSchally%26aufirst%3DA.%2BV.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520highly%2520potent%2520octapeptide%2520analogs%2520of%2520somatostatin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1986%26volume%3D83%26spage%3D1896%26epage%3D1900%26doi%3D10.1073%2Fpnas.83.6.1896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cyr, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guaraldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azure, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lister-James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinkelborg, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, R. T.</span></span> <span> </span><span class="NLM_article-title">Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1354</span>– <span class="NLM_lpage">1364</span>, <span class="refDoi"> DOI: 10.1021/jm061290i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061290i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1354-1364&author=J.+E.+Cyrauthor=D.+A.+Pearsonauthor=D.+M.+Wilsonauthor=C.+A.+Nelsonauthor=M.+Guaraldiauthor=M.+T.+Azureauthor=J.+Lister-Jamesauthor=L.+M.+Dinkelborgauthor=R.+T.+Dean&title=Somatostatin+receptor-binding+peptides+suitable+for+tumor+radiotherapy+with+Re-188+or+Re-186.+Chemistry+and+initial+biological+studies&doi=10.1021%2Fjm061290i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm061290i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061290i%26sid%3Dliteratum%253Aachs%26aulast%3DCyr%26aufirst%3DJ.%2BE.%26aulast%3DPearson%26aufirst%3DD.%2BA.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DNelson%26aufirst%3DC.%2BA.%26aulast%3DGuaraldi%26aufirst%3DM.%26aulast%3DAzure%26aufirst%3DM.%2BT.%26aulast%3DLister-James%26aufirst%3DJ.%26aulast%3DDinkelborg%26aufirst%3DL.%2BM.%26aulast%3DDean%26aufirst%3DR.%2BT.%26atitle%3DSomatostatin%2520receptor-binding%2520peptides%2520suitable%2520for%2520tumor%2520radiotherapy%2520with%2520Re-188%2520or%2520Re-186.%2520Chemistry%2520and%2520initial%2520biological%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1354%26epage%3D1364%26doi%3D10.1021%2Fjm061290i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schär, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppeler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäcke, H. R.</span></span> <span> </span><span class="NLM_article-title">Affinity profiles for human somatostatin receptor subtypes sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use</span>. <i>Eur. J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.1007/s002590050034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1007%2Fs002590050034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10774879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhsVWns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2000&pages=273-282&author=J.+C.+Reubiauthor=J.-C.+Sch%C3%A4rauthor=B.+Waserauthor=S.+Wengerauthor=A.+Heppelerauthor=J.+Schmittauthor=H.+R.+M%C3%A4cke&title=Affinity+profiles+for+human+somatostatin+receptor+subtypes+sst1-sst5+of+somatostatin+radiotracers+selected+for+scintigraphic+and+radiotherapeutic+use&doi=10.1007%2Fs002590050034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use</span></div><div class="casAuthors">Reubi, Jean Claude; Schar, Jean-Claude; Waser, Beatrice; Wenger, Sandra; Heppeler, Axel; Schmitt, Jorg S.; Macke, Helmut R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-282</span>CODEN:
                <span class="NLM_cas:coden">EJNMD9</span>;
        ISSN:<span class="NLM_cas:issn">0340-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">In vivo somatostatin receptor scintigraphy using Octreoscan is a valuable method for the visualization of human endocrine tumors and their metastases.  Recently, several new, alternative somatostatin radioligands have been synthesized for diagnostic and radiotherapeutic use in vivo.  Since human tumors are known to express various somatostatin receptor subtypes, it is mandatory to assess the receptor subtype affinity profile of such somatostatin radiotracers.  Using cell lines transfected with somatostatin receptor subtypes sst1, sst2, sst3, sst4 and sst5, we have evaluated the in vitro binding characteristics of labeled (indium, yttrium, gallium) and unlabeled DOTA-[Tyr3]-octreotide, DOTA-octreotide, DOTA-lanreotide, DOTA-vapreotide, DTPA-[Tyr3]-octreotate and DOTA-[Tyr3]-octreotate.  Small structural modifications, chelator substitution or metal replacement were shown to considerably affect the binding affinity.  A marked improvement of sst2 affinity was found for Ga-DOTA-[Tyr3]-octreotide (IC50 2.5 nM) compared with the Y-labeled compd. and Octreoscan.  An excellent binding affinity for sst2 in the same range was also found for In-DTPA-[Tyr3]-octreotate (IC50 1.3 nM) and for Y-DOTA-[Tyr3]-octreotate (IC50 1.6 nM).  Remarkably, Ga-DOTA-[Tyr3]-octreotate bound at sst2 with a considerably higher affinity (IC50 0.2 nM).  An up to 30-fold improvement in sst3 affinity was obsd. for unlabeled or Y-labeled DOTA-octreotide compared with their Tyr3-contg. analog, suggesting that replacement of Tyr3 by Phe is crucial for high sst3 affinity.  Substitution in the octreotide mol. of the DTPA by DOTA improved the sst3 binding affinity 14-fold.  Whereas Y-DOTA-lanreotide had only low affinity for sst3 and sst4, it had the highest affinity for sst5 among the tested compds. (IC50 16 nM).  Increased binding affinity for sst3 and sst5 was obsd. for DOTA-[Tyr3]-octreotide, DOTA-lanreotide and DOTA-vapreotide when they were labeled with yttrium.  These marked changes in subtype affinity profiles are due not only to the different chem. structures but also to the different charges and hydrophilicity of these compds.  Interestingly, even the coordination geometry of the radiometal complex remote from the pharmacophoric amino acids has a significant influence on affinity profiles as shown with Y-DOTA vs. Ga-DOTA in either [Tyr3]-octreotide or [Tyr3]-octreotate.  Such changes in sst affinity profiles must be identified in newly designed radiotracers used for somatostatin receptor scintigraphy in order to correctly interpret in vivo scintigraphic data.  These observations may represent basic principles relevant to the development of other peptide radioligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRKqYdWT35ELVg90H21EOLACvtfcHk0liQKPzDFbM8Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhsVWns7w%253D&md5=3f9cd3963bcc09b71c4c6d38a2487b14</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs002590050034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002590050034%26sid%3Dliteratum%253Aachs%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26aulast%3DSch%25C3%25A4r%26aufirst%3DJ.-C.%26aulast%3DWaser%26aufirst%3DB.%26aulast%3DWenger%26aufirst%3DS.%26aulast%3DHeppeler%26aufirst%3DA.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DM%25C3%25A4cke%26aufirst%3DH.%2BR.%26atitle%3DAffinity%2520profiles%2520for%2520human%2520somatostatin%2520receptor%2520subtypes%2520sst1-sst5%2520of%2520somatostatin%2520radiotracers%2520selected%2520for%2520scintigraphic%2520and%2520radiotherapeutic%2520use%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%26date%3D2000%26volume%3D27%26spage%3D273%26epage%3D282%26doi%3D10.1007%2Fs002590050034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kellogg, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovtun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leece, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteman, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, R. J.</span></span> <span> </span><span class="NLM_article-title">Disulfide-linked antibody-maytansinoid conjugates: Optimization of in vivo activity by varying the steric hinderance at carbon atoms adjacent to the disulfide linkage</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1021/bc100480a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc100480a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFKnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=717-727&author=B.+A.+Kelloggauthor=L.+Garrettauthor=Y.+Kovtunauthor=K.+C.+Laiauthor=B.+Leeceauthor=M.+Millerauthor=G.+Payneauthor=R.+Steevesauthor=K.+R.+Whitemanauthor=W.+Widdisonauthor=H.+Xieauthor=R.+Singhauthor=R.+V.+J.+Chariauthor=J.+M.+Lambertauthor=R.+J.+Lutz&title=Disulfide-linked+antibody-maytansinoid+conjugates%3A+Optimization+of+in+vivo+activity+by+varying+the+steric+hinderance+at+carbon+atoms+adjacent+to+the+disulfide+linkage&doi=10.1021%2Fbc100480a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage</span></div><div class="casAuthors">Kellogg, Brenda A.; Garrett, Lisa; Kovtun, Yelena; Lai, Katharine C.; Leece, Barbara; Miller, Michael; Payne, Gillian; Steeves, Rita; Whiteman, Kathleen R.; Widdison, Wayne; Xie, Hongsheng; Singh, Rajeeva; Chari, Ravi V. J.; Lambert, John M.; Lutz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">717-727</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this report, we describe the synthesis of a panel of disulfide-linked huC242 (anti-CanAg) antibody maytansinoid conjugates (AMCs), which have varying levels of steric hindrance around the disulfide bond, in order to investigate the relationship between stability to redn. of the disulfide linker and antitumor activity of the conjugate in vivo.  The conjugates were first tested for stability to redn. by dithiothreitol in vitro and for plasma stability in CD1 mice.  It was found that the conjugates having the more sterically hindered disulfide linkages were more stable to reductive cleavage of the maytansinoid in both settings.  When the panel of conjugates was tested for in vivo efficacy in two human colon cancer xenograft models in SCID mice, it was found that the conjugate with intermediate disulfide bond stability having two Me groups on the maytansinoid side of the disulfide bond and no Me groups on the linker side of the disulfide bond (huC242-SPDB-DM4) displayed the best efficacy.  The ranking of in vivo efficacies of the conjugates was not predicted by their in vitro potencies, since all conjugates were highly active in vitro, including a huC242-SMCC-DM1 conjugate with a noncleavable linkage which showed only marginal activity in vivo.  These data suggest that factors in addn. to intrinsic conjugate potency and conjugate half-life in plasma influence the magnitude of antitumor activity obsd. for an AMC in vivo.  We provide evidence that bystander killing of neighboring nontargeted tumor cells by diffusible cytotoxic metabolites produced from target cell processing of disulfide-linked antibody-maytansinoid conjugates may be one addnl. factor contributing to the activity of these conjugates in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGmGw-cH238bVg90H21EOLACvtfcHk0liQKPzDFbM8Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFKnsro%253D&md5=ef2969ceaaea23e81da2edf06f62ea7e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbc100480a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc100480a%26sid%3Dliteratum%253Aachs%26aulast%3DKellogg%26aufirst%3DB.%2BA.%26aulast%3DGarrett%26aufirst%3DL.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DK.%2BC.%26aulast%3DLeece%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DPayne%26aufirst%3DG.%26aulast%3DSteeves%26aufirst%3DR.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DWiddison%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26atitle%3DDisulfide-linked%2520antibody-maytansinoid%2520conjugates%253A%2520Optimization%2520of%2520in%2520vivo%2520activity%2520by%2520varying%2520the%2520steric%2520hinderance%2520at%2520carbon%2520atoms%2520adjacent%2520to%2520the%2520disulfide%2520linkage%26jtitle%3DBioconjugate%2520Chem.%26date%3D2011%26volume%3D22%26spage%3D717%26epage%3D727%26doi%3D10.1021%2Fbc100480a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12a','cit12b','cit12c','cit12d'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b','cit16c','cit16d','cit16e'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 14 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matt  Lechner</span>, <span class="hlFld-ContribAuthor ">Volker H.  Schartinger</span>, <span class="hlFld-ContribAuthor ">Christopher D.  Steele</span>, <span class="hlFld-ContribAuthor ">Wen Long  Nei</span>, <span class="hlFld-ContribAuthor ">Marc Lucas  Ooft</span>, <span class="hlFld-ContribAuthor ">Liesa-Marie  Schreiber</span>, <span class="hlFld-ContribAuthor ">Christodoulos P.  Pipinikas</span>, <span class="hlFld-ContribAuthor ">Grace Tin-Yun  Chung</span>, <span class="hlFld-ContribAuthor ">Yuk Yu  Chan</span>, <span class="hlFld-ContribAuthor ">Feng  Wu</span>, <span class="hlFld-ContribAuthor ">Ka-Fai  To</span>, <span class="hlFld-ContribAuthor ">Chi Man  Tsang</span>, <span class="hlFld-ContribAuthor ">Wayne  Pearce</span>, <span class="hlFld-ContribAuthor ">Daniele  Morelli</span>, <span class="hlFld-ContribAuthor ">Martin  Philpott</span>, <span class="hlFld-ContribAuthor ">Liam  Masterson</span>, <span class="hlFld-ContribAuthor ">Reshma  Nibhani</span>, <span class="hlFld-ContribAuthor ">Graham  Wells</span>, <span class="hlFld-ContribAuthor ">Christopher G.  Bell</span>, <span class="hlFld-ContribAuthor ">Julia  Koller</span>, <span class="hlFld-ContribAuthor ">Susanne  Delecluse</span>, <span class="hlFld-ContribAuthor ">Yim Ling  Yip</span>, <span class="hlFld-ContribAuthor ">Jacklyn  Liu</span>, <span class="hlFld-ContribAuthor ">Cillian T.  Forde</span>, <span class="hlFld-ContribAuthor ">Martin D.  Forster</span>, <span class="hlFld-ContribAuthor ">Amrita  Jay</span>, <span class="hlFld-ContribAuthor ">József  Dudás</span>, <span class="hlFld-ContribAuthor ">Annika  Krapp</span>, <span class="hlFld-ContribAuthor ">Simon  Wan</span>, <span class="hlFld-ContribAuthor ">Christian  Uprimny</span>, <span class="hlFld-ContribAuthor ">Susanne  Sprung</span>, <span class="hlFld-ContribAuthor ">Johannes  Haybaeck</span>, <span class="hlFld-ContribAuthor ">Tim R.  Fenton</span>, <span class="hlFld-ContribAuthor ">Kerry  Chester</span>, <span class="hlFld-ContribAuthor ">Christina  Thirlwell</span>, <span class="hlFld-ContribAuthor ">Gary  Royle</span>, <span class="hlFld-ContribAuthor ">Teresa  Marafioti</span>, <span class="hlFld-ContribAuthor ">Rajeev  Gupta</span>, <span class="hlFld-ContribAuthor ">Sagung Rai  Indrasari</span>, <span class="hlFld-ContribAuthor ">Camelia  Herdini</span>, <span class="hlFld-ContribAuthor ">Mohd Afiq Mohd  Slim</span>, <span class="hlFld-ContribAuthor ">I.  Indrawati</span>, <span class="hlFld-ContribAuthor ">Liam  Sutton</span>, <span class="hlFld-ContribAuthor ">Renske  Fles</span>, <span class="hlFld-ContribAuthor ">Bing  Tan</span>, <span class="hlFld-ContribAuthor ">Joe  Yeong</span>, <span class="hlFld-ContribAuthor ">Amit  Jain</span>, <span class="hlFld-ContribAuthor ">Shuting  Han</span>, <span class="hlFld-ContribAuthor ">Haitao  Wang</span>, <span class="hlFld-ContribAuthor ">Kelvin S. H.  Loke</span>, <span class="hlFld-ContribAuthor ">Wan  He</span>, <span class="hlFld-ContribAuthor ">Ruilian  Xu</span>, <span class="hlFld-ContribAuthor ">Hongtao  Jin</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Cheng</span>, <span class="hlFld-ContribAuthor ">David  Howard</span>, <span class="hlFld-ContribAuthor ">Peter H.  Hwang</span>, <span class="hlFld-ContribAuthor ">Quynh-Thu  Le</span>, <span class="hlFld-ContribAuthor ">Joshua K.  Tay</span>, <span class="hlFld-ContribAuthor ">Robert B.  West</span>, <span class="hlFld-ContribAuthor ">Sai Wah  Tsao</span>, <span class="hlFld-ContribAuthor ">Tim  Meyer</span>, <span class="hlFld-ContribAuthor ">Herbert  Riechelmann</span>, <span class="hlFld-ContribAuthor ">Udo  Oppermann</span>, <span class="hlFld-ContribAuthor ">Henri-Jacques  Delecluse</span>, <span class="hlFld-ContribAuthor ">Stefan M.  Willems</span>, <span class="hlFld-ContribAuthor ">Melvin L. K.  Chua</span>, <span class="hlFld-ContribAuthor ">Pierre  Busson</span>, <span class="hlFld-ContribAuthor ">Kwok Wai  Lo</span>, <span class="hlFld-ContribAuthor ">Guido  Wollmann</span>, <span class="hlFld-ContribAuthor ">Nischalan  Pillay</span>, <span class="hlFld-ContribAuthor ">Bart  Vanhaesebroeck</span>, <span class="hlFld-ContribAuthor ">Valerie J.  Lund</span>. </span><span class="cited-content_cbyCitation_article-title">Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-020-20308-8" title="DOI URL">https://doi.org/10.1038/s41467-020-20308-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-020-20308-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-020-20308-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DSomatostatin%252Breceptor%252B2%252Bexpression%252Bin%252Bnasopharyngeal%252Bcancer%252Bis%252Binduced%252Bby%252BEpstein%252BBarr%252Bvirus%252Binfection%25253A%252Bimpact%252Bon%252Bprognosis%25252C%252Bimaging%252Band%252Btherapy%26aulast%3DLechner%26aufirst%3DMatt%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaqi  Zhou</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Li</span>, <span class="hlFld-ContribAuthor ">Wenlong  Huang</span>, <span class="hlFld-ContribAuthor ">Wei  Shi</span>, <span class="hlFld-ContribAuthor ">Hai  Qian</span>. </span><span class="cited-content_cbyCitation_article-title">Source and exploration of the peptides used to construct peptide-drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113712. <a href="https://doi.org/10.1016/j.ejmech.2021.113712" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113712</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113712%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSource%252Band%252Bexploration%252Bof%252Bthe%252Bpeptides%252Bused%252Bto%252Bconstruct%252Bpeptide-drug%252Bconjugates%26aulast%3DZhou%26aufirst%3DJiaqi%26date%3D2021%26volume%3D224%26spage%3D113712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew T.  Lucas</span>, <span class="hlFld-ContribAuthor ">Amber  Moody</span>, <span class="hlFld-ContribAuthor ">Allison N.  Schorzman</span>, <span class="hlFld-ContribAuthor ">William C.  Zamboni</span>. </span><span class="cited-content_cbyCitation_article-title">Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective. </span><span class="cited-content_cbyCitation_journal-name">Antibodies</span><span> <strong>2021,</strong> <em>10 </em>
                                    (3)
                                     , 30. <a href="https://doi.org/10.3390/antib10030030" title="DOI URL">https://doi.org/10.3390/antib10030030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antib10030030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantib10030030%26sid%3Dliteratum%253Aachs%26jtitle%3DAntibodies%26atitle%3DImportance%252Band%252BConsiderations%252Bof%252BAntibody%252BEngineering%252Bin%252BAntibody-Drug%252BConjugates%252BDevelopment%252Bfrom%252Ba%252BClinical%252BPharmacologist%2525E2%252580%252599s%252BPerspective%26aulast%3DLucas%26aufirst%3DAndrew%2BT.%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D3%26spage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaotian  Zhong</span>, <span class="hlFld-ContribAuthor ">Aaron M.  D’Antona</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics. </span><span class="cited-content_cbyCitation_journal-name">Antibodies</span><span> <strong>2021,</strong> <em>10 </em>
                                    (2)
                                     , 13. <a href="https://doi.org/10.3390/antib10020013" title="DOI URL">https://doi.org/10.3390/antib10020013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antib10020013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantib10020013%26sid%3Dliteratum%253Aachs%26jtitle%3DAntibodies%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BMolecular%252BDesign%252Band%252BApplications%252Bof%252BMultispecific%252BBiotherapeutics%26aulast%3DZhong%26aufirst%3DXiaotian%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D2%26spage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E.  Vitali</span>, <span class="hlFld-ContribAuthor ">S.  Piccini</span>, <span class="hlFld-ContribAuthor ">G.  Trivellin</span>, <span class="hlFld-ContribAuthor ">V.  Smiroldo</span>, <span class="hlFld-ContribAuthor ">E.  Lavezzi</span>, <span class="hlFld-ContribAuthor ">A.  Zerbi</span>, <span class="hlFld-ContribAuthor ">G.  Pepe</span>, <span class="hlFld-ContribAuthor ">A.G.  Lania</span>. </span><span class="cited-content_cbyCitation_article-title">The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors. </span><span class="cited-content_cbyCitation_journal-name">Molecular and Cellular Endocrinology</span><span> <strong>2021,</strong> <em>527 </em>, 111226. <a href="https://doi.org/10.1016/j.mce.2021.111226" title="DOI URL">https://doi.org/10.1016/j.mce.2021.111226</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mce.2021.111226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mce.2021.111226%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520and%2520Cellular%2520Endocrinology%26atitle%3DThe%252Bimpact%252Bof%252BSST2%252Btrafficking%252Band%252Bsignaling%252Bin%252Bthe%252Btreatment%252Bof%252Bpancreatic%252Bneuroendocrine%252Btumors%26aulast%3DVitali%26aufirst%3DE.%26date%3D2021%26volume%3D527%26spage%3D111226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  La Salvia</span>, <span class="hlFld-ContribAuthor ">Paula  Espinosa-Olarte</span>, <span class="hlFld-ContribAuthor ">Maria Del Carmen  Riesco-Martinez</span>, <span class="hlFld-ContribAuthor ">Beatriz  Anton-Pascual</span>, <span class="hlFld-ContribAuthor ">Rocío  Garcia-Carbonero</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms?. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (7)
                                     , 1701. <a href="https://doi.org/10.3390/cancers13071701" title="DOI URL">https://doi.org/10.3390/cancers13071701</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13071701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13071701%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTargeted%252BCancer%252BTherapy%25253A%252BWhat%2525E2%252580%252599s%252BNew%252Bin%252Bthe%252BField%252Bof%252BNeuroendocrine%252BNeoplasms%25253F%26aulast%3DLa%2BSalvia%26aufirst%3DAnna%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D7%26spage%3D1701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carl M.  Gay</span>, <span class="hlFld-ContribAuthor ">C. Allison  Stewart</span>, <span class="hlFld-ContribAuthor ">Elizabeth M.  Park</span>, <span class="hlFld-ContribAuthor ">Lixia  Diao</span>, <span class="hlFld-ContribAuthor ">Sarah M.  Groves</span>, <span class="hlFld-ContribAuthor ">Simon  Heeke</span>, <span class="hlFld-ContribAuthor ">Barzin Y.  Nabet</span>, <span class="hlFld-ContribAuthor ">Junya  Fujimoto</span>, <span class="hlFld-ContribAuthor ">Luisa M.  Solis</span>, <span class="hlFld-ContribAuthor ">Wei  Lu</span>, <span class="hlFld-ContribAuthor ">Yuanxin  Xi</span>, <span class="hlFld-ContribAuthor ">Robert J.  Cardnell</span>, <span class="hlFld-ContribAuthor ">Qi  Wang</span>, <span class="hlFld-ContribAuthor ">Giulia  Fabbri</span>, <span class="hlFld-ContribAuthor ">Kasey R.  Cargill</span>, <span class="hlFld-ContribAuthor ">Natalie I.  Vokes</span>, <span class="hlFld-ContribAuthor ">Kavya  Ramkumar</span>, <span class="hlFld-ContribAuthor ">Bingnan  Zhang</span>, <span class="hlFld-ContribAuthor ">Carminia M.  Della Corte</span>, <span class="hlFld-ContribAuthor ">Paul  Robson</span>, <span class="hlFld-ContribAuthor ">Stephen G.  Swisher</span>, <span class="hlFld-ContribAuthor ">Jack A.  Roth</span>, <span class="hlFld-ContribAuthor ">Bonnie S.  Glisson</span>, <span class="hlFld-ContribAuthor ">David S.  Shames</span>, <span class="hlFld-ContribAuthor ">Ignacio I.  Wistuba</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Vito  Quaranta</span>, <span class="hlFld-ContribAuthor ">John  Minna</span>, <span class="hlFld-ContribAuthor ">John V.  Heymach</span>, <span class="hlFld-ContribAuthor ">Lauren Averett  Byers</span>. </span><span class="cited-content_cbyCitation_article-title">Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell</span><span> <strong>2021,</strong> <em>39 </em>
                                    (3)
                                     , 346-360.e7. <a href="https://doi.org/10.1016/j.ccell.2020.12.014" title="DOI URL">https://doi.org/10.1016/j.ccell.2020.12.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccell.2020.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccell.2020.12.014%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%26atitle%3DPatterns%252Bof%252Btranscription%252Bfactor%252Bprograms%252Band%252Bimmune%252Bpathway%252Bactivation%252Bdefine%252Bfour%252Bmajor%252Bsubtypes%252Bof%252BSCLC%252Bwith%252Bdistinct%252Btherapeutic%252Bvulnerabilities%26aulast%3DGay%26aufirst%3DCarl%2BM.%26date%3D2021%26volume%3D39%26issue%3D3%26spage%3D346%26epage%3D360.e7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satya  Das</span>, <span class="hlFld-ContribAuthor ">Arvind  Dasari</span>. </span><span class="cited-content_cbyCitation_article-title">Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Medical Oncology</span><span> <strong>2021,</strong> <em>13 </em>, 175883592110180. <a href="https://doi.org/10.1177/17588359211018047" title="DOI URL">https://doi.org/10.1177/17588359211018047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/17588359211018047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F17588359211018047%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Medical%2520Oncology%26atitle%3DNovel%252Btherapeutics%252Bfor%252Bpatients%252Bwith%252Bwell-differentiated%252Bgastroenteropancreatic%252Bneuroendocrine%252Btumors%26aulast%3DDas%26aufirst%3DSatya%26date%3D2021%26date%3D2021%26volume%3D13%26spage%3D175883592110180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mauro  Cives</span>, <span class="hlFld-ContribAuthor ">Eleonora  Pelle’</span>, <span class="hlFld-ContribAuthor ">Jonathan  Strosberg</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Medicine</span><span> <strong>2020,</strong> <em>9 </em>
                                    (11)
                                     , 3655. <a href="https://doi.org/10.3390/jcm9113655" title="DOI URL">https://doi.org/10.3390/jcm9113655</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jcm9113655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjcm9113655%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Medicine%26atitle%3DEmerging%252BTreatment%252BOptions%252Bfor%252BGastroenteropancreatic%252BNeuroendocrine%252BTumors%26aulast%3DCives%26aufirst%3DMauro%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D11%26spage%3D3655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guido  Rindi</span>, <span class="hlFld-ContribAuthor ">Bertram  Wiedenmann</span>. </span><span class="cited-content_cbyCitation_article-title">Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Endocrinology</span><span> <strong>2020,</strong> <em>16 </em>
                                    (10)
                                     , 590-607. <a href="https://doi.org/10.1038/s41574-020-0391-3" title="DOI URL">https://doi.org/10.1038/s41574-020-0391-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41574-020-0391-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41574-020-0391-3%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Endocrinology%26atitle%3DNeuroendocrine%252Bneoplasia%252Bof%252Bthe%252Bgastrointestinal%252Btract%252Brevisited%25253A%252Btowards%252Bprecision%252Bmedicine%26aulast%3DRindi%26aufirst%3DGuido%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D10%26spage%3D590%26epage%3D607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laurence  Gauzy-Lazo</span>, <span class="hlFld-ContribAuthor ">Ingrid  Sassoon</span>, <span class="hlFld-ContribAuthor ">Marie-Priscille  Brun</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2020,</strong> <em>25 </em>
                                    (8)
                                     , 843-868. <a href="https://doi.org/10.1177/2472555220912955" title="DOI URL">https://doi.org/10.1177/2472555220912955</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555220912955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555220912955%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DAdvances%252Bin%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252BDesign%25253A%252BCurrent%252BClinical%252BLandscape%252Band%252BFuture%252BInnovations%26aulast%3DGauzy-Lazo%26aufirst%3DLaurence%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D8%26spage%3D843%26epage%3D868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rongjun  He</span>, <span class="hlFld-ContribAuthor ">Jia  Pan</span>, <span class="hlFld-ContribAuthor ">John P.  Mayer</span>, <span class="hlFld-ContribAuthor ">Fa  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">The Chemical Methods of Disulfide Bond Formation and Their Applications to Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Current Organic Chemistry</span><span> <strong>2020,</strong> <em>23 </em>
                                    (25)
                                     , 2802-2821. <a href="https://doi.org/10.2174/1385272823666191202111723" title="DOI URL">https://doi.org/10.2174/1385272823666191202111723</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1385272823666191202111723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1385272823666191202111723%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Organic%2520Chemistry%26atitle%3DThe%252BChemical%252BMethods%252Bof%252BDisulfide%252BBond%252BFormation%252Band%252BTheir%252BApplications%252Bto%252BDrug%252BConjugates%26aulast%3DHe%26aufirst%3DRongjun%26date%3D2020%26volume%3D23%26issue%3D25%26spage%3D2802%26epage%3D2821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satya  Das</span>, <span class="hlFld-ContribAuthor ">Taymeyah  Al-Toubah</span>, <span class="hlFld-ContribAuthor ">Ghassan  El-Haddad</span>, <span class="hlFld-ContribAuthor ">Jonathan  Strosberg</span>. </span><span class="cited-content_cbyCitation_article-title">177
              Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Gastroenterology & Hepatology</span><span> <strong>2019,</strong> <em>13 </em>
                                    (11)
                                     , 1023-1031. <a href="https://doi.org/10.1080/17474124.2019.1685381" title="DOI URL">https://doi.org/10.1080/17474124.2019.1685381</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17474124.2019.1685381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17474124.2019.1685381%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Gastroenterology%2520%2526%2520Hepatology%26atitle%3D177%252BLu-DOTATATE%252Bfor%252Bthe%252Btreatment%252Bof%252Bgastroenteropancreatic%252Bneuroendocrine%252Btumors%26aulast%3DDas%26aufirst%3DSatya%26date%3D2019%26date%3D2019%26volume%3D13%26issue%3D11%26spage%3D1023%26epage%3D1031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kerry A.  Whalen</span>, <span class="hlFld-ContribAuthor ">Brian H.  White</span>, <span class="hlFld-ContribAuthor ">James M.  Quinn</span>, <span class="hlFld-ContribAuthor ">Kristina  Kriksciukaite</span>, <span class="hlFld-ContribAuthor ">Rossitza  Alargova</span>, <span class="hlFld-ContribAuthor ">Tsun P.  Au Yeung</span>, <span class="hlFld-ContribAuthor ">Patrick  Bazinet</span>, <span class="hlFld-ContribAuthor ">Adam  Brockman</span>, <span class="hlFld-ContribAuthor ">Michelle M.  DuPont</span>, <span class="hlFld-ContribAuthor ">Haley  Oller</span>, <span class="hlFld-ContribAuthor ">James  Gifford</span>, <span class="hlFld-ContribAuthor ">Charles-Andre  Lemelin</span>, <span class="hlFld-ContribAuthor ">Patrick  Lim Soo</span>, <span class="hlFld-ContribAuthor ">Samantha  Perino</span>, <span class="hlFld-ContribAuthor ">Benoît  Moreau</span>, <span class="hlFld-ContribAuthor ">Gitanjali  Sharma</span>, <span class="hlFld-ContribAuthor ">Rajesh  Shinde</span>, <span class="hlFld-ContribAuthor ">Beata  Sweryda-Krawiec</span>, <span class="hlFld-ContribAuthor ">Mark T.  Bilodeau</span>, <span class="hlFld-ContribAuthor ">Richard  Wooster</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2019,</strong> <em>18 </em>
                                    (11)
                                     , 1926-1936. <a href="https://doi.org/10.1158/1535-7163.MCT-19-0022" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-0022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-0022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-0022%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DTargeting%252Bthe%252BSomatostatin%252BReceptor%252B2%252Bwith%252Bthe%252BMiniaturized%252BDrug%252BConjugate%25252C%252BPEN-221%25253A%252BA%252BPotent%252Band%252BNovel%252BTherapeutic%252Bfor%252Bthe%252BTreatment%252Bof%252BSmall%252BCell%252BLung%252BCancer%26aulast%3DWhalen%26aufirst%3DKerry%2BA.%26date%3D2019%26date%3D2019%26volume%3D18%26issue%3D11%26spage%3D1926%26epage%3D1936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0015.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Payload/Linker Combinations<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2,2′-dipyridyldisulfide, dimethylformamide (DMF), AcOH, 0.2 M NaOAc; (b) 2-(2-pyridinyldithio)ethanol <i>p</i>-nitrophenyl carbonate, 4-dimethylaminopyridine (DMAP), dichloromethane (DCM); (c) 2-(2-pyridinyldithio)ethanol <i>p</i>-nitrophenyl carbonate, DMF, diisopropylethylamine; (d) dicyclohexyl carbodiimide, <i>N</i>-hydroxysuccinimide, DMF, 3-aminopropylmaleimide, diisopropylethylamine; (e) trifluoroacetic acid (TFA); (f) DM1, DMF, pH 5.6 acetate buffer; and (g) 6-maleimidohexanoic acid isobutyl carbonic anhydride, DMF, pyridine, 0 °C.</p></p></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Octreotide, Vapreotide, Tyr<sup>3</sup>–Octreotate, and Cyclic 6-mer Conjugates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BocOSu, DMF, −40 °C to room temperature; (b) <i>S</i>-trityl 3-mercaptopropionaldehyde, NaBH(OAc)<sub>3</sub>; (c) TFA, triisopropylsilane; (d) <b>1</b>, DMF, pH 7.4 phosphate buffer; (e) <b>2</b>, DMF, pH 5.6 acetate buffer; (f) <b>3</b>, DMF, pH 5.6 acetate buffer; (g) <b>5</b>, DMF, pH 5.6 acetate buffer; (h) iterative solid phase peptide synthesis (SPPS) with: <i>N</i>α-fluorenylmethyloxycarbonyl (Fmoc)-<i>N</i>ε-Boc-lysine, <i>N</i>α-Fmoc-N<sup>in</sup>-Boc-<span class="smallcaps smallerCapital">d</span>-tryptophan, Fmoc-tyrosine(<i>t</i>Bu), <i>N</i>α-Fmoc-<i>N</i>ε-(<i>S</i>-trityl-3-mercaptopropionate)-lysine, Fmoc-phenylalanine; (i) 1% TFA in DCM; (j) <i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate (HATU), 1-hydroxy-7-azabenzotriazole, DMF, <i>i</i>Pr<sub>2</sub>NEt; and (k) 95:2.5:2.5 TFA/1,2-ethanedithiol (EDT)/water.</p></p></figure><figure data-id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Tyr<sup>3</sup>–Octreotate/DM1 Conjugates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) iterative SPPS with Fmoc-<i>S</i>-trityl-cysteine, Fmoc-threonine(<i>t</i>Bu), <i>N</i>α-Fmoc-<i>N</i>ε-Boc lysine, <i>N</i>α-Fmoc-<i>N</i><sup>in</sup>-Boc-<span class="smallcaps smallerCapital">d</span>-tryptophan, Fmoc-tyrosine(<i>t</i>Bu), Fmoc-<i>S</i>-trityl-cysteine; (b) 95:2.5:2.5 TFA/EDT/water; (c) I<sub>2</sub>, CH<sub>3</sub>CN/water; (d) Boc<sub>2</sub>O, <i>i</i>Pr<sub>2</sub>NEt, DMF; (e) Et<sub>2</sub>NH, DCM; (f) Boc-<i>O</i>-(<i>S</i>-trityl-2-mercaptoethyl)-<span class="smallcaps smallerCapital">d</span>-tyrosine <i>N</i>-hydroxysuccinimide ester, DMF, <i>i</i>Pr<sub>2</sub>NEt; (g) TFA, iPr<sub>3</sub>SiH; (h) <b>1</b>, DMF, <i>i</i>Pr<sub>2</sub>NEt; (i) Boc<sub>2</sub>O, DMF, <i>i</i>Pr<sub>2</sub>NEt; (j) <i>S</i>-trityl cysteamine HCl, DMF, HATU, <i>i</i>Pr<sub>2</sub>NEt; (k) iterative SPPS with: Fmoc-threonine(<i>t</i>Bu), <i>N</i>α-Fmoc-<i>N</i>ε-Boc lysine, <i>N</i>α-Fmoc-<i>N</i><sup>in</sup>-Boc-<span class="smallcaps smallerCapital">d</span>-tryptophan, Fmoc-tyrosine(<i>t</i>Bu), Fmoc-<i>S</i>-trityl-cysteine, Boc-<span class="smallcaps smallerCapital">d</span>-phenylalanine; (l) I<sub>2</sub>, DMF; (m) 20% trifluoroethanol in DCM; (n) HATU, CH<sub>2</sub>Cl<sub>2</sub>, <i>S</i>-trityl-cysteine amide, <i>i</i>Pr<sub>2</sub>NEt; (o) 2,2′-dithiodipyridine, 1,1,3,3-tetramethyldisiloxane, trifluoroethanol, 12N HCl; and (p) DM1, THF, pH 3.7 acetate buffer.</p></p></figure><figure data-id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of C-Terminal Side Chain Conjugates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HATU, CH<sub>2</sub>Cl<sub>2</sub>, TrtS–CH<sub>2</sub>–CH(R)–NH<sub>2</sub>; (b) 2,2′-dithiodipyridine, 1,1,3,3-tetramethyldisiloxane, trifluoroethanol, 12N HCl; (c) HATU, CH<sub>2</sub>Cl<sub>2</sub>, TrtS–CR<sub>2</sub><sup>2</sup>–CH(R<sup>1</sup>)–NH<sub>2</sub><i>i</i>Pr<sub>2</sub>NEt; (d) TFA, thioanisole, water, triisopropylsilane; (e) Dap(Dde)-NH<sub>2</sub>, HATU, CH<sub>2</sub>Cl<sub>2</sub>, <i>i</i>Pr<sub>2</sub>NEt; (f) hydrazine, DMF; (g) maleimidoacetic acid, HATU, CH<sub>2</sub>Cl<sub>2</sub>; (h) 92.5:2.5:2.5:2.5 TFA/thioanisole/water/triisopropylsilane; (i) DM1, DMF, pH 4.6 acetate buffer; (j) <b>1</b>, DMF, pH 4.6 acetate buffer; (k) <b>1</b>, DMF, pH 7.4 phosphate buffer; (l) DM4, DMF, pH 7.4 phosphate buffer; (m) DM1, DMF, 0.2 M NaOAc; (n) <b>2</b>, DMF, pH 5.6 acetate buffer; and (o) <b>3</b>, DMF, pH 5.6 acetate buffer.</p></p></figure><figure data-id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Nonbinding Control<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) iterative SPPS with Fmoc-threonine(<i>t</i>Bu), <i>N</i>α-Fmoc-<i>N</i>ε-Boc lysine, <i>N</i>α-Fmoc-<i>N</i><sup>in</sup>-Boc-<span class="smallcaps smallerCapital">d</span>-tryptophan, Fmoc-tyrosine(<i>t</i>Bu), Fmoc-<i>S</i>-trityl-cysteine, Fmoc-<span class="smallcaps smallerCapital">d</span>-phenylalanine; (b) 92.5:2.5:2.5:2.5 TFA/thioanisole/water/triisopropylsilane; (c) I<sub>2</sub>, CH<sub>3</sub>CN/water; (d) <i>N</i>-Boc-<i>N</i>′-(4-nitrophenylcarbamate)-1,6-hexanediamine, THF, <i>i</i>Pr<sub>2</sub>NEt, DMAP, 50 °C; (e) <i>S</i>-trityl-cysteine amide, DMF, HATU, <i>i</i>Pr<sub>2</sub>NEt; (f) piperidine, DMF; (g) TFA, triisopropylsilane; and (h) <b>1</b>, DMF, pH 7.4 phosphate buffer.</p></p></figure><figure data-id="fig1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0013.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Payload and conjugate cytotoxicity of <b>7</b> and <b>8</b> in NCI-H524 cells with and without receptor blockade, plus their respective payloads.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0014.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Dose-normalized DM1 levels in NCI-H69 tumors 24 h after conjugate dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. SSTR2 internalization by <b>22</b>, <b>33</b>, and SST28.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Stability of <b>22</b> and <b>30</b> in 5 mM GSH at 37 °C.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Beagle dog pharmacokinetics (<i>n</i> = 1) of 0.1 mg/kg <b>22</b> and <b>30</b> iv.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>22</b> and <b>30</b> in NCI-H69 xenograft efficacy. Arrows indicate dosing days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <b>22</b> and <b>37</b> in NCI-H69 xenograft efficacy. Arrows indicate dosing days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/medium/jm-2018-02036m_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0011.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <b>22</b> in HCC-33 (top) and IMR-32 (bottom) xenografts. Arrows indicate dosing days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b02036/20190308/images/large/jm-2018-02036m_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02036&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i31">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84300" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84300" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 25 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnock-Jones, K. P.</span></span> <span> </span><span class="NLM_article-title">Brentuximab vedotin: A review of its use in patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0031-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1007%2Fs40265-013-0031-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=23494187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmtLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=371-381&author=K.+P.+Garnock-Jones&title=Brentuximab+vedotin%3A+A+review+of+its+use+in+patients+with+Hodgkin+lymphoma+and+systemic+anaplastic+large+cell+lymphoma+following+previous+treatment+failure&doi=10.1007%2Fs40265-013-0031-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure</span></div><div class="casAuthors">Garnock-Jones, Karly P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-381</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Brentuximab vedotin (ADCETRIS) is an antibody-drug conjugate that is specifically targeted against CD30-pos. cancer cells such as those in Hodgkin lymphoma or systemic anaplastic large cell lymphoma (ALCL).  I.v. brentuximab vedotin was assocd. with an overall objective response rate (primary endpoint) of 75 % in 102 patients with Hodgkin lymphoma who had relapsed after high-dose chemotherapy and autologous haematopoietic stem cell transplantation, in a noncomparative, multicentre, phase II trial.  In 58 patients with relapsed systemic ALCL after at least one prior treatment, i.v. brentuximab vedotin was assocd. with an overall objective response rate (primary endpoint) of 86 % in a noncomparative, multicentre, phase II trial.  Tumor redns. were obsd. in 94 % of patients with Hodgkin lymphoma and 97 % of patients with systemic ALCL, and most tumors decreased in size by >65 % and >85 %, resp.  The estd. 12-mo survival rates were 89 % and 52 %, resp.  Brentuximab vedotin was generally well tolerated in these trials.  The most common adverse event was peripheral neuropathy; approx. one-half of patients with this adverse event experienced complete resoln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1oswD_tecebVg90H21EOLACvtfcHk0ljkpF2vo9gdVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmtLzE&md5=88bc8455c2c215b86c1913d71385328c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0031-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0031-5%26sid%3Dliteratum%253Aachs%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DBrentuximab%2520vedotin%253A%2520A%2520review%2520of%2520its%2520use%2520in%2520patients%2520with%2520Hodgkin%2520lymphoma%2520and%2520systemic%2520anaplastic%2520large%2520cell%2520lymphoma%2520following%2520previous%2520treatment%2520failure%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D371%26epage%3D381%26doi%3D10.1007%2Fs40265-013-0031-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V.</span></span> <span> </span><span class="NLM_article-title">Ado-trastuzumab emtansine (T-DM1): An antibody-drug conjugate (ADC) for HER2-positive breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6949</span>– <span class="NLM_lpage">6964</span>, <span class="refDoi"> DOI: 10.1021/jm500766w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500766w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGlu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6949-6964&author=J.+M.+Lambertauthor=R.+V.+Chari&title=Ado-trastuzumab+emtansine+%28T-DM1%29%3A+An+antibody-drug+conjugate+%28ADC%29+for+HER2-positive+breast+cancer&doi=10.1021%2Fjm500766w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer</span></div><div class="casAuthors">Lambert, John M.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6949-6964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that combines the antitumor properties of the humanized anti-human epidermal growth factor receptor 2 (HER2) antibody, trastuzumab, with the maytansinoid, DM1, a potent microtubule-disrupting agent, joined by a stable linker.  Upon binding to HER2, the conjugate is internalized via receptor-mediated endocytosis, and an active deriv. of DM1 is subsequently released by proteolytic degrdn. of the antibody moiety within the lysosome.  Initial clin. evaluation led to a phase III trial in advanced HER2-pos. breast cancer patients who had relapsed after prior treatment with trastuzumab and a taxane, which showed that T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine.  In 2013, T-DM1 received FDA approval for the treatment of patients with HER2-pos. metastatic breast cancer who had previously received trastuzumab and a taxane, sep. or in combination, the first ADC to receive full approval based on a randomized study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYAu4MvRWFwLVg90H21EOLACvtfcHk0ljoIqzlEbwGiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGlu7rE&md5=3ddee50cc227097126dd47e7683a6ac7</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm500766w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500766w%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DAdo-trastuzumab%2520emtansine%2520%2528T-DM1%2529%253A%2520An%2520antibody-drug%2520conjugate%2520%2528ADC%2529%2520for%2520HER2-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6949%26epage%3D6964%26doi%3D10.1021%2Fjm500766w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner-Johnston, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehmann, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ananthakrishnan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandendries, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, M.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radiotherapy</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">571</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1111/bjh.14094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1111%2Fbjh.14094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=27101934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GlurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2016&pages=571-581&author=A.+Goyauthor=A.+Foreroauthor=N.+Wagner-Johnstonauthor=W.+C.+Ehmannauthor=M.+Tsaiauthor=K.+Hatakeauthor=R.+Ananthakrishnanauthor=A.+Volkertauthor=E.+Vandendriesauthor=M.+Ogura&title=A+phase+2+study+of+inotuzumab+ozogamicin+in+patients+with+indolent+B-cell+non-Hodgkin+lymphoma+refractory+to+rituximab+alone%2C+rituximab+and+chemotherapy%2C+or+radiotherapy&doi=10.1111%2Fbjh.14094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy</span></div><div class="casAuthors">Goy, Andre; Forero, Andres; Wagner-Johnston, Nina; Christopher Ehmann, W.; Tsai, Michaela; Hatake, Kiyohiko; Ananthakrishnan, Revathi; Volkert, Angela; Vandendries, Erik; Ogura, Michinori</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">571-581</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">This phase 2 study evaluated the efficacy and safety of inotuzumab ozogamicin (InO) in patients with indolent B-cell non-Hodgkin lymphoma (NHL) refractory to rituximab alone, rituximab plus chemotherapy or anti-CD20 radioimmunotherapy.  Patients received InO 1·8 mg/m2 i.v. on a 28-d cycle for a planned 4-8 cycles.  The initial InO dose and schedule could be adjusted for tolerability and patients were allowed to receive 2 addnl. cycles (up to 8 total) after achieving a complete response (CR).  The primary endpoint was overall response.  Eighty-one patients were enrolled, among whom 48 (59%) received ≥3 InO cycles and 13 (16%) completed the treatment phase.  The overall response rate was 67% (CR, 31%).  Median (95% confidence interval) progression-free survival was 12·7 (8·9-26·9) months; median overall survival was not reached.  Haematol. adverse events (AEs) were common, particularly thrombocytopenia (74%) and neutropenia (56%).  These were also the most common AEs leading to treatment discontinuation (37% and 11%, resp.); 58% of patients reported AEs leading to treatment discontinuation.  InO demonstrated robust activity in these heavily pretreated patients, although treatment duration was limited by haematol. toxicities.  Addnl. studies may det. dosing regimens that allow for reduced toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlYcLyGqN9e7Vg90H21EOLACvtfcHk0ljoIqzlEbwGiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GlurvJ&md5=cee25294b1cd1a32e22744ec8e5c3517</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fbjh.14094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.14094%26sid%3Dliteratum%253Aachs%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DForero%26aufirst%3DA.%26aulast%3DWagner-Johnston%26aufirst%3DN.%26aulast%3DEhmann%26aufirst%3DW.%2BC.%26aulast%3DTsai%26aufirst%3DM.%26aulast%3DHatake%26aufirst%3DK.%26aulast%3DAnanthakrishnan%26aufirst%3DR.%26aulast%3DVolkert%26aufirst%3DA.%26aulast%3DVandendries%26aufirst%3DE.%26aulast%3DOgura%26aufirst%3DM.%26atitle%3DA%2520phase%25202%2520study%2520of%2520inotuzumab%2520ozogamicin%2520in%2520patients%2520with%2520indolent%2520B-cell%2520non-Hodgkin%2520lymphoma%2520refractory%2520to%2520rituximab%2520alone%252C%2520rituximab%2520and%2520chemotherapy%252C%2520or%2520radiotherapy%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2016%26volume%3D174%26spage%3D571%26epage%3D581%26doi%3D10.1111%2Fbjh.14094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span> <span> </span><span class="NLM_article-title">Transport of molecules, particles, and cells in solid tumors</span>. <i>Annu. Rev. Biomed. Eng.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1146/annurev.bioeng.1.1.241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1146%2Fannurev.bioeng.1.1.241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=11701489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADyaK1MXnvFyit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1999&pages=241-263&author=R.+K.+Jain&title=Transport+of+molecules%2C+particles%2C+and+cells+in+solid+tumors&doi=10.1146%2Fannurev.bioeng.1.1.241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Transport of molecules, particles, and cells in solid tumors</span></div><div class="casAuthors">Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biomedical Engineering</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">241-263, 5plates</span>CODEN:
                <span class="NLM_cas:coden">ARBEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-9829</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 177 refs.  Extraordinary advances in mol. biol. and biotechnol. have led to the development of a vast no. of therapeutic anticancer agents.  To reach cancer cells in a tumor, a blood-borne therapeutic mol., particle, or cell must make its way into the blood vessels of the tumor and across the vessel wall into the interstitium, which it then must migrate through.  Unfortunately, tumors often develop in ways that hinder these steps.  The goal of research in this area is to analyze each of these steps exptl. and theor. and integrate the resulting information into a unified theor. framework.  This paradigm of anal. and synthesis has fostered a better understanding of physiol. barriers in solid tumors and aided in the development of novel strategies to exploit and/or overcome these barriers for improved cancer detection and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4aSvBc5FwIbVg90H21EOLACvtfcHk0lgTWuSzqlIeSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnvFyit7c%253D&md5=3a5f87c8d6604d7ddf2a8d35f173a270</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1146%2Fannurev.bioeng.1.1.241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.bioeng.1.1.241%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DTransport%2520of%2520molecules%252C%2520particles%252C%2520and%2520cells%2520in%2520solid%2520tumors%26jtitle%3DAnnu.%2520Rev.%2520Biomed.%2520Eng.%26date%3D1999%26volume%3D1%26spage%3D241%26epage%3D263%26doi%3D10.1146%2Fannurev.bioeng.1.1.241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span> <span> </span><span class="NLM_article-title">Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution</span>. <i>Microvasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1016/0026-2862(91)90026-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1016%2F0026-2862%2891%2990026-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=2051960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A280%3ADyaK3M3ntVWltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1991&pages=252-272&author=L.+T.+Baxterauthor=R.+K.+Jain&title=Transport+of+fluid+and+macromolecules+in+tumors.+IV.+A+microscopic+model+of+the+perivascular+distribution&doi=10.1016%2F0026-2862%2891%2990026-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution</span></div><div class="casAuthors">Baxter L T; Jain R K</div><div class="citationInfo"><span class="NLM_cas:title">Microvascular research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">252-72</span>
        ISSN:<span class="NLM_cas:issn">0026-2862</span>.
    </div><div class="casAbstract">The therapeutic efficacy of various genetically engineered macromolecules is determined by their delivery and distribution in tumors.  We have recently developed mathematical models which describe the interstitial velocity, pressure, and concentration profiles of macromolecules over the length scale of a solid tumor (Baxter and Jain, Microvas.  Res. 1989, 1990, 1991).  Nonspecific and specific antibodies and antibody fragments were chosen as typical macromolecules.  The focus of the present investigation was microscopic transport, i.e., the distribution of pressure and solutes around individual blood vessels.  Analytical solutions were obtained for interstitial velocities and pressures, while the concentration profiles were calculated numerically using the finite element method.  The microscopic model describes flow patterns around an individual blood vessel in an infinite medium and concentration profiles around a single blood vessel in a network of capillaries.  Our analysis is novel in that it incorporates interstitial convection, asymmetric filtration, and transcapillary convection to describe interstitial transport in tumors.  The purpose of this model was to determine the effect of extravascular binding and interstitial convection on the distribution of macromolecules on a microscopic scale and to test the continuum hypothesis assumed in our previously published macroscopic models.  An approximate one-dimensional model was compared with a more accurate two-dimensional model.  The results of our microscopic model confirm that the continuum hypothesis used in our previous macroscopic model is reasonable.  On a microscopic length scale diffusion is dominant, and short range distortions in the flow field do not significantly affect the penetration of macromolecules into the tissue.  In addition, our model confirms the results of Fujimori et al. (Cancer Res., 1989) concerning a "binding site barrier." The implications of our results for cancer therapy are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVeX6-t8nFPpPlX7E30qdzfW6udTcc2eY7aRuoSLj1Ibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M3ntVWltQ%253D%253D&md5=105d5c53fcf7658ee554430fbdd2425b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2F0026-2862%2891%2990026-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0026-2862%252891%252990026-8%26sid%3Dliteratum%253Aachs%26aulast%3DBaxter%26aufirst%3DL.%2BT.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DTransport%2520of%2520fluid%2520and%2520macromolecules%2520in%2520tumors.%2520IV.%2520A%2520microscopic%2520model%2520of%2520the%2520perivascular%2520distribution%26jtitle%3DMicrovasc.%2520Res.%26date%3D1991%26volume%3D41%26spage%3D252%26epage%3D272%26doi%3D10.1016%2F0026-2862%2891%2990026-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beckman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiner, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, H. M.</span></span> <span> </span><span class="NLM_article-title">Antibody constructs in cancer therapy</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1002/cncr.22402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1002%2Fcncr.22402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=17154393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhs1yrs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=170-179&author=R.+A.+Beckmanauthor=L.+M.+Weinerauthor=H.+M.+Davis&title=Antibody+constructs+in+cancer+therapy&doi=10.1002%2Fcncr.22402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors</span></div><div class="casAuthors">Beckman, Robert A.; Weiner, Louis M.; Davis, Hugh M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">170-179</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Whereas over 85% of human cancers are solid tumors, of the 8 monoclonal antibodies (mAbs) currently approved for cancer therapy, 25% are directed at solid tumor surface antigens (Ags).  This shortfall may be due to barriers to achieving adequate exposure in solid tumors.  Advancements in tumor biol., protein engineering, and theor. modeling of macromol. transport are currently enabling identification of crit. phys. properties for antitumor Abs.  It is now possible to structurally modify Abs or even replace full Abs with a plethora of Ab constructs.  These constructs include Fab and Fab'2 fragments, scFvs, multivalent scFvs (e.g., diabodies and tribodies), minibodies (e.g., scFv-CH3 dimers), bispecific Abs, and camel variable functional heavy chain domains.  The purpose of the article is to provide investigators with a conceptual framework for exploiting the recent scientific advancements.  The focus is on 2 properties that govern tumor exposure: 1) phys. properties that enable penetration of and retention by tumors, and 2) favorable plasma pharmacokinetics.  It is demonstrated that manipulating mol. size, charge, valence, and binding affinity can optimize these properties.  These manipulations hold the key to promoting tumor exposure and to ultimately creating successful Ab therapies for solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXPq7VKRTrJ7Vg90H21EOLACvtfcHk0lgTWuSzqlIeSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhs1yrs74%253D&md5=17855fd18999c717f902117ecdeb4cca</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fcncr.22402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.22402%26sid%3Dliteratum%253Aachs%26aulast%3DBeckman%26aufirst%3DR.%2BA.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26aulast%3DDavis%26aufirst%3DH.%2BM.%26atitle%3DAntibody%2520constructs%2520in%2520cancer%2520therapy%26jtitle%3DCancer%26date%3D2007%26volume%3D109%26spage%3D170%26epage%3D179%26doi%3D10.1002%2Fcncr.22402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vrettos, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezö, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzakos, A. G.</span></span> <span> </span><span class="NLM_article-title">On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site</span>. <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.3762/bjoc.14.80</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.3762%2Fbjoc.14.80" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=29765474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOnsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=930-954&author=E.+I.+Vrettosauthor=G.+Mez%C3%B6author=A.+G.+Tzakos&title=On+the+design+principles+of+peptide-drug+conjugates+for+targeted+drug+delivery+to+the+malignant+tumor+site&doi=10.3762%2Fbjoc.14.80"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site</span></div><div class="casAuthors">Vrettos, Eirinaios I.; Mezo, Gabor; Tzakos, Andreas G.</div><div class="citationInfo"><span class="NLM_cas:title">Beilstein Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">930-954</span>CODEN:
                <span class="NLM_cas:coden">BJOCBH</span>;
        ISSN:<span class="NLM_cas:issn">1860-5397</span>.
    
            (<span class="NLM_cas:orgname">Beilstein-Institut zur Foerderung der Chemischen Wissenschaften</span>)
        </div><div class="casAbstract">Cancer is the second leading cause of death affecting nearly one in two people, and the appearance of new cases is projected to rise by >70% by 2030.  To effectively combat the menace of cancer, a variety of strategies have been exploited.  Among them, the development of peptide-drug conjugates (PDCs) is considered as an inextricable part of this armamentarium and is continuously explored as a viable approach to target malignant tumors.  The general architecture of PDCs consists of three building blocks: the tumor-homing peptide, the cytotoxic agent and the biodegradable connecting linker.  The aim of the current review is to provide a spherical perspective on the basic principles governing PDCs, as also the methodol. to construct them.  We aim to offer basic and integral knowledge on the rational design towards the construction of PDCs through analyzing each building block, as also to highlight the overall progress of this rapidly growing field.  Therefore, we focus on several intriguing examples from the recent literature, including important PDCs that have progressed to phase III clin. trials.  Last, we address possible difficulties that may emerge during the synthesis of PDCs, as also report ways to overcome them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRxpOdZLKXfrVg90H21EOLACvtfcHk0lj6tVmIx_6Asg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOnsLvP&md5=595fce13e61b3e6f58a8ae6969e8b2c8</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.14.80&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.14.80%26sid%3Dliteratum%253Aachs%26aulast%3DVrettos%26aufirst%3DE.%2BI.%26aulast%3DMez%25C3%25B6%26aufirst%3DG.%26aulast%3DTzakos%26aufirst%3DA.%2BG.%26atitle%3DOn%2520the%2520design%2520principles%2520of%2520peptide-drug%2520conjugates%2520for%2520targeted%2520drug%2520delivery%2520to%2520the%2520malignant%2520tumor%2520site%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2018%26volume%3D14%26spage%3D930%26epage%3D954%26doi%3D10.3762%2Fbjoc.14.80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vergote, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leamon, C. P.</span></span> <span> </span><span class="NLM_article-title">Vintafolide: A novel targeted therapy for the treatment of folate receptor expressing tumors</span>. <i>Ther. Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1177/1758834015584763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1177%2F1758834015584763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=26136852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslSisLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=206-218&author=I.+Vergoteauthor=C.+P.+Leamon&title=Vintafolide%3A+A+novel+targeted+therapy+for+the+treatment+of+folate+receptor+expressing+tumors&doi=10.1177%2F1758834015584763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors</span></div><div class="casAuthors">Vergote, Ignace; Leamon, Christopher P.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">206-218</span>CODEN:
                <span class="NLM_cas:coden">TAMOB8</span>;
        ISSN:<span class="NLM_cas:issn">1758-8340</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite advances in the development of molecularly targeted therapies, limited improvements in overall survival have been noted among many cancer patients with solid tumors, primarily due to development of drug resistance.  Accordingly, there is an unmet need for new targeted therapies and treatment approaches for cancer, esp. for overcoming resistance.  Expression of the folate receptor is upregulated in many tumor types and thus represents an ideal target for cancer treatment.  Several folate receptor targeted therapies are in development, including the small mol. drug conjugate vintafolide, the monoclonal antibody farletuzumab, and the antibody-drug conjugate IMGN853.  The role of the folate receptor as a target in cancer progression and resistance as well as emerging preclin. and clin. data from studies on those folate receptor targeted agents that are in development with a focus on vintafolide are reviewed.  The folate receptor has several unique properties, such as high expression in several tumor types, that make it a rational target for cancer treatment, and allow for selective delivery of folate receptor targeted agents.  Earlystage clin. data in lung and ovarian cancer suggest that vintafolide has the potential for combination with other std. approved agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI7r6KUhT807Vg90H21EOLACvtfcHk0lj6tVmIx_6Asg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslSisLvJ&md5=72a74bbe7e67ad2c02989d8601555d63</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1177%2F1758834015584763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758834015584763%26sid%3Dliteratum%253Aachs%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DLeamon%26aufirst%3DC.%2BP.%26atitle%3DVintafolide%253A%2520A%2520novel%2520targeted%2520therapy%2520for%2520the%2520treatment%2520of%2520folate%2520receptor%2520expressing%2520tumors%26jtitle%3DTher.%2520Adv.%2520Med.%2520Oncol.%26date%3D2015%26volume%3D7%26spage%3D206%26epage%3D218%26doi%3D10.1177%2F1758834015584763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittrup, K. D.</span></span> <span> </span><span class="NLM_article-title">A modeling analysis on the effects of molecular size and binding affinity on tumor targeting</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2861</span>– <span class="NLM_lpage">2871</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1158%2F1535-7163.MCT-09-0195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=19825804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2861-2871&author=M.+M.+Schmidtauthor=K.+D.+Wittrup&title=A+modeling+analysis+on+the+effects+of+molecular+size+and+binding+affinity+on+tumor+targeting&doi=10.1158%2F1535-7163.MCT-09-0195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A modeling analysis of the effects of molecular size and binding affinity on tumor targeting</span></div><div class="casAuthors">Schmidt, Michael M.; Wittrup, K. Dane</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2861-2871</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A diverse array of tumor targeting agents ranging in size from peptides to nanoparticles is currently under development for applications in cancer imaging and therapy.  However, it remains largely unclear how size differences among these mols. influence their targeting properties.  Here, we develop a simple, mechanistic model that can be used to understand and predict the complex interplay between mol. size, affinity, and tumor uptake.  Empirical relationships between mol. radius and capillary permeability, interstitial diffusivity, available vol. fraction, and plasma clearance were obtained using data in the literature.  These relationships were incorporated into a compartmental model of tumor targeting using MATLAB to predict the magnitude, specificity, time dependence, and affinity dependence of tumor uptake for mols. across a broad size spectrum.  In the typical size range for proteins, the model uncovers a complex trend in which intermediate-sized targeting agents (MW, ∼25 kDa) have the lowest tumor uptake, whereas higher tumor uptake levels are achieved by smaller and larger agents.  Small peptides accumulate rapidly in the tumor but require high affinity to be retained, whereas larger proteins can achieve similar retention with >100-fold weaker binding.  For mols. in the size range of liposomes, the model predicts that antigen targeting will not significantly increase tumor uptake relative to untargeted mols.  All model predictions are shown to be consistent with exptl. observations from published targeting studies.  The results and techniques have implications for drug development, imaging, and therapeutic dosing. [Mol Cancer Ther 2009;8(10):2861-71].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIy-sqAvgserVg90H21EOLACvtfcHk0lj6tVmIx_6Asg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7K&md5=da1ea6be17fad4873d808e883eacbf78</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0195%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DM.%2BM.%26aulast%3DWittrup%26aufirst%3DK.%2BD.%26atitle%3DA%2520modeling%2520analysis%2520on%2520the%2520effects%2520of%2520molecular%2520size%2520and%2520binding%2520affinity%2520on%2520tumor%2520targeting%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2861%26epage%3D2871%26doi%3D10.1158%2F1535-7163.MCT-09-0195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pimstone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kronheim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berelowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, M.</span></span> <span> </span><span class="NLM_article-title">Metabolic clearance and plasma half-disappearance time exogenous somatostatin in man</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1210/jcem-48-1-50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1210%2Fjcem-48-1-50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=422706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADyaE1MXotFantA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1979&pages=50-53&author=M.+Sheppardauthor=B.+Shapiroauthor=B.+Pimstoneauthor=S.+Kronheimauthor=M.+Berelowitzauthor=M.+Gregory&title=Metabolic+clearance+and+plasma+half-disappearance+time+exogenous+somatostatin+in+man&doi=10.1210%2Fjcem-48-1-50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man</span></div><div class="casAuthors">Sheppard, Michael; Shapiro, Brahm; Pimstone, Bernard; Kronheim, Shirley; Berelowitz, Michael; Gregory, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-3</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    </div><div class="casAbstract">The metabolic clearance rate (MCR) and half-disappearance time of exogenously administered somatostatin  [51110-01-1] were measured during and after cessation of a const. infusion.  Studies were performed on normal volunteers and patients with chronic liver disease and chronic renal failure.  Normal subjects had a mean MCR of 1949 mL/min, similar to values found in 5 patients with chronic liver disease.  However, patients with chronic renal failure showed a highly significant lowering of the MCR (501 mL/min).  The rate of disappearance of somatostatin after infusion was linear for 7-10 min, after which a much slower component was obsd.  In normal subjects, the t1/2 of the 1st component varied from 1.1-3.0 min, in patients with liver disease it varied from 1.2-4.8 min, and in patients with chronic renal failure it varied from 2.6-4.9 min.  The kidney hay have a role in the metabolic clearance of exogenously administered somatostatin, or uremia may impair catabolism nonspecifically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoumdLZ6AdD6LVg90H21EOLACvtfcHk0ljiQxdIC1t5sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXotFantA%253D%253D&md5=79af9924ff1b57f189d95f45a736ef61</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1210%2Fjcem-48-1-50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem-48-1-50%26sid%3Dliteratum%253Aachs%26aulast%3DSheppard%26aufirst%3DM.%26aulast%3DShapiro%26aufirst%3DB.%26aulast%3DPimstone%26aufirst%3DB.%26aulast%3DKronheim%26aufirst%3DS.%26aulast%3DBerelowitz%26aufirst%3DM.%26aulast%3DGregory%26aufirst%3DM.%26atitle%3DMetabolic%2520clearance%2520and%2520plasma%2520half-disappearance%2520time%2520exogenous%2520somatostatin%2520in%2520man%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D1979%26volume%3D48%26spage%3D50%26epage%3D53%26doi%3D10.1210%2Fjcem-48-1-50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hannon, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weckbecker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troxler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span> <span> </span><span class="NLM_article-title">Drug design at peptide receptors</span>. <i>J. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1385/JMN:18:1-2:15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1385%2FJMN%3A18%3A1-2%3A15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=11931345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD38XisVShs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2002&pages=15-27&author=J.+P.+Hannonauthor=C.+Nunnauthor=B.+Stolzauthor=C.+Brunsauthor=G.+Weckbeckerauthor=I.+Lewisauthor=T.+Troxlerauthor=K.+Hurthauthor=D.+Hoyer&title=Drug+design+at+peptide+receptors&doi=10.1385%2FJMN%3A18%3A1-2%3A15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Drug design at peptide receptors: somatostatin receptor ligands</span></div><div class="casAuthors">Hannon, Jason P.; Nunn, Caroline; Stolz, Barbara; Bruns, Christian; Weckbecker, Gisbert; Lewis, Ian; Troxler, Thomas; Hurth, Konstanze; Hoyer, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">15-27</span>CODEN:
                <span class="NLM_cas:coden">JMNEES</span>;
        ISSN:<span class="NLM_cas:issn">0895-8696</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review.  Somatostatin (SRIF, somatotropin release inhibiting factor), discovered for its inhibitory action on growth hormone (GH) secretion from pituitary, is an abundant neuropeptide.  Two forms, SRIF14 and SRIF28 exist.  Recently, a second family of peptides with very similar sequences and features was described; the cortistatins (CST), CST17 and CST29 which are brain selective.  The five cloned SRIF receptors (sst1-5) belong to the G-protein coupled/heptathelical receptor family.  Structural and operational features distinguish two classes of receptors; SRIF1-sst2/sst3/sst5 (high affinity for octreotide or seglitide) and SRIF2=sst1/sst4 (very low affinity for the aforementioned ligands).  The affinity of SRIF receptors for somatostatins and cortistatins is equally high, and it is not clear whether selective receptors do exist for one or the other of the peptides.  Several radiologlands label all SRIF receptors, e.g., [125I] LTT-SRIF28, [125I] CGP23996, [125I] Tyr10cortistatin or [125I] Tyr11SRIF14.  In contrast, [125I] Tyr3octreotide, [125I] BIM23027, [125I] MK678 or [125I] D-Trp8SRIF14 label predominantly SRIF1 sites, esp. sst2 and possibly sst5 receptors.  In brain, [125I]Tyr3octreotide binding equates with sst2 receptor mRNA distribution.  Native SRIF2 receptors can be labeled with [125I]SRIF14 in the presence of high NaCl in brain (sst1) or lung (sst4) tissue.  Short cyclic or linear peptide analogs show selectivity for sst2/sst5 (octreotide, lanreotide, BIM 23027), sst1 (CH-275), sst3 (sst3-ODN-8), or sst5 receptors (BIM 23268); although claims for selectivity have not always been confirmed.  Beta peptides with affinity for SRIF receptors are also reported.  The general lack of SRIF receptor antagonists is unique for peptide receptors, although CYN 154806 is a selective and potent sst2 antagonist.  Nonpeptide ligands are still rare, although a no. of mols. have been reported with selectivity and potency for sst1 (L757,519), sst2 (L779,976), sst3 (L796,778), sst4 (NNC 26-9100, L803,087) or sst1/sst5 receptors (L817,018).  Such mols. are essential to establish the role of SRIF receptors, e.g., sst1 in hypothalamic glutamate currents: sst2 in inhibiting release of GH, glucagon, TSH, gastric acid secretion, pain, seizures and tumor growth, and sst5 in vascular remodeling and inhibition of insulin and GH release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1Db87Wp-xlrVg90H21EOLACvtfcHk0ljiQxdIC1t5sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XisVShs7k%253D&md5=5fcec52cbf5fe4f7dd0dae9eb8fda5c4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1385%2FJMN%3A18%3A1-2%3A15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FJMN%253A18%253A1-2%253A15%26sid%3Dliteratum%253Aachs%26aulast%3DHannon%26aufirst%3DJ.%2BP.%26aulast%3DNunn%26aufirst%3DC.%26aulast%3DStolz%26aufirst%3DB.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DWeckbecker%26aufirst%3DG.%26aulast%3DLewis%26aufirst%3DI.%26aulast%3DTroxler%26aufirst%3DT.%26aulast%3DHurth%26aufirst%3DK.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DDrug%2520design%2520at%2520peptide%2520receptors%26jtitle%3DJ.%2520Mol.%2520Neurosci.%26date%3D2002%26volume%3D18%26spage%3D15%26epage%3D27%26doi%3D10.1385%2FJMN%3A18%3A1-2%3A15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doepfner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huguenin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petcher, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pless, J.</span></span> <span> </span><span class="NLM_article-title">SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1140</span>, <span class="refDoi"> DOI: 10.1016/0024-3205(82)90087-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1016%2F0024-3205%2882%2990087-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=6128648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADyaL38XlslGhtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1982&pages=1133-1140&author=W.+Bauerauthor=U.+Brinerauthor=W.+Doepfnerauthor=R.+Hallerauthor=R.+Hugueninauthor=P.+Marbachauthor=T.+J.+Petcherauthor=J.+Pless&title=SMS+201-995%3A+A+very+potent+and+selective+octapeptide+analogue+of+somatostatin+with+prolonged+action&doi=10.1016%2F0024-3205%2882%2990087-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">SMS 201-995:  a very potent and selective octapeptide analog of somatostatin with prolonged action</span></div><div class="casAuthors">Bauer, Wilfried; Briner, Ulrich; Doepfner, Wolfgang; Haller, Roland; Huguenin, Rene; Marbach, Peter; Petcher, Trevor J.; Pless, Janos</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1133-40</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    </div><div class="casAbstract">Cyclic H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol) (SMS 201-995)  [83150-76-9] in vitro is 3 times more potent than the native hormone in inhibiting the secretion of growth hormone.  SMS 201-995 is highly resistant to degrdn. by pure enzymes and by tissue homogenates.  In vivo in rat and rhesus monkey it is at least 20 times more active than somatostatin  [38916-34-6], is much longer acting, and in both species is much more selective in inhibiting the secretion of growth hormone than that of insulin.  The compd. is active by several routes of administration including oral and is well-tolerated both in lab. animals and in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8bqAn6MorPbVg90H21EOLACvtfcHk0ljiQxdIC1t5sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XlslGhtLg%253D&md5=4c532216bf02dd0e17b2e7bc324fd5eb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2882%2990087-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252882%252990087-X%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DW.%26aulast%3DBriner%26aufirst%3DU.%26aulast%3DDoepfner%26aufirst%3DW.%26aulast%3DHaller%26aufirst%3DR.%26aulast%3DHuguenin%26aufirst%3DR.%26aulast%3DMarbach%26aufirst%3DP.%26aulast%3DPetcher%26aufirst%3DT.%2BJ.%26aulast%3DPless%26aufirst%3DJ.%26atitle%3DSMS%2520201-995%253A%2520A%2520very%2520potent%2520and%2520selective%2520octapeptide%2520analogue%2520of%2520somatostatin%2520with%2520prolonged%2520action%26jtitle%3DLife%2520Sci.%26date%3D1982%26volume%3D31%26spage%3D1133%26epage%3D1140%26doi%3D10.1016%2F0024-3205%2882%2990087-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szepeshazi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shally, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carney, D. N.</span></span> <span> </span><span class="NLM_article-title">Somatostatin receptor expression in lung cancer</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1682</span>– <span class="NLM_lpage">1687</span>, <span class="refDoi"> DOI: 10.1016/0959-8049(94)00351-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1016%2F0959-8049%2894%2900351-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1994&pages=1682-1687&author=K.+J.+O%E2%80%99Byrneauthor=G.+Halmosauthor=J.+Pinskiauthor=K.+Grootauthor=K.+Szepeshaziauthor=A.+V.+Shallyauthor=D.+N.+Carney&title=Somatostatin+receptor+expression+in+lung+cancer&doi=10.1016%2F0959-8049%2894%2900351-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1016%2F0959-8049%2894%2900351-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0959-8049%252894%252900351-5%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26aulast%3DHalmos%26aufirst%3DG.%26aulast%3DPinski%26aufirst%3DJ.%26aulast%3DGroot%26aufirst%3DK.%26aulast%3DSzepeshazi%26aufirst%3DK.%26aulast%3DShally%26aufirst%3DA.%2BV.%26aulast%3DCarney%26aufirst%3DD.%2BN.%26atitle%3DSomatostatin%2520receptor%2520expression%2520in%2520lung%2520cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D1994%26volume%3D30%26spage%3D1682%26epage%3D1687%26doi%3D10.1016%2F0959-8049%2894%2900351-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaer, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laissue, J. A.</span></span> <span> </span><span class="NLM_article-title">Somatostatin receptor sst1-5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands</span>. <i>Eur. J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">836</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.1007/s002590100541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1007%2Fs002590100541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=11504080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvVWltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2001&pages=836-846&author=J.+C.+Reubiauthor=B.+Waserauthor=J.+C.+Schaerauthor=J.+A.+Laissue&title=Somatostatin+receptor+sst1-5+expression+in+normal+and+neoplastic+human+tissues+using+receptor+autoradiography+with+subtype-selective+ligands&doi=10.1007%2Fs002590100541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands</span></div><div class="casAuthors">Reubi, Jean Claude; Waser, Beatrice; Schaer, Jean-Claude; Laissue, Jean A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">836-846</span>CODEN:
                <span class="NLM_cas:coden">EJNMD9</span>;
        ISSN:<span class="NLM_cas:issn">0340-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Somatostatin receptors are known to be expressed in a large no. of human tumors and represent the basis for in vivo tumor targeting.  Stable somatostatin derivs. such as octreotide or lanreotide are the most frequently used radiopharmaceuticals acting through specific binding to somatostatin receptors; however, they do not bind with high affinity to all five receptor subtypes.  Whereas the mRNAs for most receptor subtypes have been detected in tumors, it is in most cases unclear which of the receptor subtype proteins are expressed.  Since in vitro receptor binding methods are close correlates and predictors of in vivo peptide receptor targeting, we took advantage of the recently developed subtype-selective analogs and evaluated approx. 200 tumors for their receptor subtype protein expression in specific binding assays using autoradiog. with 125I-[Leu8, D-Trp22, Tyr25]-somatostatin-28 and displacement by subtype-selective analogs.  The majority of the tested neuroblastomas, meningiomas, medulloblastomas, breast carcinomas, lymphomas, renal cell carcinomas, paragangliomas, small cell lung carcinomas and hepatocellular carcinomas predominantly expressed sst2.  The prostate carcinomas and sarcomas preferentially expressed sst1, while a majority of inactive pituitary adenomas displayed sst3 and, to a lesser extent, sst2.  Growth hormone-secreting pituitary adenomas preferentially expressed sst2 and sst5; gastroenteropancreatic tumors and phaeochromocytomas frequently displayed sst2 and/or sst1.  Non-neoplastic human tissues such as vessels, nerve plexus, pancreatic islets, prostatic stroma, adrenal medulla, spleen and germinal centers of the lymphoid tissues preferentially expressed sst2.  However, the human gastric mucosa predominantly expressed sst1 while colonic mucosa displayed sst2.  Interestingly, a minority of tumors showed a strong 125I-[Leu8, D-Trp22, Tyr25]-somatostatin-28 binding, of which less than 50% could be displaced by the sum of the five subtype-selective analogs.  This observation suggests the existence of an as yet unknown subtype in selected tumors.  This study is the first report to analyze the somatostatin receptor subtype expression in tumors with binding methods.  We conclude that sst2, with high affinity for current radiopharmaceuticals such as Octreoscan, is predominantly expressed in a majority of tumors.  Fewer tumor types (sarcomas, prostate cancers, inactive pituitary adenomas) preferentially express another subtype.  This information is of importance with regard to the clin. applications and development of somatostatin analogs with distinct receptor subtype selectivities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSjHWWOv5NoLVg90H21EOLACvtfcHk0lh8vUyAlO6rUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvVWltL0%253D&md5=4ed6a5fc97c34cceb64c50f6257c763f</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1007%2Fs002590100541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002590100541%26sid%3Dliteratum%253Aachs%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26aulast%3DWaser%26aufirst%3DB.%26aulast%3DSchaer%26aufirst%3DJ.%2BC.%26aulast%3DLaissue%26aufirst%3DJ.%2BA.%26atitle%3DSomatostatin%2520receptor%2520sst1-5%2520expression%2520in%2520normal%2520and%2520neoplastic%2520human%2520tissues%2520using%2520receptor%2520autoradiography%2520with%2520subtype-selective%2520ligands%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%26date%3D2001%26volume%3D28%26spage%3D836%26epage%3D846%26doi%3D10.1007%2Fs002590100541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Callison, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massion, P. P.</span></span> <span> </span><span class="NLM_article-title">Somatostatin receptors in lung cancer: From function to molecular imaging and therapeutics</span>. <i>J. Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.6058/jlc.2011.10.2.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.6058%2Fjlc.2011.10.2.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=25663834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFWitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=69-76&author=J.+C.+Callisonauthor=R.+C.+Walkerauthor=P.+P.+Massion&title=Somatostatin+receptors+in+lung+cancer%3A+From+function+to+molecular+imaging+and+therapeutics&doi=10.6058%2Fjlc.2011.10.2.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Somatostatin receptors in lung cancer: from function to molecular imaging and therapeutics</span></div><div class="casAuthors">Callison, J. Clay, Jr.; Walker, Ronald C.; Massion, Pierre P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-76</span>CODEN:
                <span class="NLM_cas:coden">JLCOAQ</span>;
        ISSN:<span class="NLM_cas:issn">1598-7809</span>.
    
            (<span class="NLM_cas:orgname">Korean Association for the Study of Lung Cancer</span>)
        </div><div class="casAbstract">A review.  Lung cancer is a deadly disease that is difficult to diagnose and even more difficult to treat effectively.  Many pathways are known to affect tumor growth, and targeting these pathways provides the cornerstone by which cancer is treated.  Somatostatin receptors (SSTR) are a family of G protein coupled receptors that signal to alter hormonal secretion, increase apoptosis, and decrease cellular proliferation.  These receptors are expressed in many normal and malignant cells, including both small cell and non-small cell lung cancer.  Synthetic analogs of SSTRs are com. available, but their effects in lung cancer are still largely uncertain.  Signaling pathway studies have shown that SSTRs signal through phosphotyrosine phosphatases to induce apoptosis as well as to decrease cell proliferation.  Radiolabeled SSTR2 analogs are utilized for radiog. imaging of tumors, which, when combined with positron emission tomog.-computed tomog. (PET-CT) may improve detection of lung cancer.  These radiolabeled SSTR2 analogs also hold promise for targeted chemotherapy as well as radiotherapy.  In this review, we summarize what is known about SSTRs and focus our discussion on the knowledge as it relates to lung cancer biol., as well as discuss current and future uses of these receptors for imaging and therapy of lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEXZMGo-vLIrVg90H21EOLACvtfcHk0lh8vUyAlO6rUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFWitrw%253D&md5=ff577795f05694bad9987327e2ff4fa9</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.6058%2Fjlc.2011.10.2.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.6058%252Fjlc.2011.10.2.69%26sid%3Dliteratum%253Aachs%26aulast%3DCallison%26aufirst%3DJ.%2BC.%26aulast%3DWalker%26aufirst%3DR.%2BC.%26aulast%3DMassion%26aufirst%3DP.%2BP.%26atitle%3DSomatostatin%2520receptors%2520in%2520lung%2520cancer%253A%2520From%2520function%2520to%2520molecular%2520imaging%2520and%2520therapeutics%26jtitle%3DJ.%2520Lung%2520Cancer%26date%3D2011%26volume%3D10%26spage%3D69%26epage%3D76%26doi%3D10.6058%2Fjlc.2011.10.2.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barbieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajetto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattarozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Würth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thellung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizzari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florio, T.</span></span> <span> </span><span class="NLM_article-title">Peptide receptor targeting in cancer: The somatostatin paradigm</span>. <i>Int. J. Pept.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>, <span class="NLM_elocation-id">926295</span> <span class="refDoi"> DOI: 10.1155/2013/926295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1155%2F2013%2F926295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=23476673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVSqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+Barbieriauthor=A.+Bajettoauthor=A.+Pattarozziauthor=M.+Gattiauthor=R.+W%C3%BCrthauthor=S.+Thellungauthor=A.+Corsaroauthor=V.+Villaauthor=M.+Nizzariauthor=T.+Florio&title=Peptide+receptor+targeting+in+cancer%3A+The+somatostatin+paradigm&doi=10.1155%2F2013%2F926295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">peptide receptor targeting in cancer: the somatostatin paradigm</span></div><div class="casAuthors">Barbieri, Federica; Bajetto, Adriana; Pattarozzi, Alessandra; Gatti, Monica; Wurth, Roberto; Thellung, Stefano; Corsaro, Alessandro; Villa, Valentina; Nizzari, Mario; Florio, Tullio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptides</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">926295, 20 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJPNJ4</span>;
        ISSN:<span class="NLM_cas:issn">1687-9775</span>.
    
            (<span class="NLM_cas:orgname">Hindawi Publishing Corp.</span>)
        </div><div class="casAbstract">A review.  Peptide receptors involved in pathophysiol. processes represent promising therapeutic targets.  Neuropeptide somatostatin (SST) is produced by specialized cells in a large no. of human organs and tissues.  SST primarily acts as inhibitor of endocrine and exocrine secretion via the activation of five G-protein-coupled receptors, named sst1-5, while in central nervous system, SST acts as a neurotransmitter/neuromodulator, regulating locomotory and cognitive functions.  Crit. points of SST/SST receptor biol., such as signaling pathways of individual receptor subtypes, homo- and hetero-dimerization, trafficking, and cross-talk with growth factor receptors, have been extensively studied, although functions assocd. with several pathol. conditions, including cancer, are still not completely unraveled.  Importantly, SST exerts antiproliferative and antiangiogenic effects on cancer cells in vitro, and on exptl. tumors in vivo.  Moreover, SST agonists are clin. effective as antitumor agents for pituitary adenomas and gastro-pancreatic neuroendocrine tumors.  However, SST receptors being expressed by tumor cells of various tumor histotypes, their pharmacol. use is potentially extendible to other cancer types, although to date no significant results have been obtained.  In this paper the most recent findings on the expression and functional roles of SST and SST receptors in tumor cells are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAJks4TkHrkrVg90H21EOLACvtfcHk0lj_3BadyvipJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVSqt7c%253D&md5=fc543678cb04c7297fc77cf0aeb24941</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1155%2F2013%2F926295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F926295%26sid%3Dliteratum%253Aachs%26aulast%3DBarbieri%26aufirst%3DF.%26aulast%3DBajetto%26aufirst%3DA.%26aulast%3DPattarozzi%26aufirst%3DA.%26aulast%3DGatti%26aufirst%3DM.%26aulast%3DW%25C3%25BCrth%26aufirst%3DR.%26aulast%3DThellung%26aufirst%3DS.%26aulast%3DCorsaro%26aufirst%3DA.%26aulast%3DVilla%26aufirst%3DV.%26aulast%3DNizzari%26aufirst%3DM.%26aulast%3DFlorio%26aufirst%3DT.%26atitle%3DPeptide%2520receptor%2520targeting%2520in%2520cancer%253A%2520The%2520somatostatin%2520paradigm%26jtitle%3DInt.%2520J.%2520Pept.%26date%3D2013%26doi%3D10.1155%2F2013%2F926295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">de Herder, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofland, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Lely, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberts, S. W. J.</span></span> <span> </span><span class="NLM_article-title">Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumors</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1677/erc.0.0100451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1677%2Ferc.0.0100451" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=451-458&author=W.+W.+de+Herderauthor=L.+J.+Hoflandauthor=A.+J.+van+der%0ALelyauthor=S.+W.+J.+Lamberts&title=Somatostatin+receptors+in+gastroentero-pancreatic+neuroendocrine+tumors&doi=10.1677%2Ferc.0.0100451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1677%2Ferc.0.0100451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.0.0100451%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BHerder%26aufirst%3DW.%2BW.%26aulast%3DHofland%26aufirst%3DL.%2BJ.%26aulast%3Dvan%2Bder%2BLely%26aufirst%3DA.%2BJ.%26aulast%3DLamberts%26aufirst%3DS.%2BW.%2BJ.%26atitle%3DSomatostatin%2520receptors%2520in%2520gastroentero-pancreatic%2520neuroendocrine%2520tumors%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2003%26volume%3D10%26spage%3D451%26epage%3D458%26doi%3D10.1677%2Ferc.0.0100451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Öberg, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwekkeboom, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenning, E. P.</span></span> <span> </span><span class="NLM_article-title">Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2010.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1053%2Fj.gastro.2010.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=20637207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A280%3ADC%252BC3cjptlGgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2010&pages=742-753&author=K.+E.+%C3%96bergauthor=J.+C.+Reubiauthor=D.+J.+Kwekkeboomauthor=E.+P.+Krenning&title=Role+of+somatostatins+in+gastroenteropancreatic+neuroendocrine+tumor+development+and+therapy&doi=10.1053%2Fj.gastro.2010.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy</span></div><div class="casAuthors">Oberg Kjell E; Reubi Jean-Claude; Kwekkeboom Dik J; Krenning Eric P</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">742-53, 753.e1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have increased in the past 20 years.  GEP-NETs are heterogeneous tumors, in terms of clinical and biological features, that originate from the pancreas or the intestinal tract.  Some GEP-NETs grow very slowly, some grow rapidly and do not cause symptoms, and others cause hormone hypersecretion and associated symptoms.  Most GEP-NETs overexpress receptors for somatostatins.  Somatostatins inhibit the release of many hormones and other secretory proteins; their effects are mediated by G protein-coupled receptors that are expressed in a tissue-specific manner.  Most GEP-NETs overexpress the somatostatin receptor SSTR2; somatostatin analogues are the best therapeutic option for functional neuroendocrine tumors because they reduce hormone-related symptoms and also have antitumor effects.  Long-acting formulations of somatostatin analogues stabilize tumor growth over long periods.  The development of radioactive analogues for imaging and peptide receptor radiotherapy has improved the management of GEP-NETs.  Peptide receptor radiotherapy has significant antitumor effects, increasing overall survival times of patients with tumors that express a high density of SSTRs, particularly SSTR2 and SSTR5.  The multi-receptor somatostatin analogue SOM230 (pasireotide) and chimeric molecules that bind SSTR2 and the dopamine receptor D2 are also being developed to treat patients with GEP-NETs.  Combinations of radioactive labeled and unlabeled somatostatin analogues and therapeutics that inhibit other signaling pathways, such as mammalian target of rapamycin (mTOR) and vascular endothelial growth factor, might be the most effective therapeutics for GEP-NETs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTu3Hef0q6yg5ZoeNcnHOQ9fW6udTcc2eYQxKAy3fRwWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjptlGgtA%253D%253D&md5=102bf2e644f11f9c9e4a15a8f6a6975e</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2010.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2010.07.002%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2596berg%26aufirst%3DK.%2BE.%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26aulast%3DKwekkeboom%26aufirst%3DD.%2BJ.%26aulast%3DKrenning%26aufirst%3DE.%2BP.%26atitle%3DRole%2520of%2520somatostatins%2520in%2520gastroenteropancreatic%2520neuroendocrine%2520tumor%2520development%2520and%2520therapy%26jtitle%3DGastroenterology%26date%3D2010%26volume%3D139%26spage%3D742%26epage%3D753%26doi%3D10.1053%2Fj.gastro.2010.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofland, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberts, S. W. J.</span></span> <span> </span><span class="NLM_article-title">Somatostatin receptor subtype expression in human tumors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">S31</span>– <span class="NLM_lpage">S36</span>, <span class="refDoi"> DOI: 10.1093/annonc/12.suppl_2.S31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1093%2Fannonc%2F12.suppl_2.S31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=11762349" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=S31-S36&author=L.+J.+Hoflandauthor=S.+W.+J.+Lamberts&title=Somatostatin+receptor+subtype+expression+in+human+tumors&doi=10.1093%2Fannonc%2F12.suppl_2.S31"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2F12.suppl_2.S31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252F12.suppl_2.S31%26sid%3Dliteratum%253Aachs%26aulast%3DHofland%26aufirst%3DL.%2BJ.%26aulast%3DLamberts%26aufirst%3DS.%2BW.%2BJ.%26atitle%3DSomatostatin%2520receptor%2520subtype%2520expression%2520in%2520human%2520tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2001%26volume%3D12%26spage%3DS31%26epage%3DS36%26doi%3D10.1093%2Fannonc%2F12.suppl_2.S31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cescato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eltschinger, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivier, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wester, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginj, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonbrunn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span> <span> </span><span class="NLM_article-title">Internalization of sst2, sst3, and sst5 receptors: Effects of somatostatin agonists and antagonists</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">502</span>– <span class="NLM_lpage">511</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=502-511&author=R.+Cescatoauthor=S.+Schulzauthor=B.+Waserauthor=V.+Eltschingerauthor=J.+E.+Rivierauthor=H.-J.+Westerauthor=M.+Cullerauthor=M.+Ginjauthor=Q.+Liuauthor=A.+Schonbrunnauthor=J.+C.+Reubi&title=Internalization+of+sst2%2C+sst3%2C+and+sst5+receptors%3A+Effects+of+somatostatin+agonists+and+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCescato%26aufirst%3DR.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DWaser%26aufirst%3DB.%26aulast%3DEltschinger%26aufirst%3DV.%26aulast%3DRivier%26aufirst%3DJ.%2BE.%26aulast%3DWester%26aufirst%3DH.-J.%26aulast%3DCuller%26aufirst%3DM.%26aulast%3DGinj%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSchonbrunn%26aufirst%3DA.%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26atitle%3DInternalization%2520of%2520sst2%252C%2520sst3%252C%2520and%2520sst5%2520receptors%253A%2520Effects%2520of%2520somatostatin%2520agonists%2520and%2520antagonists%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2006%26volume%3D47%26spage%3D502%26epage%3D511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schally, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armatis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, R.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csernus, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovács, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppán, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szepesházi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahán, Z.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">1794</span>– <span class="NLM_lpage">1799</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.4.1794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1073%2Fpnas.95.4.1794" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=1794-1799&author=A.+Nagyauthor=A.+V.+Schallyauthor=G.+Halmosauthor=P.+Armatisauthor=R.-Z.+Caiauthor=V.+Csernusauthor=M.+Kov%C3%A1csauthor=M.+Kopp%C3%A1nauthor=K.+Szepesh%C3%A1ziauthor=Z.+Kah%C3%A1n&title=Synthesis+and+biological+evaluation+of+cytotoxic+analogs+of+somatostatin+containing+doxorubicin+or+its+intensely+potent+derivative%2C+2-pyrrolinodoxorubicin&doi=10.1073%2Fpnas.95.4.1794"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.4.1794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.4.1794%26sid%3Dliteratum%253Aachs%26aulast%3DNagy%26aufirst%3DA.%26aulast%3DSchally%26aufirst%3DA.%2BV.%26aulast%3DHalmos%26aufirst%3DG.%26aulast%3DArmatis%26aufirst%3DP.%26aulast%3DCai%26aufirst%3DR.-Z.%26aulast%3DCsernus%26aufirst%3DV.%26aulast%3DKov%25C3%25A1cs%26aufirst%3DM.%26aulast%3DKopp%25C3%25A1n%26aufirst%3DM.%26aulast%3DSzepesh%25C3%25A1zi%26aufirst%3DK.%26aulast%3DKah%25C3%25A1n%26aufirst%3DZ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520cytotoxic%2520analogs%2520of%2520somatostatin%2520containing%2520doxorubicin%2520or%2520its%2520intensely%2520potent%2520derivative%252C%25202-pyrrolinodoxorubicin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D1794%26epage%3D1799%26doi%3D10.1073%2Fpnas.95.4.1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuselier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coy, D. H.</span></span> <span> </span><span class="NLM_article-title">A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, αVβ3/αVβ5 and MMP-2/-9</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>246</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2006.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1016%2Fj.canlet.2006.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=16644105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpvFWj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=246&publication_year=2007&pages=157-166&author=L.-C.+Sunauthor=J.+Luoauthor=V.+Mackeyauthor=J.+Fuselierauthor=D.+H.+Coy&title=A+conjugate+of+camptothecin+and+a+somatostatin+analog+against+prostate+cancer+cell+invasion+via+a+possible+signaling+pathway+involving+PI3K%2FAkt%2C+%CE%B1V%CE%B23%2F%CE%B1V%CE%B25+and+MMP-2%2F-9&doi=10.1016%2Fj.canlet.2006.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, αVβ3/αVβ5 and MMP-2/-9</span></div><div class="casAuthors">Sun, Li-Chun; Luo, Jing; Mackey, L. Vienna; Fuselier, Joseph A.; Coy, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">246</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">157-166</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Camptothecin (CPT) was conjugated to the N-terminal of a somatostatin analog (SSA) directly via a carbamate group and a basic N-terminal linking motif, D-Lys-D-Tyr-Lys-D-Tyr-D-Lys.  This new CPT-SSA conjugate termed JF-10-81 was evaluated as a receptor-specific delivery system for its anti-invasive and anti-angiogenic activities.  It was found that, in addn. to blocking migration and invasion of highly invasive prostate cancer PC-3 cells, this conjugate also inhibited in vitro capillary-like tube formation of endothelial cells and in vivo angiogenesis in C57B1/6N female mice.  JF-10-81 blocked PC-3 cell attachment to various extracellular matrix components, mainly to vitronectin, the ligand of cell surface receptors integrin αVβ3 and αVβ5.  Addnl., JF-10-81 reduced expression of integrins αVβ3 and αVβ5 on PC-3 cell surfaces, without effects on β1 or any αβ1 heterodimers.  This conjugate also inactivated phosphorylation of protein kinase B (PKB/Akt), down-regulated the expression of latent matrix metalloproteinase (MMP)-2 and MMP-9, but had little effect on MMP-3/-10.  Meanwhile, membrane type-1 matrix metalloproteinase (MT1-MMP) and the tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) were not detectable in PC-3 cells.  αVβ3/αVβ5 and MMP-2/-9 are known to be highly expressed in many tumor cells and play an important role in tumor progression.  The authors' results support that this conjugate could possibly inhibit prostate cancer PC-3 cell invasion through a signaling pathway involving PI3K/Akt, αVβ3/αVβ5 and MMP-2/-9, and this SSA could be used as an efficient vector to deliver CPT or other cytotoxic agents to target sites for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocuJklhNUdEbVg90H21EOLACvtfcHk0lhkKBAArSaAcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpvFWj&md5=d1d681020c32108405c6935e666dd5fc</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2006.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2006.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.-C.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DMackey%26aufirst%3DV.%26aulast%3DFuselier%26aufirst%3DJ.%26aulast%3DCoy%26aufirst%3DD.%2BH.%26atitle%3DA%2520conjugate%2520of%2520camptothecin%2520and%2520a%2520somatostatin%2520analog%2520against%2520prostate%2520cancer%2520cell%2520invasion%2520via%2520a%2520possible%2520signaling%2520pathway%2520involving%2520PI3K%252FAkt%252C%2520%25CE%25B1V%25CE%25B23%252F%25CE%25B1V%25CE%25B25%2520and%2520MMP-2%252F-9%26jtitle%3DCancer%2520Lett.%26date%3D2007%26volume%3D246%26spage%3D157%26epage%3D166%26doi%3D10.1016%2Fj.canlet.2006.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Delpassand, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samarghandi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamiditabar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espenan, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erion, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dorisio, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kvols, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfangel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenning, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mojtahedi, A.</span></span> <span> </span><span class="NLM_article-title">Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: The first US phase 2 experience</span>. <i>Pancreas</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">518</span>– <span class="NLM_lpage">525</span>, <span class="refDoi"> DOI: 10.1097/MPA.0000000000000113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1097%2FMPA.0000000000000113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=24632546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFCkur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=518-525&author=E.+S.+Delpassandauthor=A.+Samarghandiauthor=S.+Zamanianauthor=E.+M.+Wolinauthor=M.+Hamiditabarauthor=G.+D.+Espenanauthor=J.+L.+Erionauthor=T.+M.+O%E2%80%99Dorisioauthor=L.+K.+Kvolsauthor=J.+Simonauthor=R.+Wolfangelauthor=A.+Campauthor=E.+P.+Krenningauthor=A.+Mojtahedi&title=Peptide+receptor+radionuclide+therapy+with+177Lu-DOTATATE+for+patients+with+somatostatin+receptor-expressing+neuroendocrine+tumors%3A+The+first+US+phase+2+experience&doi=10.1097%2FMPA.0000000000000113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor-Expressing Neuroendocrine Tumors: The First US Phase 2 Experience</span></div><div class="casAuthors">Delpassand, Ebrahim S.; Samarghandi, Amin; Zamanian, Sara; Wolin, Edward M.; Hamiditabar, Mohammadali; Espenan, Gregory D.; Erion, Jack L.; O'Dorisio, Thomas M.; Kvols, Larry K.; Simon, Jaime; Wolfangel, Robert; Camp, Arthur; Krenning, Eric P.; Mojtahedi, Alireza</div><div class="citationInfo"><span class="NLM_cas:title">Pancreas (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">518-525</span>CODEN:
                <span class="NLM_cas:coden">PANCE4</span>;
        ISSN:<span class="NLM_cas:issn">0885-3177</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs is a novel method of treatment in patients with metastatic neuroendocrine tumors (NETs).  For the first time in the United States, we present preliminary results of the treatment with Lutetium 177 (Lu) DOTATATE in patients with progressive NETs.  Methods: Thirty-seven patients with grade 1 and grade 2 disseminated and progressive gastroenteropancreatic NET were enrolled in a nonrandomized, phase 2 clin. trial.  Repeated cycles of 200 mCi (7.4 GBq; ±10%) were administered up to the cumulative dose of 800 mCi (29.6 GBq; ±10%).  Results: Among 32 evaluable patients, partial response and minimal response to treatment were seen in 28% and 3%, resp., and stable disease was seen in 41% of patients.  A total of 28% had progressive disease.  A response to treatment was significantly assocd. with lower burden of disease in the liver.  No significant acute or delayed hematol. or kidney toxicity was obsd.  An impressive improvement of performance status and quality of life were seen after Lu-DOTATATE therapy.  Conclusions: Treatment with multiple cycles of Lu-DOTATATE peptide receptor radionuclide therapy is well tolerated.  This treatment results in control of the disease in most patients, whereas systemic toxicities are limited and reversible.  Quality of life is also improved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLYzCnwZKdbVg90H21EOLACvtfcHk0lgp7654VxOXQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFCkur8%253D&md5=b2e9414467870ee7e72b3ce50cd2ee6c</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1097%2FMPA.0000000000000113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMPA.0000000000000113%26sid%3Dliteratum%253Aachs%26aulast%3DDelpassand%26aufirst%3DE.%2BS.%26aulast%3DSamarghandi%26aufirst%3DA.%26aulast%3DZamanian%26aufirst%3DS.%26aulast%3DWolin%26aufirst%3DE.%2BM.%26aulast%3DHamiditabar%26aufirst%3DM.%26aulast%3DEspenan%26aufirst%3DG.%2BD.%26aulast%3DErion%26aufirst%3DJ.%2BL.%26aulast%3DO%25E2%2580%2599Dorisio%26aufirst%3DT.%2BM.%26aulast%3DKvols%26aufirst%3DL.%2BK.%26aulast%3DSimon%26aufirst%3DJ.%26aulast%3DWolfangel%26aufirst%3DR.%26aulast%3DCamp%26aufirst%3DA.%26aulast%3DKrenning%26aufirst%3DE.%2BP.%26aulast%3DMojtahedi%26aufirst%3DA.%26atitle%3DPeptide%2520receptor%2520radionuclide%2520therapy%2520with%2520177Lu-DOTATATE%2520for%2520patients%2520with%2520somatostatin%2520receptor-expressing%2520neuroendocrine%2520tumors%253A%2520The%2520first%2520US%2520phase%25202%2520experience%26jtitle%3DPancreas%26date%3D2014%26volume%3D43%26spage%3D518%26epage%3D525%26doi%3D10.1097%2FMPA.0000000000000113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Redko, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragozin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreii, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helena, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amnon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talia, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, O.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genady, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gary, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, drug release, and biological evaluation of new anticancer drug–bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety</span>. <i>Biopolymers</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">743</span>– <span class="NLM_lpage">752</span>, <span class="refDoi"> DOI: 10.1002/bip.22694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1002%2Fbip.22694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=26058565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWlu7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2015&pages=743-752&author=B.+Redkoauthor=E.+Ragozinauthor=B.+Andreiiauthor=T.+Helenaauthor=A.+Amnonauthor=S.+Z.+Taliaauthor=O.-H.+Morauthor=K.+Genadyauthor=G.+Gary&title=Synthesis%2C+drug+release%2C+and+biological+evaluation+of+new+anticancer+drug%E2%80%93bioconjugates+containing+somatostatin+backbone+cyclic+analog+as+a+targeting+moiety&doi=10.1002%2Fbip.22694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16dR"><div class="casContent"><span class="casTitleNuber">16d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety</span></div><div class="casAuthors">Redko, Boris; Ragozin, Elena; Andreii, Bazylevich; Helena, Tuchinsky; Amnon, Albeck; Talia, Shekhter Zahavi; Mor, Oron-Herman; Genady, Kostenich; Gary, Gellerman</div><div class="citationInfo"><span class="NLM_cas:title">Biopolymers</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">743-752</span>CODEN:
                <span class="NLM_cas:coden">BIPMAA</span>;
        ISSN:<span class="NLM_cas:issn">0006-3525</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Peptide conjugates contg. somatostatin (SST) cyclic analogs as a targeting moiety are able to deliver chemotherapeutic agents specifically to cancer cells expressing SST receptors (SSTRs), and hence increasing their local efficacy while limiting the peripheral toxicity.  Here, we report on the synthesis and biochem. characterization of new SSTR-specific anticancer peptide conjugates, with different anticancer payloads acting through different oncogenic mechanisms to evaluate their biol. activities and to provide a comparative study of their drug release profiles.  The SSTR2-specific backbone cyclic peptide 3207-86 was chosen for the synthesis of a variety of novel anticancer drug conjugates with a broad drug release capabilities.  The N-terminus of 3207-86 was equipped with GABA to generate free amino group available for the conjugation of chlorambucil, Camptothecin (CPT), Combretastatin 4A, ABT-751, and Amonafide through the formation of various biodegradable bonds.  The chemo- and biostability/drug release of all the synthetic compds. was investigated at various pHs and in the presence of mouse liver homogenate, resp.  Their selective cytotoxic effect was evaluated on several human cancer cell lines that overexpress SSTR2.  Compared with the free drugs, our peptide-drug conjugates exhibited considerable cytotoxic effect on cancer cell lines vs. low SSTR2-expressed human embryonic kidney cells.  Functional versatility of the conjugates was reflected in the variability of their drug release profiles, whereas the conserved sequence of a selective binding to the SSTR2 likely preserved their binding to the receptor and consequently their favorable toxicity toward targeted cancer cells. © 2015 Wiley Periodicals, Inc.  Biopolymers (Pept Sci) 104: 743-752, 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBjf0vFF_RnrVg90H21EOLACvtfcHk0lgCjiS-lo0ZcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWlu7nO&md5=e2d73778caf77a1bc42e54f252b10d8d</span></div><a href="/servlet/linkout?suffix=cit16d&amp;dbid=16384&amp;doi=10.1002%2Fbip.22694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.22694%26sid%3Dliteratum%253Aachs%26aulast%3DRedko%26aufirst%3DB.%26aulast%3DRagozin%26aufirst%3DE.%26aulast%3DAndreii%26aufirst%3DB.%26aulast%3DHelena%26aufirst%3DT.%26aulast%3DAmnon%26aufirst%3DA.%26aulast%3DTalia%26aufirst%3DS.%2BZ.%26aulast%3DMor%26aufirst%3DO.-H.%26aulast%3DGenady%26aufirst%3DK.%26aulast%3DGary%26aufirst%3DG.%26atitle%3DSynthesis%252C%2520drug%2520release%252C%2520and%2520biological%2520evaluation%2520of%2520new%2520anticancer%2520drug%25E2%2580%2593bioconjugates%2520containing%2520somatostatin%2520backbone%2520cyclic%2520analog%2520as%2520a%2520targeting%2520moiety%26jtitle%3DBiopolymers%26date%3D2015%26volume%3D104%26spage%3D743%26epage%3D752%26doi%3D10.1002%2Fbip.22694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ragozin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazylevich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuchinsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bovina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekhter Zahavi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oron-Herman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luboshits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gellerman, G.</span></span> <span> </span><span class="NLM_article-title">New somatostatin-drug conjugates for effective targeting pancreatic cancer</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3825</span>– <span class="NLM_lpage">3836</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.06.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1016%2Fj.bmc.2018.06.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=3825-3836&author=E.+Ragozinauthor=A.+Hesinauthor=A.+Bazylevichauthor=H.+Tuchinskyauthor=A.+Bovinaauthor=T.+Shekhter+Zahaviauthor=M.+Oron-Hermanauthor=G.+Kostenichauthor=M.+A.+Firerauthor=T.+Rubinekauthor=I.+Wolfauthor=G.+Luboshitsauthor=M.+Y.+Shermanauthor=G.+Gellerman&title=New+somatostatin-drug+conjugates+for+effective+targeting+pancreatic+cancer&doi=10.1016%2Fj.bmc.2018.06.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.06.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.06.032%26sid%3Dliteratum%253Aachs%26aulast%3DRagozin%26aufirst%3DE.%26aulast%3DHesin%26aufirst%3DA.%26aulast%3DBazylevich%26aufirst%3DA.%26aulast%3DTuchinsky%26aufirst%3DH.%26aulast%3DBovina%26aufirst%3DA.%26aulast%3DShekhter%2BZahavi%26aufirst%3DT.%26aulast%3DOron-Herman%26aufirst%3DM.%26aulast%3DKostenich%26aufirst%3DG.%26aulast%3DFirer%26aufirst%3DM.%2BA.%26aulast%3DRubinek%26aufirst%3DT.%26aulast%3DWolf%26aufirst%3DI.%26aulast%3DLuboshits%26aufirst%3DG.%26aulast%3DSherman%26aufirst%3DM.%2BY.%26aulast%3DGellerman%26aufirst%3DG.%26atitle%3DNew%2520somatostatin-drug%2520conjugates%2520for%2520effective%2520targeting%2520pancreatic%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D3825%26epage%3D3836%26doi%3D10.1016%2Fj.bmc.2018.06.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanagh, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteman, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leece, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovtun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldmacher, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeves, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blättler, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span> <span> </span><span class="NLM_article-title">Semisynthetic maytansine analogues for the targeted treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4392</span>– <span class="NLM_lpage">4408</span>, <span class="refDoi"> DOI: 10.1021/jm060319f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060319f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4392-4408&author=W.+C.+Widdisonauthor=S.+D.+Wilhelmauthor=E.+E.+Cavanaghauthor=K.+R.+Whitemanauthor=B.+A.+Leeceauthor=Y.+Kovtunauthor=V.+S.+Goldmacherauthor=H.+Xieauthor=R.+M.+Steevesauthor=R.+J.+Lutzauthor=R.+Zhaoauthor=L.+Wangauthor=W.+A.+Bl%C3%A4ttlerauthor=R.+V.+J.+Chari&title=Semisynthetic+maytansine+analogues+for+the+targeted+treatment+of+cancer&doi=10.1021%2Fjm060319f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Semisynthetic Maytansine Analogs for the Targeted Treatment of Cancer</span></div><div class="casAuthors">Widdison, Wayne C.; Wilhelm, Sharon D.; Cavanagh, Emily E.; Whiteman, Kathleen R.; Leece, Barbara A.; Kovtun, Yelena; Goldmacher, Victor S.; Xie, Hongsheng; Steeves, Rita M.; Lutz, Robert J.; Zhao, Robert; Wang, Lintao; Blaettler, Walter A.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clin. trials because of unacceptable systemic toxicity.  The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells.  A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized.  The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied.  Several of these maytansinoids were found to be even more potent in vitro than maytansine.  The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozfQO-pe0iJLVg90H21EOLACvtfcHk0lg1rd18lLuGvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D&md5=a06c19d2d5166b0ca806babf9624c48b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm060319f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060319f%26sid%3Dliteratum%253Aachs%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DWilhelm%26aufirst%3DS.%2BD.%26aulast%3DCavanagh%26aufirst%3DE.%2BE.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DLeece%26aufirst%3DB.%2BA.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DSteeves%26aufirst%3DR.%2BM.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBl%25C3%25A4ttler%26aufirst%3DW.%2BA.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26atitle%3DSemisynthetic%2520maytansine%2520analogues%2520for%2520the%2520targeted%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4392%26epage%3D4408%26doi%3D10.1021%2Fjm060319f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouchet, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galmarini, C. M.</span></span> <span> </span><span class="NLM_article-title">Cabazitaxel, a new taxane with favorable properties</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1358/dot.2010.46.10.1519019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1358%2Fdot.2010.46.10.1519019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1agurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=735-742&author=B.+P.+Bouchetauthor=C.+M.+Galmarini&title=Cabazitaxel%2C+a+new+taxane+with+favorable+properties&doi=10.1358%2Fdot.2010.46.10.1519019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cabazitaxel, a new taxane with favorable properties</span></div><div class="casAuthors">Bouchet, B. P.; Galmarini, C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">735-742</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Cabazitaxel is a new taxane characterized by convenient administration, a favorable pharmacokinetic and safety profile and a decreased propensity for P-glycoprotein (Pgp)-mediated drug resistance.  In preclin. studies cabazitaxel inhibited cell growth in a wide range of human cancer cell lines, including tumor models expressing Pgp.  Phase I clin. trials established that the cabazitaxel side effect profile is similar to that reported for taxanes, with neutropenia and neuropathy being the most commonly reported toxicities.  Further clin. studies have revealed that cabazitaxel is clin. active in women with taxane-resistant metastatic breast cancer and in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.  The TROPIC phase III trial concluded that, compared to mitoxantrone/prednisone, the combination cabazitaxel/prednisone conferred a statistically significantly longer overall survival in patients after treatment with a docetaxel-contg. regimen, providing the basis for its FDA approval in 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovgWY0kdE85bVg90H21EOLACvtfcHk0lg1rd18lLuGvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1agurzI&md5=8fd4e757a1fcaa14d8774166aab2be38</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1358%2Fdot.2010.46.10.1519019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2010.46.10.1519019%26sid%3Dliteratum%253Aachs%26aulast%3DBouchet%26aufirst%3DB.%2BP.%26aulast%3DGalmarini%26aufirst%3DC.%2BM.%26atitle%3DCabazitaxel%252C%2520a%2520new%2520taxane%2520with%2520favorable%2520properties%26jtitle%3DDrugs%2520Today%26date%3D2010%26volume%3D46%26spage%3D735%26epage%3D742%26doi%3D10.1358%2Fdot.2010.46.10.1519019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doronina, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toki, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torgov, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelsohn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerveny, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chace, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBlanc, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearing, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bovee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegall, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francisco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Development of potent monoclonal antibody auristatin conjugates for cancer therapy</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">778</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1038/nbt832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1038%2Fnbt832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=12778055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFertLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=778-784&author=S.+O.+Doroninaauthor=B.+E.+Tokiauthor=M.+Y.+Torgovauthor=B.+A.+Mendelsohnauthor=C.+G.+Cervenyauthor=D.+F.+Chaceauthor=R.+L.+DeBlancauthor=R.+P.+Gearingauthor=T.+D.+Boveeauthor=C.+B.+Siegallauthor=J.+A.+Franciscoauthor=A.+F.+Wahlauthor=D.+L.+Meyerauthor=P.+D.+Senter&title=Development+of+potent+monoclonal+antibody+auristatin+conjugates+for+cancer+therapy&doi=10.1038%2Fnbt832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Development of potent monoclonal antibody auristatin conjugates for cancer therapy</span></div><div class="casAuthors">Doronina, Svetlana O.; Toki, Brian E.; Torgov, Michael Y.; Mendelsohn, Brian A.; Cerveny, Charles G.; Chace, Dana F.; DeBlanc, Ron L.; Gearing, R. Patrick; Bovee, Tim D.; Siegall, Clay B.; Francisco, Joseph A.; Wahl, Alan F.; Meyer, Damon L.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">778-784</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We describe the in vitro and in vivo properties of monoclonal antibody (mAb)-drug conjugates consisting of the potent synthetic dolastatin 10 analogs auristatin E (AE) and monomethylauristatin E (MMAE), linked to the chimeric mAbs cBR96 (specific to Lewis Y on carcinomas) and cAC10 (specific to CD30 on hematol. malignancies).  The linkers used for conjugate formation included an acid-labile hydrazone and protease-sensitive dipeptides, leading to uniformly substituted conjugates that efficiently released active drug in the lysosomes of antigen-pos. (Ag+) tumor cells.  The peptide-linked mAb-valine-citrulline-MMAE and mAb-phenylalanine-lysine-MMAE conjugates were much more stable in buffers and plasma than the conjugates of mAb and the hydrazone of 5-benzoylvaleric acid-AE ester (AEVB).  As a result, the mAb-Val-Cit-MMAE conjugates exhibited greater in vitro specificity and lower in vivo toxicity than corresponding hydrazone conjugates.  In vivo studies demonstrated that the peptide-linked conjugates induced regressions and cures of established tumor xenografts with therapeutic indexes as high as 60-fold.  These conjugates illustrate the importance of linker technol., drug potency and conjugation methodol. in developing safe and efficacious mAb-drug conjugates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro97SFKtdQ7rVg90H21EOLACvtfcHk0lij-tlwVJLJLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFertLc%253D&md5=d77716ec93de5ac7473c18a597339086</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnbt832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt832%26sid%3Dliteratum%253Aachs%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DToki%26aufirst%3DB.%2BE.%26aulast%3DTorgov%26aufirst%3DM.%2BY.%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DChace%26aufirst%3DD.%2BF.%26aulast%3DDeBlanc%26aufirst%3DR.%2BL.%26aulast%3DGearing%26aufirst%3DR.%2BP.%26aulast%3DBovee%26aufirst%3DT.%2BD.%26aulast%3DSiegall%26aufirst%3DC.%2BB.%26aulast%3DFrancisco%26aufirst%3DJ.%2BA.%26aulast%3DWahl%26aufirst%3DA.%2BF.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DDevelopment%2520of%2520potent%2520monoclonal%2520antibody%2520auristatin%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Biotechnol.%26date%3D2003%26volume%3D21%26spage%3D778%26epage%3D784%26doi%3D10.1038%2Fnbt832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henne, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doorneweerd, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenbrink, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kularatne, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and activity of a folate peptide camptothecin prodrug</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">5350</span>– <span class="NLM_lpage">5355</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.07.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1016%2Fj.bmcl.2006.07.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=16901694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlCqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=5350-5355&author=W.+A.+Henneauthor=D.+D.+Doorneweerdauthor=A.+R.+Hilgenbrinkauthor=S.+A.+Kularatneauthor=P.+S.+Low&title=Synthesis+and+activity+of+a+folate+peptide+camptothecin+prodrug&doi=10.1016%2Fj.bmcl.2006.07.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and activity of a folate peptide camptothecin prodrug</span></div><div class="casAuthors">Henne, Walter A.; Doorneweerd, Derek D.; Hilgenbrink, Andrew R.; Kularatne, Sumith A.; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5350-5355</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A folate receptor targeted camptothecin prodrug was synthesized using a hydrophilic peptide spacer linked to folate via a releasable disulfide carbonate linker.  The conjugate was found to possess high affinity for folate receptor-expressing cells and inhibited cell proliferation in human KB cells with an IC50 of 10 nM.  Activity of the prodrug was completely blocked by excess folic acid, demonstrating receptor-mediated uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqISsLYrXKp-7Vg90H21EOLACvtfcHk0lij-tlwVJLJLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlCqtL8%253D&md5=716a8d5625943d4d9f152d17ec82ba42</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.07.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.07.076%26sid%3Dliteratum%253Aachs%26aulast%3DHenne%26aufirst%3DW.%2BA.%26aulast%3DDoorneweerd%26aufirst%3DD.%2BD.%26aulast%3DHilgenbrink%26aufirst%3DA.%2BR.%26aulast%3DKularatne%26aufirst%3DS.%2BA.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DSynthesis%2520and%2520activity%2520of%2520a%2520folate%2520peptide%2520camptothecin%2520prodrug%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D5350%26epage%3D5355%26doi%3D10.1016%2Fj.bmcl.2006.07.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Omelyanenko, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopečovà, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopeček, J.</span></span> <span> </span><span class="NLM_article-title">HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">600</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1097-0215(19980209)75:4<600::AID-IJC18>3.0.CO;2-C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1002%2F%28SICI%291097-0215%2819980209%2975%3A4%3C600%3A%3AAID-IJC18%3E3.0.CO%3B2-C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=9466663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADyaK1cXhtV2ltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1998&pages=600-608&author=V.+Omelyanenkoauthor=C.+Gentryauthor=P.+Kope%C4%8Dov%C3%A0author=J.+Kope%C4%8Dek&title=HPMA+copolymer-anticancer+drug-OV-TL16+antibody+conjugates.+II.+Processing+in+epithelial+ovarian+carcinoma+cells+in+vitro&doi=10.1002%2F%28SICI%291097-0215%2819980209%2975%3A4%3C600%3A%3AAID-IJC18%3E3.0.CO%3B2-C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro</span></div><div class="casAuthors">Omelyanenko, Vladimir; Gentry, Christine; Kopeckova, Pavla; Kopecek, Jindrich</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">600-608</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The binding, internalization, subcellular trafficking and in vitro cytotoxicity of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-anti-cancer drug-OV-TL16 antibody (Ab) conjugates in the ovarian carcinoma OVCAR-3 cell line have been investigated.  Adriamycin (ADR) and meso chlorin e6 mono(N-2-aminoethylamide) (Mce6) photosensitizer were used as anti-cancer drugs.  Targeted (Ab-contg.) conjugates were compared with non-targeted HPMA copolymer-drug conjugates and with free drugs.  Targeted conjugates were taken up rapidly by cells and detected within lysosomes by confocal fluorescence microscopy.  The ADR attached to polymer chains via a degradable GFLG spacer was released from the conjugate, diffused via the lysosomal membrane into the cytoplasm and ultimately accumulated in the cell nuclei.  In contrast, conjugates contg. ADR bound via the GG spacer accumulated in the lysosomes, but no fluorescence could be detected in the cell nuclei.  Binding the drugs to a non-targeted HPMA copolymer decreased their cytotoxicity in vitro.  The IC50 dose increased from 2 pM for free ADR to 150 μM for P(GFLG)-ADR (P is the HPMA copolymer backbone) and from 0.34 pM for free Mce6 (with light) to 290 μM for P-(GG)-Mce6.  However, attachment of OV-TL16 Abs rendered HPMA copolymer-drug conjugates biorecognizable by OVCAR-3 cells and markedly increased their cytotoxicity.  The IC50 doses were 4.4 and 0.38 μM for the targeted conjugates P(GFLG)-ADR-Ab and P(GG)-Mce6-Ab (with light), resp.  Biorecognition was shown to be specific by inhibition expts. with free Ab.  The findings indicate the potential of these conjugates as effective agents in the treatment of ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMEdOuzvzGhLVg90H21EOLACvtfcHk0ljrk7S0eCOavQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtV2ltb4%253D&md5=326985aa62a3170e9e02346d71ce737e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819980209%2975%3A4%3C600%3A%3AAID-IJC18%3E3.0.CO%3B2-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819980209%252975%253A4%253C600%253A%253AAID-IJC18%253E3.0.CO%253B2-C%26sid%3Dliteratum%253Aachs%26aulast%3DOmelyanenko%26aufirst%3DV.%26aulast%3DGentry%26aufirst%3DC.%26aulast%3DKope%25C4%258Dov%25C3%25A0%26aufirst%3DP.%26aulast%3DKope%25C4%258Dek%26aufirst%3DJ.%26atitle%3DHPMA%2520copolymer-anticancer%2520drug-OV-TL16%2520antibody%2520conjugates.%2520II.%2520Processing%2520in%2520epithelial%2520ovarian%2520carcinoma%2520cells%2520in%2520vitro%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1998%26volume%3D75%26spage%3D600%26epage%3D608%26doi%3D10.1002%2F%28SICI%291097-0215%2819980209%2975%3A4%3C600%3A%3AAID-IJC18%3E3.0.CO%3B2-C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, R.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szoke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redding, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schally, A. V.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activity of highly potent octapeptide analogs of somatostatin</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">1896</span>– <span class="NLM_lpage">1900</span>, <span class="refDoi"> DOI: 10.1073/pnas.83.6.1896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1073%2Fpnas.83.6.1896" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1986&pages=1896-1900&author=R.-Z.+Caiauthor=B.+Szokeauthor=R.+Luauthor=D.+Fuauthor=T.+W.+Reddingauthor=A.+V.+Schally&title=Synthesis+and+biological+activity+of+highly+potent+octapeptide+analogs+of+somatostatin&doi=10.1073%2Fpnas.83.6.1896"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.83.6.1896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.83.6.1896%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DR.-Z.%26aulast%3DSzoke%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DD.%26aulast%3DRedding%26aufirst%3DT.%2BW.%26aulast%3DSchally%26aufirst%3DA.%2BV.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520highly%2520potent%2520octapeptide%2520analogs%2520of%2520somatostatin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1986%26volume%3D83%26spage%3D1896%26epage%3D1900%26doi%3D10.1073%2Fpnas.83.6.1896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cyr, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guaraldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azure, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lister-James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinkelborg, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, R. T.</span></span> <span> </span><span class="NLM_article-title">Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1354</span>– <span class="NLM_lpage">1364</span>, <span class="refDoi"> DOI: 10.1021/jm061290i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061290i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1354-1364&author=J.+E.+Cyrauthor=D.+A.+Pearsonauthor=D.+M.+Wilsonauthor=C.+A.+Nelsonauthor=M.+Guaraldiauthor=M.+T.+Azureauthor=J.+Lister-Jamesauthor=L.+M.+Dinkelborgauthor=R.+T.+Dean&title=Somatostatin+receptor-binding+peptides+suitable+for+tumor+radiotherapy+with+Re-188+or+Re-186.+Chemistry+and+initial+biological+studies&doi=10.1021%2Fjm061290i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm061290i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061290i%26sid%3Dliteratum%253Aachs%26aulast%3DCyr%26aufirst%3DJ.%2BE.%26aulast%3DPearson%26aufirst%3DD.%2BA.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DNelson%26aufirst%3DC.%2BA.%26aulast%3DGuaraldi%26aufirst%3DM.%26aulast%3DAzure%26aufirst%3DM.%2BT.%26aulast%3DLister-James%26aufirst%3DJ.%26aulast%3DDinkelborg%26aufirst%3DL.%2BM.%26aulast%3DDean%26aufirst%3DR.%2BT.%26atitle%3DSomatostatin%2520receptor-binding%2520peptides%2520suitable%2520for%2520tumor%2520radiotherapy%2520with%2520Re-188%2520or%2520Re-186.%2520Chemistry%2520and%2520initial%2520biological%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1354%26epage%3D1364%26doi%3D10.1021%2Fjm061290i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schär, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppeler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäcke, H. R.</span></span> <span> </span><span class="NLM_article-title">Affinity profiles for human somatostatin receptor subtypes sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use</span>. <i>Eur. J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.1007/s002590050034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10.1007%2Fs002590050034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=10774879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhsVWns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2000&pages=273-282&author=J.+C.+Reubiauthor=J.-C.+Sch%C3%A4rauthor=B.+Waserauthor=S.+Wengerauthor=A.+Heppelerauthor=J.+Schmittauthor=H.+R.+M%C3%A4cke&title=Affinity+profiles+for+human+somatostatin+receptor+subtypes+sst1-sst5+of+somatostatin+radiotracers+selected+for+scintigraphic+and+radiotherapeutic+use&doi=10.1007%2Fs002590050034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use</span></div><div class="casAuthors">Reubi, Jean Claude; Schar, Jean-Claude; Waser, Beatrice; Wenger, Sandra; Heppeler, Axel; Schmitt, Jorg S.; Macke, Helmut R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-282</span>CODEN:
                <span class="NLM_cas:coden">EJNMD9</span>;
        ISSN:<span class="NLM_cas:issn">0340-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">In vivo somatostatin receptor scintigraphy using Octreoscan is a valuable method for the visualization of human endocrine tumors and their metastases.  Recently, several new, alternative somatostatin radioligands have been synthesized for diagnostic and radiotherapeutic use in vivo.  Since human tumors are known to express various somatostatin receptor subtypes, it is mandatory to assess the receptor subtype affinity profile of such somatostatin radiotracers.  Using cell lines transfected with somatostatin receptor subtypes sst1, sst2, sst3, sst4 and sst5, we have evaluated the in vitro binding characteristics of labeled (indium, yttrium, gallium) and unlabeled DOTA-[Tyr3]-octreotide, DOTA-octreotide, DOTA-lanreotide, DOTA-vapreotide, DTPA-[Tyr3]-octreotate and DOTA-[Tyr3]-octreotate.  Small structural modifications, chelator substitution or metal replacement were shown to considerably affect the binding affinity.  A marked improvement of sst2 affinity was found for Ga-DOTA-[Tyr3]-octreotide (IC50 2.5 nM) compared with the Y-labeled compd. and Octreoscan.  An excellent binding affinity for sst2 in the same range was also found for In-DTPA-[Tyr3]-octreotate (IC50 1.3 nM) and for Y-DOTA-[Tyr3]-octreotate (IC50 1.6 nM).  Remarkably, Ga-DOTA-[Tyr3]-octreotate bound at sst2 with a considerably higher affinity (IC50 0.2 nM).  An up to 30-fold improvement in sst3 affinity was obsd. for unlabeled or Y-labeled DOTA-octreotide compared with their Tyr3-contg. analog, suggesting that replacement of Tyr3 by Phe is crucial for high sst3 affinity.  Substitution in the octreotide mol. of the DTPA by DOTA improved the sst3 binding affinity 14-fold.  Whereas Y-DOTA-lanreotide had only low affinity for sst3 and sst4, it had the highest affinity for sst5 among the tested compds. (IC50 16 nM).  Increased binding affinity for sst3 and sst5 was obsd. for DOTA-[Tyr3]-octreotide, DOTA-lanreotide and DOTA-vapreotide when they were labeled with yttrium.  These marked changes in subtype affinity profiles are due not only to the different chem. structures but also to the different charges and hydrophilicity of these compds.  Interestingly, even the coordination geometry of the radiometal complex remote from the pharmacophoric amino acids has a significant influence on affinity profiles as shown with Y-DOTA vs. Ga-DOTA in either [Tyr3]-octreotide or [Tyr3]-octreotate.  Such changes in sst affinity profiles must be identified in newly designed radiotracers used for somatostatin receptor scintigraphy in order to correctly interpret in vivo scintigraphic data.  These observations may represent basic principles relevant to the development of other peptide radioligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRKqYdWT35ELVg90H21EOLACvtfcHk0lh9D5i8gRjhyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhsVWns7w%253D&md5=3f9cd3963bcc09b71c4c6d38a2487b14</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs002590050034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002590050034%26sid%3Dliteratum%253Aachs%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26aulast%3DSch%25C3%25A4r%26aufirst%3DJ.-C.%26aulast%3DWaser%26aufirst%3DB.%26aulast%3DWenger%26aufirst%3DS.%26aulast%3DHeppeler%26aufirst%3DA.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DM%25C3%25A4cke%26aufirst%3DH.%2BR.%26atitle%3DAffinity%2520profiles%2520for%2520human%2520somatostatin%2520receptor%2520subtypes%2520sst1-sst5%2520of%2520somatostatin%2520radiotracers%2520selected%2520for%2520scintigraphic%2520and%2520radiotherapeutic%2520use%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%26date%3D2000%26volume%3D27%26spage%3D273%26epage%3D282%26doi%3D10.1007%2Fs002590050034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kellogg, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovtun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leece, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteman, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, R. J.</span></span> <span> </span><span class="NLM_article-title">Disulfide-linked antibody-maytansinoid conjugates: Optimization of in vivo activity by varying the steric hinderance at carbon atoms adjacent to the disulfide linkage</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1021/bc100480a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc100480a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFKnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=717-727&author=B.+A.+Kelloggauthor=L.+Garrettauthor=Y.+Kovtunauthor=K.+C.+Laiauthor=B.+Leeceauthor=M.+Millerauthor=G.+Payneauthor=R.+Steevesauthor=K.+R.+Whitemanauthor=W.+Widdisonauthor=H.+Xieauthor=R.+Singhauthor=R.+V.+J.+Chariauthor=J.+M.+Lambertauthor=R.+J.+Lutz&title=Disulfide-linked+antibody-maytansinoid+conjugates%3A+Optimization+of+in+vivo+activity+by+varying+the+steric+hinderance+at+carbon+atoms+adjacent+to+the+disulfide+linkage&doi=10.1021%2Fbc100480a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage</span></div><div class="casAuthors">Kellogg, Brenda A.; Garrett, Lisa; Kovtun, Yelena; Lai, Katharine C.; Leece, Barbara; Miller, Michael; Payne, Gillian; Steeves, Rita; Whiteman, Kathleen R.; Widdison, Wayne; Xie, Hongsheng; Singh, Rajeeva; Chari, Ravi V. J.; Lambert, John M.; Lutz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">717-727</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this report, we describe the synthesis of a panel of disulfide-linked huC242 (anti-CanAg) antibody maytansinoid conjugates (AMCs), which have varying levels of steric hindrance around the disulfide bond, in order to investigate the relationship between stability to redn. of the disulfide linker and antitumor activity of the conjugate in vivo.  The conjugates were first tested for stability to redn. by dithiothreitol in vitro and for plasma stability in CD1 mice.  It was found that the conjugates having the more sterically hindered disulfide linkages were more stable to reductive cleavage of the maytansinoid in both settings.  When the panel of conjugates was tested for in vivo efficacy in two human colon cancer xenograft models in SCID mice, it was found that the conjugate with intermediate disulfide bond stability having two Me groups on the maytansinoid side of the disulfide bond and no Me groups on the linker side of the disulfide bond (huC242-SPDB-DM4) displayed the best efficacy.  The ranking of in vivo efficacies of the conjugates was not predicted by their in vitro potencies, since all conjugates were highly active in vitro, including a huC242-SMCC-DM1 conjugate with a noncleavable linkage which showed only marginal activity in vivo.  These data suggest that factors in addn. to intrinsic conjugate potency and conjugate half-life in plasma influence the magnitude of antitumor activity obsd. for an AMC in vivo.  We provide evidence that bystander killing of neighboring nontargeted tumor cells by diffusible cytotoxic metabolites produced from target cell processing of disulfide-linked antibody-maytansinoid conjugates may be one addnl. factor contributing to the activity of these conjugates in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGmGw-cH238bVg90H21EOLACvtfcHk0lh9D5i8gRjhyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFKnsro%253D&md5=ef2969ceaaea23e81da2edf06f62ea7e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbc100480a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc100480a%26sid%3Dliteratum%253Aachs%26aulast%3DKellogg%26aufirst%3DB.%2BA.%26aulast%3DGarrett%26aufirst%3DL.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DK.%2BC.%26aulast%3DLeece%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DPayne%26aufirst%3DG.%26aulast%3DSteeves%26aufirst%3DR.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DWiddison%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26atitle%3DDisulfide-linked%2520antibody-maytansinoid%2520conjugates%253A%2520Optimization%2520of%2520in%2520vivo%2520activity%2520by%2520varying%2520the%2520steric%2520hinderance%2520at%2520carbon%2520atoms%2520adjacent%2520to%2520the%2520disulfide%2520linkage%26jtitle%3DBioconjugate%2520Chem.%26date%3D2011%26volume%3D22%26spage%3D717%26epage%3D727%26doi%3D10.1021%2Fbc100480a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i29"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b02036">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_48556"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b02036">10.1021/acs.jmedchem.8b02036</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Mouse body weights for the NCI-H69 xenograft study (<a id="rightTab-" class=" internalNav" href="#fig6">Figure <a id="rightTab-" class=" internalNav" href="#fig6">6</a></a>), GPCR screening data, and molecular formula strings and biological data in <a class="ref showTableEvent internalNav" href="#tbl1">Tables <a class="ref showTableEvent internalNav" href="#tbl1">1</a></a>, <a class="ref showTableEvent internalNav" href="#tbl2">2</a>, and <a class="ref showTableEvent internalNav" href="#tbl4">4</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b02036/suppl_file/jm8b02036_si_001.csv">CSV</a>)</p></li><li><p class="inline">Procedures for the synthesis of compounds <b>1</b>–<b>19</b> and <b>23</b>–<b>37</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b02036/suppl_file/jm8b02036_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b02036/suppl_file/jm8b02036_si_001.csv">jm8b02036_si_001.csv (6.63 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b02036/suppl_file/jm8b02036_si_002.pdf">jm8b02036_si_002.pdf (2.89 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b02036&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-5%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b02036%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b02036" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67996dcbcf723d24","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
